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1  Introduction 
A Introduction 
1. Insulin-degrading enzyme 
The insulin-degrading enzyme (IDE), also called insulysin or insulinase earlier, was discovered 
as an insulin-degrading protease by Mirsky and Broh-Kahn in several tissue extracts in 1949 
(Broh-Kahn & Mirsky, 1949). IDE, a 110 kDa neutral Zn2+ metalloprotease, is ubiquitously 
expressed and most abundant in liver, testis, muscle and the brain (Kuo, et al., 1993; Shen, et 
al., 2006). Interestingly, the sequence of IDE is highly conserved from bacteria to humans. In 
eukaryotes homology includes both exon and intron regions, indicating a functional importance 
of the enzyme in general and, second, that both proteolytic and potential gene expression 
regulation are conserved as well (Qiu & Folstein, 2006; Fujita, et al., 1994; Affholter, et al., 
1988; Kuo, et al., 1990; Shen, et al., 2006). IDE is predominantly localised in the cytosol. In 
addition, IDE was also detected in mitochondria, the nucleus, rough endoplasmic reticulum 
(ER) and at the cell surface, as well as in peroxisomes (Qiu, et al., 1998; Duckworth, et al., 
1998; Bulloj, et al., 2008; Vekrellis, et al., 2000; Leissring, et al., 2004). Furthermore, IDE was 
found to be secreted into extracellular fluids by several different cell types (Qiu, et al., 1998; 
Bulloj, et al., 2010; Zhao, et al., 2009; Glebov, et al., 2011; Son, et al., 2015). The substrates 
of IDE are highly diverse and share little or no sequence homology. The selectivity of IDE 
seems to be not determined by a particular sequence, but rather the size of the polypeptides 
and their secondary structure (Malito, et al., 2008; Guo, et al., 2010). Additionally to insulin, 
from which it received its name, IDE degrades several small peptides as e.g. glucagon, 
ȕ-endorphin, transforming growth factor α (TGF α), amylin and somatostatin (Wang, et al., 
2006; Ciaccio, et al., 2009; Qiu & Folstein, 2006; Bennett, et al., 2000). In 1994, Kurochkin and 
colleagues found out that IDE is furthermore cleaving Amyloid-ȕ (Aȕ) (Kurochkin & Goto, 
1994), which suggested a potential involvement in AD. IDE is able to degrade soluble forms of 
the main variants, Aȕ1-40 and Aȕ1-42, and AICD. AICD is the intracellular cleavage product of 
Ȗ-secretase processing of APP (Edbauer, et al., 2002; Sastre, et al., 2001; Pérez, et al., 2000). 
 
1.1 IDE structure and mechanism of degrading short polypeptides 
A large number of IDE substrates shows the propensity to form ȕ-sheet-containing amyloid 
fibrils. Examples are Aȕ playing a role in the pathogenesis of Alzheimer’s disease, and amylin 
forming islet amyloid deposits in type 2 diabetes mellitus (Bennett, et al., 2000; Kurochkin, 
2001). Therefore IDE is assumed to be involved in the catabolic regulation to avoid amyloid 
deposits through the elimination of its basic components (Qiu & Folstein, 2006). 
The enzyme can be subdivided into two parts of around 56 kDa each. The N-terminal part 
(IDE-N; aa 43-515 in human IDE) and the C-terminal part (IDE-C; aa 542-1016 in human IDE)  
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Figure 1. Structure and functional mechanism of IDE. (A) Secondary structure of human IDE-E111Q in complex 
with the B chain of insulin after X-ray crystallography. The mutation E111Q was integrated to prevent substrate 
cleavage and enable visualization of an enzyme-substrate complex. The insulin B chain is coloured in orange and 
the bound Zn2+ ion is presented in magenta. (B) Model of the IDE mechanism of substrate binding and recognition 
including a conformational switch from an open (IDEo) to a closed (IDEc) conformation. Binding of Aȕ is here shown 
as an example. The binding of Aȕ occurs in the open state, proper recognition, conformational changes in the 
substrates and cleavage occur in the closed state of IDE. (A) and (B) from (Shen, et al., 2006). 
are connected via a 28 amino acid-long loop (see Figure 1A). These two domains form an 
enclosed chamber that can switch to an open conformation to incorporate the substrate. Due 
to its dimensions, the catalytic chamber limits the size of the substrates to less than 50 amino 
acids. After binding the substrate, the enzyme switches to the closed conformation enabling 
precise recognition and digestion of the peptide and also preventing the binding of a further 
substrate (see Figure 1B). The peptide undergoes certain conformational changes and can 
subsequently be cleaved at one or multiple sites. The switch between open and closed 
conformations of the enzyme is crucial for the proteolytic process. Mutations, that prevent or 
facilitate the open conformation, inhibit or increase, respectively, the catalytic rate of the 
enzyme (Shen, et al., 2006). 
The active site in IDE-N consists of the amino acid sequence histidine-X-X-glutamate-histidine 
(HXXEH, aa 108-112 in human IDE), with the X symbolizing a variable amino acid. This 
sequence is highly conserved. The two histidine residues and an additional glutamate (aa 189 
in human IDE) residue coordinate the Zn2+ ion. The glutamate residue and a catalytic water 
molecule is further necessary for the nucleophilic attack on the peptide bond of the peptide 
substrate (Becker & Roth, 1992; Perlman & Rosner, 1994; Im, et al., 2007). IDE substrates 
show similarities that are involved in the catalytic process. They possess a 7-13 amino acid 
sequence that contains a large hydrophobic group and is prone to form a ȕ-sheet. IDE-N is 
capable to interact with this ȕ-sheet and also with the first 3-5 amino acids of the peptide. The 
internal chamber for catalysis is formed by both IDE-N and IDE-C. IDE-N holding the active 
site contributes neutral or negative charges, whereas IDE-C donates predominantly positive 
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charges and is rather responsible for the substrate recognition (Shen, et al., 2006; Li, et al., 
2006).  
IDE-C is further involved in the oligomerization of IDE. The enzyme primarily exists as a dimer 
and can also form tetrameric structures in a concentration-dependent manner. The interaction 
of two IDE dimers, however, can favour the closed conformation of the enzyme and therefore 
regulate also the catalytic activity of the enzyme (Safavi, et al., 1996; Song, et al., 2003; Li, et 
al., 2006; Shen, et al., 2006). 
 
1.2 IDE in Alzheimer’s disease 
AD is a devastating neurodegenerative disease and the most common cause of dementia. It 
is characterised by a progressive loss of neuronal cells and synapses especially in brain areas 
that are responsible for learning and memory. This leads to deficits in memory, orientation and 
language. There are two forms of AD. The most common, so-called late-onset AD (LOAD) 
starting after the age of 65 years and the early-onset AD (EOAD) that begins before that age 
(Alzheimer's association, 2014; Tanzi, 2012). Primarily ageing itself is the most important risk 
factor for the disease, especially for LOAD. Only 1-5% of all cases are based on dominantly 
inherited forms of AD, the rest occur sporadically. Pathological hallmarks of AD are 
intraneuronal neurofibrillary tangles and extracellular senile plaques. The neurofibrillary 
tangles are formed by hyperphosphorylated and aggregated tau, a tubulin-interacting protein 
being involved in stabilization of microtubule assemblies (Grundke-Iqbal, et al., 1986; Alonso, 
et al., 2001). The senile plaques, however, consist mainly of aggregated fibrillar Aȕ (Selkoe, 
2001). Aȕ results from the sequential processing of the transmembrane glycoprotein amyloid 
precursor protein (APP) by ȕ- and Ȗ-secretase (De Strooper, et al., 1998; Wolfe, et al., 1999; 
Haass & Steiner, 2002; Vassar & Citron, 2000; Montoliu-Gaya & Villegas, 2015). Several 
studies underline the strong association of Aȕ accumulation to the pathogenesis of AD 
(Näslund, et al., 2000; Hsiao, et al., 1996; Gandy, 2005; Karran, et al., 2011). The so-called 
amyloid cascade hypothesis states that cerebral accumulation of Aȕ is the first critical step in 
the pathogenesis of AD that results in the subsequent development of neurofibrillary tangles, 
neuroinflammation, loss of synapses, neuronal death and in conclusion to the manifestation of 
the dementia (Montoliu-Gaya & Villegas, 2015; Hardy & Higgins, 1992). 
In contrast to the inherited form of AD, where an increase in overall Aȕ production or an 
enhanced aggregation propensity of Aȕ play a role, in sporadic AD rather a decreased 
degradation rate of Aȕ is considered to cause the disease (Mawuenyega, et al., 2010; Miners, 
et al., 2011). Removal and degradation of Aȕ in the brain include multiple processes as 
drainage along perivascular basement membranes, possibly to cervix lymph nodes and the 
cerebrospinal fluid (CSF), as well as cell surface receptor-mediated transport across vessel 
walls and the blood brain barrier into the circulation e.g. by low-density lipoprotein receptor 
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(LDLR)-related protein 1 (LRP1) that is followed by clathrin-mediated endocytosis. In addition, 
Aȕ can be phagocytosed by microglia or proteolytically degraded by several enzymes (Miners, 
et al., 2011; Bohm, et al., 2015). The neutral endopeptidase IDE was, next to the 
transmembrane Zn2+ metalloprotease neprilysin, discovered as the main protease being 
involved in the clearance of soluble monomeric Aȕ in the brain (Lee & Landreth, 2010; 
Hickman, et al., 2008; Qiu, et al., 1998; Tamboli, et al., 2010). In the context of an impaired 
clearance of Aȕ that contributes to the pathogenesis of sporadic AD, it is also discussed, if a 
decline in the expression of Aȕ-degrading enzymes or decreased proteolytic activity is 
causative of an accumulation and aggregation of the peptide (Miners, et al., 2011). Indeed, a 
decline in IDE expression in brains of both an AD transgenic mouse model and AD patients 
was reported (Pérez, et al., 2000; Cook, et al., 2003; Zhao, et al., 2004; Miners, et al., 2009; 
Miners, et al., 2008; Caccamo, et al., 2005). Notably, in the hippocampus, a brain region highly 
affected during AD, the levels of IDE mRNA and protein are significantly decreased and 
negatively correlate with the load of Aȕ. Additional to the histo- and biochemical observations 
also a genetic linkage of IDE as a potential susceptibility gene for AD was suggested. Several 
studies already showed an association between IDE polymorphisms and AD. First, a 
susceptibility locus linked to an increased risk for sporadic LOAD was identified in a region of 
chromosome 10 that also harbours the gene of IDE (Bertram, et al., 2000; Ertekin-Taner, et 
al., 2000; Myers, et al., 2000; Li, et al., 2002; Blacker, et al., 2003). The role of IDE in the 
degradation of Aȕ and the identification of the genetic linkage of the region of chromosome 10 
to AD made IDE a strong functional and positional candidate gene for sporadic LOAD 
(Nowotny, et al., 2005). Several research groups subsequently screened IDE polymorphisms 
for their association with AD and could confirm an association between specific IDE haplotypes 
and the clinical diagnosis of sporadic LOAD or an accumulation of Aȕ1-42 in the plasma (Edland, 
et al., 2003; Edland, et al., 2004; Prince, et al., 2003; Ertekin-Taner, et al., 2004; Bian, et al., 
2004; Björk, et al., 2007). However, other studies did not show a significant association of IDE 
haplotypes and AD (Abraham, et al., 2001; Boussaha, et al., 2002; Nowotny, et al., 2005). 
A further link connecting diminished IDE activity in Aȕ degradation and AD is the discovery 
that patients suffering from type 2 diabetes mellitus (DM2) have an increased risk to develop 
AD (Arvanitakis, et al., 2004; Grodstein, et al., 2001; Leibson, et al., 1997; Ott, et al., 1999; 
Peila, et al., 2002; Xu, et al., 2004). IDE as an insulin- and Aȕ-degrading enzyme attracted 
research on both DM2 and AD. A functional link between IDE and these two diseases was 
additionally supported by IDE-knockout mice that showed characteristic hallmarks of both 
diseases like decreased Aȕ degradation and increased cerebral accumulation of Aȕ in the 
brain, and reduced insulin removal in the liver, hyperinsulinemia, and glucose intolerance 
(Farris, et al., 2003). An IDE-deficient mouse model, where IDE expression is disrupted by a 
gene trap insertion (homo- or heterozygous), and a DM2 rat model, the Goto-Kakizaki (GK) rat 
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carrying a partial loss-of-function mutation in the IDE gene, revealed similar observations 
(Miller, et al., 2003; Farris, et al., 2004). DM2 is a chronic metabolic disorder. In contrast to 
type 1 diabetes (DM1) that is caused by a loss of insulin-producing ȕ-cells, DM2 is 
characterised by an insulin resistance leading to impaired insulin signalling. Its incidence and 
prevalence increased over the past 25 years and is closely related to the strongly growing 
prevalence of obesity. To date, the current treatment is based on lifestyle modifications, oral 
hypoglycaemic agents and insulin sensitizers which show beneficial effects especially at early 
stages of the disease (Eckel, et al., 2011; Olokoba, et al., 2012; Tang, 2015). Also, IDE was 
just recently discussed as potential target for DM2 treatment (Tang, 2015; Costes & Butler, 
2015). Initially, it was observed that in AD cohorts the percentage of patients with DM2 is 
significantly higher than in the non-AD control group (Kuusisto, et al., 1997; Ott, et al., 1996; 
Stewart & Liolitsa, 1999). Subsequent studies suggested a two-fold increased risk of DM2 
patients to develop AD (Arvanitakis, et al., 2004; Leibson, et al., 1997; Ott, et al., 1999; Peila, 
et al., 2002; Gudala, et al., 2013). Leibson and colleagues furthermore discovered that the 
incidence of AD among DM2 patients that have suffered from the disease for more than 5 
years is higher than for patients with a disease duration of less than 5 years. This suggests 
that the pathogenic effect of DM2 on AD development is a rather gradual process and requires 
time until its manifestation. It is discussed that the medication to treat DM2, that is often based 
on ȕ-cell stimulation to increase the insulin secretion and raises insulin serum levels, as for 
example treatment with sulfonylureas or glinides, might be causative for a higher AD risk. Also 
other studies showed that an increase in insulin levels is associated with AD (Leibson, et al., 
1997; Ott, et al., 1999). Elevated insulin serum levels are characteristics of both diseases, AD 
(Carantoni, et al., 2000; Kuusisto, et al., 1997; Fujisawa, et al., 1991; Razay & Wilcock, 1994) 
and DM2 (preclinical syndrome and after onset) (Weyer, et al., 2000; Laakso, 1993; Shanik, 
et al., 2008). Hyperinsulinemia that establishes in the course of DM2 rather than other 
consequences of the disease might now be suggested to promote AD pathology. It is 
discussed that elevated insulin serum levels lead to competitive effects with the degradation 
of Aȕ by IDE. Insulin shows a lower KM (KM = 0.1 M) for IDE than Aȕ (KM >2 M) and therefore 
IDE has an approximately 20-fold higher affinity to insulin than Aȕ (Qiu & Folstein, 2006). 
Furthermore, insulin resistance interferes with insulin-mediated signalling which is, inter alia, 
responsible for the expression regulation of IDE. Thus, the insulin-mediated up-regulation of 
IDE would be impaired (Zhao, et al., 2004). It was already observed that during AD also insulin 
signalling is disturbed (Candeias, et al., 2012; De Felice & Ferreira, 2014). A study of Pedersen 
and colleagues supports this (Pedersen, et al., 2006). They show a reduction of Aȕ1-42 levels 
and memory deficits after treatment with rosiglitazone that decreases insulin resistance by 
activating the peroxisome proliferator-activated receptor Ȗ (PPARȖ) which elevates the 
peripheral insulin sensitivity. The activated PPARȖ-mediated signalling by rosiglitazone 
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increased IDE mRNA levels and IDE activity in the brains of an AD transgenic mouse model 
causing decreased levels of Aȕ1-42 and improved learning and memory deficits (Pedersen, et 
al., 2006).  
Taken together, decreased expression and activity of IDE in DM2 and AD might contribute to 
the pathogenesis of both diseases. Thus, it will be interesting to further examine the role of 
IDE in AD and DM2, and to assess its potential as a therapeutic target (Tang, 2015; Abdul-
Hay, et al., 2015; Moreira, et al., 2013; Haque & Nazir, 2014; Costes & Butler, 2015). 
 
2. Secretion of IDE via exosomes 
The discovery of IDE as insulin-degrading enzyme in 1949 (Broh-Kahn & Mirsky, 1949) and 
as an Aȕ-degrading enzyme in 1994 (Kurochkin & Goto, 1994) raised questions regarding the 
location of IDE interaction with these two substrates. Insulin, for example, was shown to be 
degraded in endosomal compartments (Duckworth, et al., 1998; Hamel, et al., 1991; Hamel, 
et al., 1988). Insulin binds to the insulin receptor and the complex is internalized into 
endosomes where its degradation starts with the cleavage of the insulin B chain by IDE prior 
to endosomal acidification (Hamel, et al., 1988; Hamel, et al., 1991). For Aȕ, however, rather 
the extracellular compartment is proposed as the site of interaction with IDE and subsequent 
degradation (Qiu, et al., 1998; Bulloj, et al., 2010). Almost 20 years ago, Qiu and colleagues 
suggested that additional to an elevated Aȕ production a decreased Aȕ degradation could 
contribute to the deposition of Aȕ plaques in the brain (Qiu, et al., 1997). It had been 
established that Aȕ is constitutively secreted by several cell types and that an Aȕ accumulation 
promotes its aggregation, but still nothing was known about extracellular degradation of Aȕ. 
Therefore, Qiu et al. screened several neural and non-neural cell lines for their ability to release 
proteases being able to degrade Aȕ. They identified IDE as the major Aȕ-degrading protease, 
that is secreted predominantly by microglial cells (Qiu, et al., 1997; Qiu, et al., 1998). The 
association of IDE with the outer layer of the plasma membrane further supports the hypothesis 
of an extracellular degradation of Aȕ and possibly also insulin (Yaso, et al., 1987; Bulloj, et al., 
2008; Vekrellis, et al., 2000). Until the discovery of Qiu and colleagues in the end of the 1990s 
nothing was known about potential export pathways for IDE and only 10 years later Zhao and 
colleagues found out that IDE is not secreted by the classical but via an unconventional 
secretory pathway (Zhao, et al., 2009). Two parallel studies subsequently discovered that IDE 
is released from the cell by unconventional secretion via exosomes (Bulloj, et al., 2010; 
Tamboli, et al., 2010).  
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2.1 Conventional and unconventional secretory pathways 
Many eukaryotic proteins that are released by cells follow the so-called conventional secretory 
pathway via Golgi and ER (Lodish, et al., 2000; Pollard, et al., 2008; Nickel & Rabouille, 2009). 
They contain an amino-terminal or internal signal peptide leading to their sorting to the ER 
after translation at the ribosome. The nascent proteins are directed into the ER by the signal 
recognition particles. After folding and further modification the protein leaves the ER at so-
called ER exit sites in vesicles that are coated by coat protein complex II (COPII) proteins. 
COPII complexes consist of several subunits and contain, among others, the small GTPase 
Sar1A. They are responsible for vesicle budding but also mediate cargo selection by specific 
cargo receptors. The COPII-coated vesicles fuse with the cis-Golgi or form a new stack of the 
cis-Golgi network and the protein is transported further through the Golgi where it can undergo 
additional posttranslational modifications. From the trans-Golgi network, proteins are sorted 
and directed to their final destination. The intra-Golgi transport, also named cisternal migration, 
is realized via COPI-coated vesicles. COPI-coated vesicles also mediate retrograde movement 
from Golgi back to ER. COPI complexes comprise among other proteins the small GTPase 
ADP ribosylation factor 1 (ARF1). ARF1 recruitment to the Golgi is effectively blocked by 
Brefeldin A, thereby inhibiting formation of COPI vesicles leading to a collapse of the Golgi into 
the ER and finally preventing conventional protein secretion. 
From the trans-Golgi network the proteins destined for secretion are either sorted into vesicles 
for regulated or constitutive secretion. Vesicles for constitutively secreted proteins directly 
move to the plasma membrane and the enclosed proteins are released by exocytosis from the 
cell. In the regulated secretion, however, the so-called secretory vesicles are initially stored 
intracellularly. Their exocytosis is triggered by a stimulating signal, as, for example, an increase 
in intracellular Ca2+ ([Ca2+]i) in response to hormonal or neural stimulation.  
Besides the high efficiency and accuracy of the ER/Golgi system in protein export (Nickel & 
Rabouille, 2009; Trombetta & Parodi, 2003) a substantial number of proteins not showing a 
classical ER-signal peptide sequence are released via an unconventional secretory pathway. 
For these proteins, four different main pathways were proposed (Nickel & Rabouille, 2009; 
Rabouille, et al., 2012): translocation across the plasma membrane, the autophagosome-
dependent pathway, the secretion via microvesicles and the exosome-associated release. 
The translocation across the plasma membrane was described in detail for the secretion of the 
fibroblast growth factor 2 (FGF2). The cytosolic protein is first directed to the inner leaflet of 
the plasma membrane by binding to phosphoinositide phosphatidyl-inositol-4,5-biphosphate 
(PtdIns(4,5)P2) (Temmerman, et al., 2008). PtdIns(4,5)P2 induces the oligomerization and 
subsequent integration of FGF2 into the membrane. Translocation through the membrane is 
assumed to occur by the formation of a lipidic membrane pore (Steringer, et al., 2012). 
Heparan sulphate proteoglycans as components of the extracellular matrix were found to be 
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involved in the unconventional secretion of FGF2, likely by binding the FGF2 molecules after 
membrane translocation (Zehe, et al., 2006). This proposed process of membrane insertion 
and translocation as an unconventional secretory pathway is suggested also for other proteins 
as HIV-1 Tat, annexin A2 and FGF1 (Rabouille, et al., 2012). Another non-vesicular secretory 
mechanism involving direct translocation across the plasma membrane is the ABC-transporter-
based secretion. This pathway seems to be used in particular for the translocation of lipidated 
proteins and peptides and is ATP-dependent (Rabouille, et al., 2012). 
Unconventional secretory pathways that involve intracellular vesicles as “transport 
intermediates” include not only the formation of secreted microvesicles, but also the secretion 
via autophagosome-like structures and the release of exosomes (Rabouille, et al., 2012). 
Secreted so-called microvesicles or shedding vesicles, are produced by direct outward 
budding of the plasma membrane. Together with apoptotic vesicles, that are released during 
apoptosis, and exosomes they constitute the group of extracellular vesicles (Raposo & 
Stoorvogel, 2013; Yáñez-Mó, et al., 2015). In comparison to exosomes, microvesicles lack 
typical late-endosomal marker proteins (see below), show in the majority a larger size and 
differ in their lipid composition that indicate their origin from the plasma membrane (Nabhan, 
et al., 2012; Cocucci, et al., 2009; Record, et al., 2014). The process of outward budding of the 
plasma membrane is well examined in virus amplification that results in the budding of new 
virus particles at the plasma membrane. Human immunodeficiency virus (HIV) and some other 
viruses recruit the host endosomal sorting complex required for transport (ESCRT) machinery 
from endosomal membranes to the plasma membrane to mediate the budding process (Martin-
Serano & Neil, 2011; Nabhan, et al., 2012). Therefore, it has been discussed that also 
microvesicle budding is dependent on the ESCRT machinery. Nabhan and colleagues then 
found a virus-independent process of microvesicle production in eukaryotic cells that indeed 
involves the recruitment of certain members of the ESCRT machinery to the plasma 
membrane. The arrestin domain-containing protein 1 (ARRDC1) being located to the plasma 
membrane through its arrestin domain is able to interact with the ESCRT member tumor 
susceptibility gene 101 (Tsg101, mammalian) and recruit it to the plasma membrane. Tsg101 
in turn may recruit further ESCRT proteins which then mediate the budding of microvesicles 
(Nabhan, et al., 2012). 
A new mechanism for the unconventional secretion mediated by autophagosome-like 
structures, as shown for the mammalian protein acyl-coenzyme A-binding protein A (AcbA, 
Acb1 in yeast), was proposed approximately five years ago (Bruns, et al., 2011; Rabouille, et 
al., 2012; Malhotra, 2013). It describes the formation of a specific compartment for 
unconventional secretion (CUP), a cup-shaped membrane structure, that is generated near 
ER exit sites in response to starvation (Malhotra, 2013). It has been shown that the formation 
process of these CUPs and the whole secretion process of AcbA/Acb1 involves several factors 
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that are required for the biogenesis of autophagic vesicles. Additionally, effectors of endosomal 
fusion and proteins of the multivesicular body (MVB) pathway as members of the ESCRT 
machinery do participate, as well as the unconventional secretion-related mammalian proteins 
GRASP55/65 (Grh1 in yeast and GRASP in Drosophila) (Rabouille, et al., 2012). However, 
this process is not triggered by rapamycin, which actually induces autophagy by inhibition of 
the protein kinase mTOR. It is suggested that the CUPs, which contain the proteins destined 
for secretion, fuse with endosomes which then further develop to MVBs by inward budding, 
thereby producing the protein-containing intraluminal vesicles (ILVs, see below in 2.2) that are 
released after fusion with the plasma membrane (Malhotra, 2013).  
Also proteins that are secreted via exosomes are sorted to ILVs of MVBs, however, by other 
mechanisms, dependent or independent of the ESCRT machinery (see in more detail in 2.2 
below). 
 
2.2 Exosomes and the regulation of exosome biogenesis 
Exosomes are small extracellular vesicles with a size of 30-100 nm that are released by viable 
cells either constitutively or upon a stimulating signal. Release of exosomes seems to be a 
general characteristic of all cells and tissues in the body, but could strongly vary in extent 
(quantitatively) and composition (qualitatively). Exosomes are found in several body fluids like 
blood, urine and CSF (Record, et al., 2014; Urbanelli, et al., 2013). Exosomes are now 
attributed to a new class of signal mediators that could regulate cell-to-cell communication 
(Urbanelli, et al., 2013). Due to their endosomal origin (explained in more detail below), 
exosomes contain proteins involved in membrane transport and fusion like Rab GTPases, 
annexins and flotillins. Furthermore, they harbour proteins of MVB biogenesis as Alix and 
Tsg101 as well as integrins and tetraspanins that are associated to lipid microdomains. 
Additionally, exosomes enclose proteins that are cell-type-specific like MHC class I or II 
proteins, proteins linked to the cytoskeleton or to metabolism as well as mediators of signalling 
pathways (Urbanelli, et al., 2013). Despite its strong cell-type-specific arrangement also the 
lipid composition of exosomes is in part characteristic. In particular lysobisphosphatidic acid 
(LBPA, also named BMP) and other lipids associated to lipid rafts like sphingomyelin, 
cholesterol and ceramides are found in all exosomes. 
Exosomes are generated as intraluminal vesicles (ILVs) by inward budding of the limiting 
membrane of late endosomes which are then named MVBs (see Figure 2), sometimes also 
multivesicular endosomes (MVEs). The MVB pathway is used primarily for the selective 
transport of proteins that are destined for lysosomal degradation. Fusion of MVBs with the 
lysosome releases the cargo-containing ILVs into the lysosomal lumen and both, ILVs and 
cargo proteins are exposed to the proteolytic function of the lysosomal hydrolases. This serves 
both the quality control in the cell and the attenuation of receptor-mediated signalling 
pathways.  
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Figure 2. The origin of exosomes. Exosomes are generated as intraluminal vesicles (ILVs) at the limited 
membrane of endosomes. These endosomes are named multivesicular bodies (MVBs) that can contain hundreds 
of ILVs. ILVs enclose, among other biomolecules, cytosolic and transmembrane proteins like internalized receptors. 
MVBs can fuse with lysosomes taking the degradative way leading to the proteolytic degradation of ILVs and their 
content. Instead they can also fuse with the plasma membrane and release the ILVs as exosomes into the 
extracellular space. Figure taken and adapted from (Urbanelli, et al., 2013). 
Misfolded membrane proteins and excessive membranes as well as activated growth factor, 
hormone and cytokine receptors are removed from the cell, mainly triggered by a negative 
feedback loop (Gruenberg & Stenmark, 2004; Katzmann, et al., 2002). First, it was assumed 
that MVBs exclusively fuse with lysosomes. However, they can also fuse with the plasma 
membrane resulting in the release of the ILVs to extracellular fluids, then referred to as 
exosomes (Johnstone, et al., 1987; Simons & Raposo, 2009).  
As in the proteasomal degradation pathway ubiquitin tags initiate the proper sorting into the 
MVB pathway. In comparison to proteasomal degradation cargo proteins are polyubiquitinated 
via Lys-63-linked instead of Lys-48-linked conjugation or they are monoubiquitinated several 
times. The ubiquitin tags are recognized by the ESCRT machinery. It also mediates the sorting 
to invaginations in endosomal membranes, the deformation of the membrane and its inward 
budding and the abscission of the ILVs into the lumen of the endosome (Raiborg & Stenmark, 
2009).  
The ESCRT machinery consists of four soluble multiprotein complexes named ESCRT-0, -I, -II 
and -III that are sequentially recruited to the membrane, suggesting a directional stepwise 
delivery of cargo from one complex to the other (see Figure 3). Important accessory proteins 
binding to the ESCRT complexes and being involved in cargo recognition, sorting, and inward 
budding are e.g. Alix and the ATPase Vps4A/B (mammalian). ESCRT-0 can bind PtdIns(3)P 
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via its subunit hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs, mammalian), 
which directs it to the endosomal membrane. Furthermore, ESCRT-0 subunits contain 
ubiquitin- and clathrin-binding domains that mediate recognition and concentration of 
ubiquitinated cargo proteins in the endosomal membrane in certain microdomains. In addition, 
ESCRT-0 ensures recruitment of ESCRT-I complexes by binding its subunit Tsg101. ESCRT-I 
is also able to recognize ubiquitinated cargo and it recruits ESCRT-II. Most likely, it is also 
 
Figure 3. ESCRT machinery in the sorting of ubiquitinylated cargo into ILVs into the lumen of MVBs. (A) 
Composition and interaction of the four ESCRT complexes 0, I, II, and III. (B) Mechanism of ESCRT machinery: 
I) Cargo recognition and ESCRT-I recruitment by ESCRT-0. Clathrin mediates cargo recognition and concentration 
in microdomains. ESCRT-II recruitment and contribution to membrane deformation through ESCRT-I. II) ESCRT-II 
and Alix (not shown) recruit ESCRT-III for further membrane deformation, gating of cargo into invaginations and 
recruitment of DUBs. III) Final membrane abscission by ESCRT-III and accessory proteins. The ATPase Vps4 
enters the invagination to recycle ESCRT-III subunits for further rounds of budding. DUB – deubiquitylating 
enzymes. (A) and (B) from (Raiborg & Stenmark, 2009). 
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involved in the invagination of the endosomal membrane. ESCRT-II then recruits ESCRT-III, 
which is the most conserved of all four complexes. It is suggested that the accessory protein 
Alix supports this recruitment or even takes over that function from ESCRT-II. Alix is able to 
build a bridge between ESCRT-I and ESCRT-III via Tsg101 and the ESCRT-III subunit Vps32 
(Raiborg & Stenmark, 2009). ESCRT-III is involved in clustering and gating the cargo into 
invaginations of the endosomal membrane and the recruitment of deubiquitylating enzymes 
that remove the ubiquitin tags from the cargo proteins. It further navigates the invagination and 
the final abscission of the ILVs into the endosomal lumen. ESCRT-III complexes are 
disassembled by the ATPase Vps4A/B for recycling, which enables further rounds of budding 
(Raiborg & Stenmark, 2009; Wollert, et al., 2009). 
Indeed, for several proteins that are released via exosomes an involvement of the ESCRT 
machinery could be proven. It could be shown that particular ESCRT members as Hrs, Tsg101, 
Chmp2A, Chmp4A/B/C and the accessory proteins Alix and Vps4A/B play a role in the release 
of certain exosomal proteins (Tamai, et al., 2010; Baietti, et al., 2012; Géminard, et al., 2004).  
For instance, Baietti et al. analysed the function of Alix in the secretion of syntenin-containing 
exosomes in MCF-7 cells which represent 50% of the total number of exosomes in this cell 
type and found that Alix by interaction with syntenin and syndecan heparan sulphate 
proteoglycans is not only involved in sorting cargo, but furthermore needed for exosome 
formation by recruiting the ESCRT machinery (Baietti, et al., 2012; Hurley & Odorizzi, 2012). 
The secretion of other exosome-associated proteins could also occur independent of ESCRT 
complexes and ubiquitination of cargo proteins (Trajkovic, et al., 2008; van Niel, et al., 2011; 
Alonso, et al., 2011; Buschow, et al., 2009). Trajkovic and colleagues found a lipid-dependent 
mechanism that drives the formation of ILVs independent of the ESCRT machinery. The 
neutral sphingomyelinase generates ceramide that, enriched and clustered in microdomains 
in the endosomal membrane, due to its polar hydrogen bond-forming headgroup and its cone-
shaped structure, promotes and induces the inward budding to ILVs (Trajkovic, et al., 2008; 
Hurley & Odorizzi, 2012). RNAi-mediated or pharmacological inhibition of neutral 
sphingomyelinase 2 reduced exosome-associated secretion in an oligodendroglial (Trajkovic, 
et al., 2008) and in a neuroblastoma cell line (Yuyama, et al., 2012), but did e.g. not influence 
exosome release in a prostate cancer (Phuyal, et al., 2014) or in a melanoma cell line (van 
Niel, et al., 2011). Although a detailed mechanism still needs to be investigated also the 
involvement of tetraspanins, being organised as microdomains in endocytic membranes and 
found to be enriched in exosomes, in the formation of MVBs represent another ESCRT-
independent mechanism for exosome biogenesis (Andreu & Yáñez-Mó, 2014). Most likely, 
several distinct mechanisms exist depending on the cargo protein and also the cell type. 
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2.3 Unconventional release of IDE 
The discovery to find IDE being secreted by several cell types and representing one of the 
main, if not the major protease in the extracellular Aȕ degradation, especially in microglial cells 
(Qiu, et al., 1997; Qiu, et al., 1998), marked an important step in the research dealing with 
proteolytic Aȕ degradation in the brain mediated by IDE. As described above, subsequently 
IDE was discovered to be released by the unconventional secretory pathway via exosomes 
(Bulloj, et al., 2010; Tamboli, et al., 2010). IDE lacks a classical signal peptide that would lead 
it to the conventional secretory pathway via ER and Golgi. Furthermore, the release of IDE is 
not blocked by typical inhibitors of classical secretion as Monensin or Brefeldin A (Bulloj, et al., 
2010; Zhao, et al., 2009).  
In further examinations dealing with IDE secretion and its regulation, first, Tamboli and 
colleagues found statins being able to stimulate IDE secretion from microglial cells. Statin 
treatment triggers IDE release and thereby induces increased degradation of extracellular Aȕ 
(Tamboli, et al., 2010). Statins like lovastatin were already known to have a beneficial effect 
on the risk to develop AD comparing a group of patients taking statins with patients taking no 
statins over several years (Haag, et al., 2009). Statins are a class of pharmaceuticals that 
inhibit the HMG-CoA-reductase, an important enzyme in the cholesterol synthesis, and are 
used for treatment of high cholesterol levels in the patients. Tamboli and colleagues, however, 
could show that statins are additionally able to stimulate the release of exosomes, leading to 
an enhanced IDE secretion that positively affects the degradation of extracellular Aȕ (see 
Figure 4A). This stimulating effect of statins, however, is independent of cellular cholesterol 
concentrations but assumingly leads to an impairment of the isoprenoid biosynthesis and 
protein prenylation and might interfere with the isoprenylation of Rab GTPases as Rab11, 
Rab27a and b that were also shown to be involved in the regulation of docking and fusion of 
MVBs with the plasma membrane (Tamboli, et al., 2010; Glebov & Walter, 2012).  
A further stimulating factor for IDE secretion from microglial cells is somatostatin (Tundo, et 
al., 2012). Somatostatin is a peptide hormone regulating several processes in the nervous and 
endocrine system. Its depletion was already associated to the onset of AD (van Uden, et al., 
1999) and it was discovered to be an IDE substrate but also a modulator of its activity (Ciaccio, 
et al., 2009). Tundo and colleagues observed an increasing effect of somatostatin treatment 
on the secretion and expression of IDE in microglial cells (Tundo, et al., 2012). Another recent 
study then revealed an intrinsic regulatory element of IDE release in the IDE amino acid 
sequence itself (Glebov, et al., 2011). Glebov and colleagues found a novel functional domain 
in the C-terminus of the IDE sequence named SlyX motif (853EKPPHY858; see Figure 4B) that 
promotes enzyme secretion. Mutagenesis approaches showed that the deletion of this motif 
and also the deletion of the C-terminus ranging from the SlyX domain to the PTS domain 
strongly decreased the release of IDE from the fibroblast cell line cos-7. Moreover, addition of  
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Figure 4. Export of IDE into extracellular space. (A) Suggested mechanism of statin-mediated degradation of 
Aȕ due to an increased release of exosome-associated IDE. Statins impair isoprenoid biosynthesis that prevents 
protein isoprenylation of e.g. Rab GTPases that are involved in the fusion event of exosome-containing MVBs with 
the plasma membrane. Decreased protein prenylation leads to an increase in these fusion events and enhances 
IDE release. From (Glebov & Walter, 2012). (B) Diagram of IDE amino acid sequence. The relative size scale 
(aa – amino acid) above the diagram shows the position of featured domains. Protease domain I contains the 
insulinase activity of IDE. Protease domain II and III are inactive. The SlyX motif being involved in the secretion 
regulation of IDE is located in the protease domain III at aa 853-858. NLS – nuclear localisation domain, PTS – 
peroxisomal targeting sequence. From (Glebov, et al., 2011). 
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the SlyX motif to GFP, which is predominantly localised in the cytosol, strongly increased the 
secretion of GFP into cell supernatants. 
 
3. Microglia 
Microglia are the intrinsic phagocytic cells of the CNS and represent the resident endogenous 
brain defence and immune system to protect the brain against all kinds of pathogenic factors. 
But they also create and maintain an intact tissue homeostasis to support the neuronal cells 
(Kettenmann, 2011; Kierdorf & Prinz, 2013). The origin of microglia is still under debate. It was 
long assumed that microglia are of mesodermal/mesenchymal origin and differentiate from 
blood-derived monocytes that migrated from the periphery and postnatally immigrated into the 
brain (Brockhaus, et al., 1993; Haas, et al., 1996; Kettenmann, 2011). Recent studies now 
indicate that there are embryonic microglia that derive from stem cells that are formed during 
primitive haematopoiesis in the yolk sac, differentiate to macrophages and seed the brain 
rudiment already during early fetal development (Ginhoux, et al., 2013; Prinz & Priller, 2014). 
It is suggested that under certain inflammatory conditions as bone marrow transplantation and 
neurodegenerative diseases also monocyte-derived progenitors are recruited to the brain and 
supplement the microglial population to some extent (Ginhoux, et al., 2013). Postnatally, 
microglia spread evenly over the whole neural tissue and adopt a microglia-specific 
morphology under physiological conditions named the resting state. It is characterised by a 
short cell body and multiple thin and branched processes. These processes are highly dynamic 
and constantly scan the surrounding for neuronal damage, protein aggregates or infectious 
agents (Kettenmann, 2011). By specific pattern recognition receptors, as for example Toll-like 
receptors, microglia are able to recognize so-called pathogen-associated molecular patterns 
(PAMPs), a set of microbial molecules, and damage-associated molecular patterns (DAMPs), 
endogenous molecules that are released by dead cells. PAMPs alert the organism to intruding 
pathogens and DAMPs signal tissue and cell damage (Bianchi, 2007; Tang, et al., 2012). 
Microglia are able to scan the whole brain area by monitoring the extracellular space and their 
cellular neighbourhood (Nimmerjahn, et al., 2005). Detection of real or potential danger to the 
CNS induces the activation of the microglia. Activation of microglia is a gradual process that 
includes changes in cellular phenotype and motility associated with specific alterations in gene 
expression. This causes the induction and rearrangement of surface proteins for cell-cell and 
cell-matrix interaction, changes in intracellular enzymes and the release of various 
proinflammatory and immunoregulatory factors and compounds. During activation, microglia 
convert from the branched resting phenotype to a so-called amoeboid phenotype which is 
characterised by thickening and retraction of the processes and an overall more round shape. 
They can actively move to a lesion or infection along gradients of chemoattractants 
(Kettenmann, 2011; Davalos, et al., 2005). If it is necessary to fight locally invading germs and 
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protect and restore tissue homeostasis, some microglia are able to return into a proliferative 
state to increase the number of microglia for the defence reaction. Furthermore, even other 
immune cell populations as monocyte-derived cells from the periphery can be recruited to the 
CNS through microglia by releasing chemoattractive factors (Saijo & Glass, 2011). T cells may 
be mobilized by antigen presentation to support the adaptive immunity. By activating their 
phagocytic properties they remove tissue debris, damaged cells or microbes. Additionally to 
the defence mechanisms microglia produce and release neurotrophic factors and physically 
associate with endangered neurons to support them (Kettenmann, 2011).  
The transformation from the resting to active states serves primarily the protection and support 
of the structural and functional integrity of the CNS as well as the restoration of the neural 
tissue homeostasis (Kettenmann, 2011; Kierdorf & Prinz, 2013). The initial signals that 
modulate microglia activity are not fully understood. They are characterised by a sudden 
appearance, an abnormal concentration or unusual format of certain factors. It is assumed that 
the state and function of microglia are controlled by a complex interplay of activating (on) and 
inactivating (off) signals. Off-signals maintain the persisting receptor signalling to keep the 
microglia in the resting state. On-signals, on the contrary, change the current receptor 
signalling and trigger microglial activation (Kettenmann, 2011; Linnartz & Neumann, 2013; 
Kierdorf & Prinz, 2013). Examples for such signalling molecules are proteins of the bacterial 
cell walls or viral envelopes, bacterial or viral DNAs or RNAs, factors that are released through 
tissue damage like high amounts of ATP, cytokines, neuropeptides and growth factors. For 
recognition of the different signals, microglia express multiple receptors as cytokine receptors, 
scavenger receptors, pattern recognition receptors and chemokine receptors. In addition, 
microglia express various neurotransmitter receptors such as glutamate, GABA, cholinergic, 
adrenergic, dopamine and serotonin receptors and thereby are able to sense a certain change 
in the release of the respective transmitters (Kettenmann, 2011; Kierdorf & Prinz, 2013). This 
versatile subset of cell surface molecules on the microglial membrane as well enables a 
communication of microglia not only with the surrounding glial cells but also with the 
neighbouring neurons (Kierdorf & Prinz, 2013). 
 
3.1 Neuron-microglia communication 
Neurons are able to modulate microglial activity and motility by the release of specific 
chemokines and neurotransmitters as well as purines and pyrimidines (Eyo & Wu, 2013; 
Sheridan & Murphy, 2013; Fields & Burnstock, 2006). One example is fractalkine, a chemokine 
which is expressed on the neuronal surface and sensed by the CX3CR1 receptor located in 
plasma membranes of microglia. Expression of fractalkine in neurons increases after neuronal 
injury, is able to influence microglial intracellular signalling pathways and provides 
neuroprotection, inter alia by inhibiting excessive microglial activation (Zhang, et al., 2011; 
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Broderick, et al., 2002; Lyons, et al., 2009). Moreover, effects of neurotransmitters on 
microglial behaviour started to be investigated in the last years. It can be already suggested 
that excitatory as well as inhibitory neurotransmission cooperate to regulate microglial activity 
and motility. However, there are differences between global and local neurotransmitter-
mediated regulation of microglia activity. For instance, it could be shown that global inhibition 
of the inhibitory GABAergic neurotransmission increased the territory surveyed by microglia, 
displaying an increased activity of microglia in scanning their surroundings (Nimmerjahn, et 
al., 2005). The global inhibition of excitatory glutamate receptors, in contrast, leads to 
decreased microglia motility. Conversely, their activation by glutamate receptor agonists 
enhanced it (Fontainhas, et al., 2011). A regulation of microglial function by local 
neurotransmission is until now not fully proven. There are controversial results showing no 
effect of local GABA or glutamate application on microglial motility in mouse brain slices (Wu 
& Zhuo, 2008; Chen, et al., 2010), but an increased microglial activity upon local glutamate 
uncaging in zebrafish optical tectum (Li, et al., 2012). 
Especially, the interaction between neurons and microglia has been investigated upon 
neuronal injury. In the 1970s it has been found that the purine nucleotide ATP and its 
metabolites ADP and adenosine in extracellular fluids can be recognized by certain cell surface 
receptors. Under physiological conditions their intracellular levels are maintained at high 
concentration whereas the extracellular levels are kept at relatively low concentration 
(Burnstock, et al., 2011; Eyo & Wu, 2013). In case of neuronal injury, purines are released 
from neurons and detected by microglia. Purines then trigger chemotaxis of microglia to the 
location of the lesion mediated by local concentration gradients. Additional to its role in injury-
induced microglial motility, purinergic signalling was also shown to be necessary under 
physiological conditions, for example to facilitate the formation of direct neuron-microglia 
contacts (Li, et al., 2012). ATP can be released by neurons, in much lower concentrations than 
from damaged cells, via activity-dependent opening of pannexin-1 hemichannels. Li et al. 
showed that this supports the formation of direct contacts between bulbous endings of resting 
microglia and neuronal soma most probably mediated by ATP/P2 purinergic receptor signalling 
in microglia (Li, et al., 2012). 
By direct physical interaction as well as the release of certain paracrine signals, microglia in 
turn are able to modulate also neuronal behaviour (Eyo & Wu, 2013). Wake et al., who 
demonstrated a direct interaction between microglial processes and neuronal dendritic spines, 
suggest that microglia form these specific contact sites to monitor neuronal function, for 
example after transient ischaemia (Wake, et al., 2009). On the other hand, Tremblay et al. 
showed that this physical interaction can also lead to an alteration of number and size of the 
neuronal spines in the healthy brain (Tremblay, et al., 2010). Additionally to the ability of direct 
interaction, microglia as well release certain factors that influence neuronal activity and 
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function. They release neuroprotective factors like neurotrophins or members of the TGFȕ and 
IL-6 families (Suzumura, 2013). Likewise, microglia secrete also pro-inflammatory and rather 
neurotoxic factors as inflammatory cytokines as IL-1ȕ, TNF-α and nitric oxide (Suzumura, 
2013). Moreover, it has been shown that microglia play a role in synaptic pruning during 
postnatal development and contribute to the build-up of neuronal circuits through different 
signalling pathways, for instance mediated via the fractalkine receptor, the complement 
receptor and DAP12 (Eyo & Wu, 2013; Paolicelli, et al., 2011; Schafer, et al., 2012; 
Wakselman, et al., 2008).  
Together, microglia not only react to brain damage or infection, but also play important roles 
in the regulation of neuronal function under physiological conditions. The bidirectional neuron-
microglia interaction can be suggested to represent an essential aspect of the normal function 
of the brain, including nervous system development and its maintenance (Eyo & Wu, 2013; 
Sheridan & Murphy, 2013; Suzumura, 2013). 
 
3.2 Microglia in Aβ degradation and AD 
Although microglia exert an important and beneficial role in the brain defence, inter alia, by the 
release of growth and anti-inflammatory factors that have neuroprotective effects, they, on the 
other hand, might play a double-edged role in the pathogenesis and pathology of AD. Aging 
itself entails also the loss of efficiency of microglial function, thus, for example, the receptors 
that promote uptake and clearance of fibrillar Aȕ are downregulated (Hickman, et al., 2008). 
Additionally, aged microglia show enhanced production of pro-inflammatory cytokines as 
TNF-α and IL-1ȕ and decreased expression of anti-inflammatory cytokines as IL-10 as well as 
phenotypic changes including dystrophic processes and abnormal clustering (Njie, et al., 2012; 
Solito & Sastre, 2012; Streit, et al., 2008). Also molecular markers typically found to be up-
regulated in activated microglia as MHC-II, Cd11b and Iba1 are increased during aging (Wong, 
2013). This suggests an increased activation of microglia, their hypersensitivity in response to 
stimulation and a decrease in the control mechanisms of microglial activation in the aged brain. 
Under neurodegenerative conditions microglia were found to be in an hyper-reactive state and 
it becomes more and more clear that neuroinflammation plays a critical role in AD, although 
its contribution to the neurodegenerative process is still not fully elucidated (Solito & Sastre, 
2012; Suzumura, 2013; Lee & Landreth, 2010). The increased production and release of pro-
inflammatory factors, observed in AD patients and AD mouse models (Sastre, et al., 2006; 
Benzing, et al., 1999; Matsuoka, et al., 2001), does not only exert neurotoxic effects that can 
cause neuronal damage and death, it has been also shown to suppress the phagocytic 
response of microglia to fibrillar Aȕ (Koenigsknecht-Talboo & Landreth, 2005; Lee & Landreth, 
2010). Aȕ and APP themselves are assumed to trigger microglial activation (Barger & Harmon, 
1997; De Giorgio, et al., 2002; Permanne, et al., 2002). Microglial activation is directly related 
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to the amyloid load. Furthermore, interaction of microglia with Aȕ activates NFκB-mediated 
pathways and cytokine production (Combs, et al., 2001; Solito & Sastre, 2012). Because 
neuroinflammation is suspected to exacerbate neurodegenerative processes, the suppression 
of pro-inflammatory or promotion of anti-inflammatory states of microglia are considered for 
therapeutical intervention. Recent studies already showed promising results: In an AD mouse 
model the treatment with rosiglitazone, a PPARȖ agonist, suppressed the microglial expression 
of pro-inflammatory mediators and decreased the amyloid pathology in the mice (Escribano, 
et al., 2010). Administration of noradrenalin to microglial cells diminished the production of 
cytokines and chemokines and also promoted phagocytosis of fibrillar Aȕ (Heneka, et al., 
2010). Moreover, anti-inflammatory cytokines as TGF-ȕ and IL-4 enhanced Aȕ clearance from 
the brain of transgenic AD mice or in primary microglia, respectively (Wyss-Coray, et al., 2001; 
Shimizu, et al., 2008). Additionally, several epidemiological studies on nonsteroidal anti-
inflammatory drugs (NSAIDs) revealed a decreased prevalence of AD upon long-term use of 
these drugs (McGeer, et al., 1996). Follow-up clinical trials and studies, however, did not reveal 
a beneficial effect in AD patients, but showed that NSAIDs use started in midlife (prior to 65 
years) in comparison to later life prevented cognitive decline during aging (Sastre & 
Gentleman, 2010). 
Additional to the assumed detrimental role of microglia during the pathogenesis of AD, 
microglia might also exert a beneficial role by contributing to the clearance of Aȕ by uptake 
and removal of Aȕ through phagocytosis (Simard, et al., 2006; Lee & Landreth, 2010). 
Although LRP1-mediated endocytosis might represent an important way of Aȕ uptake in 
neurons, it does not seem to represent the main pathway for the uptake of soluble Aȕ in 
microglia (Harris-White, et al., 2004; Mandrekar, et al., 2009). Mandrekar and colleagues 
identified another pathway in microglial cells in which soluble Aȕ, which encloses monomeric 
and small oligomeric forms of Aȕ, is predominantly taken up through constitutive fluid phase 
macropinocytosis (Mandrekar, et al., 2009; Lee & Landreth, 2010). Fibrillar, aggregated forms 
of Aȕ, on the other hand, are phagocytosed by another mechanism. They interact with 
particular fibrillar Aȕ recognition receptor complexes and thereby activate intracellular 
signalling cascades that induce their phagocytosis (Lee & Landreth, 2010). Additionally, fibrillar 
Aȕ may be also ingested through antibody- and complement system-mediated mechanisms 
(Bard, et al., 2000; Wilcock, et al., 2003; Jiang, et al., 1994; Webster, et al., 1997; Lee & 
Landreth, 2010). 
Internalized soluble Aȕ is directly transported to lysosomes for degradation via the endocytic 
pathway (Mandrekar, et al., 2009). For the degradation of fibrillar Aȕ in microglia this is still not 
fully clear. It was discovered that fibrillar Aȕ is taken up and transported to the endosomal-
lysosomal compartment in primary microglia, but only a small part is also degraded. Instead it 
was observed that microglia store fibrillar Aȕ for several weeks and, partially, release it again 
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(Chung, et al., 1999; Paresce, et al., 1997). However, it could be shown that obviously the 
activation of microglia (see above) may induce their ability to degrade fibrillar Aȕ through an 
acidification of the lysosomes (Lee & Landreth, 2010; Majumdar, et al., 2007; Majumdar, et al., 
2011). It can be assumed that Aȕ-degrading proteases as cathepsin B and D or endothelin-
converting enzyme 2 (ECE-2) with a mildly acidic pH optimum rather than neutral 
endopeptidases are involved in the lysosomal Aȕ proteolysis (Miners, et al., 2011).  
Interestingly, also APOE, the strongest known genetic risk factor for the development of LOAD, 
seems to play a critical role in the clearance of Aȕ, e.g. for the microglia-mediated removal. 
Extracellular soluble APOE primarily secreted by astrocytes stimulates the phagocytosis of Aȕ 
by microglial cells (Terwel, et al., 2011; Giunta, et al., 2008). The APOE lipidation status affects 
the binding of APOE and Aȕ. Moreover, the phagocytosis as well as the intracellular and 
extracellular degradation of both soluble and fibrillar Aȕ in microglia are affected by the 
lipidation status of APOE, whereby more highly lipidated isoforms cause a more effective 
clearance of Aȕ (Jiang, et al., 2008; Bales, et al., 2009; Lee & Landreth, 2010; Wildsmith, et 
al., 2013). 
In addition to the removal of soluble and fibrillar Aȕ through phagocytosis, the extracellular 
proteolytic degradation of Aȕ was shown to be influenced by microglia as well. Microglia 
express and release Aȕ-degrading enzymes that contribute to the extracellular degradation of 
the peptide and partially also its oligomeric forms and fibrillar deposits (Miners, et al., 2011). 
IDE was discovered to be released predominantly by microglial cells in the brain and seems 
to represent the major protease for microglia-mediated degradation of extracellular monomeric 
Aȕ (Qiu, et al., 1998; Tamboli, et al., 2010). 
 
4. Rationale and aim of the study 
An imbalance between production and degradation of Aȕ leads to its abnormal accumulation 
and extracellular deposition in senile plaques during the pathogenesis of AD. For sporadic 
LOAD, the most common form of the disease, it is speculated that rather deficiencies in the 
clearance of Aȕ than an increased production lead to its accumulation and thereby cause the 
disease (Wildsmith, et al., 2013; Miners, et al., 2011). IDE is one of the major Aȕ-degrading 
enzymes in the brain that contributes to the removal of monomeric Aȕ. The enzyme being 
released by microglial cells or associated to the outer membrane of neurons and endothelial 
cells in the brain was shown to play a role in the extracellular degradation of Aȕ (Qiu, et al., 
1998; Tamboli, et al., 2010; Vekrellis, et al., 2000; Lynch, et al., 2006). Two independent 
studies demonstrated that different cell types can secrete IDE through an unconventional 
exosome-associated secretory pathway, however, the detailed mechanism of IDE secretion, 
its regulation and its stimulation in the brain is still not fully understood. IDE secretion from 
microglial cells could be stimulated by statins leading to an enhanced degradation of 
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extracellular Aȕ. However, natural stimuli for the release of IDE that potentially function within 
the neuron-microglia communication are not known. Before this study preliminary 
investigations by Konstantin Glebov revealed a potential role for the neurotransmitter serotonin 
(5-HT) in the stimulation of IDE secretion. 
Therefore the main aim of this project was to examine the molecular mechanisms that underlie 
the unconventional release of IDE and its regulation in microglia. Here the effects of the 
neurotransmitter 5-HT on the release of IDE and potential activated signalling pathways being 
involved should be investigated using cell culture models. Furthermore, the regulation of IDE 
secretion including its trafficking and sorting into exosomes as well as its subsequent release 
should be analysed, especially regarding its dependency or independency on the ESCRT 
function. 
To this end, the secretion of IDE using predominantly the cell line BV-2 will be examined both 
upon serotonin administration and utilizing RNAi as well as pharmacological approaches to 
analyse signalling pathways and investigate ESCRT-dependent or -independent regulatory 
mechanisms. Exosome and microvesicle preparation will be applied to gain further inside into 
certain effects also at the level of extracellular vesicles. In addition, by means of a lentiviral 
transduction system stable knockdown cell lines for IDE and the ESCRT accessory protein 
Vps4B shall be established. In parallel a yeast-two hybrid screen utilizing the C-terminal 
sequence of IDE as bait will be carried out to identify potential interaction partners of IDE that 
might play a role in its intracellular trafficking or release. 
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B Material and Methods 
1. Material 
1.1 Chemicals and Reagents 
Chemical/Reagent Company 
Acetic acid Carl Roth, Karlsruhe, Germany 
Adenosine 5`- triphosphate (ATP) disodium salt 
hydrate 
Sigma-Aldrich, Steinheim, Germany 
Agar from Red alga Rhodophyceae MP Biomedicals, CA, USA 
Altanserin Tocris/R&D Systems, Wiesbaden, Germany 
6-Aminocaproic Acid Sigma-Aldrich, Steinheim, Germany 
Ammonium persulfate Sigma-Aldrich, Steinheim, Germany 
Ampicillin sodium salt Carl Roth, Karlsruhe, Germany 
Amyloid 1-40 (Batch 15/11/14) Peptide Specialty Laboratories GmbH, 
Heidelberg, Germany 
Bis-Tris Carl Roth, Karlsruhe, Germany 
Boric acid MP Biomedicals, Eschwege, Germany 
Bovine Serum Albumine (Fraction V, BSA) Carl Roth, Karlsruhe, Germany 
Brefeldin A Tocris/R&D Systems, Wiesbaden, Germany 
Bromphenole blue sodium salt MP Biomedicals, Eschwege, Germany 
Calcium chloride Life Technologies, Darmstadt, Germany 
Carbenicillin Carl Roth, Karlsruhe, Germany 
Chloroquine Sigma-Aldrich, Steinheim, Germany 
Choleratoxin B Sigma-Aldrich, Steinheim, Germany 
Coomassie Brilliant Blue G/R 250  Merck, Darmstadt, Germany 
p-Coumaric Acid Sigma-Aldrich, Steinheim, Germany 
8-CPT-2ME-cAMP (8-CPT) Tocris/R&D Systems, Wiesbaden, Germany 
Dimethyl sulfoxide Carl Roth, Karlsruhe, Germany 
Disodium phosphate (Na2HPO4) Carl Roth, Karlsruhe, Germany 
DTT (1,4-Dithiothreitol) Carl Roth, Karlsruhe, Germany 
EDTA (Ethylene diamine tetraacetic acid) Carl Roth, Karlsruhe, Germany 
EGTA (Ethylene glycol-bis(2-aminoethyether)- 
N,N,N’,N’-tetraacetic acid) 
Carl Roth, Karlsruhe, Germany 
Ethanol absolute Merck, Darmstadt, Germany 
m-3m3FBS (3m3FBS) Tocris/R&D Systems, Wiesbaden, Germany 
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D(+)-Glucose Sigma-Aldrich, Steinheim, Germany 
Glycerine 86% Carl Roth, Karlsruhe, Germany 
Glycin Carl Roth, Karlsruhe, Germany 
GR113808 Tocris/R&D Systems, Wiesbaden, Germany 
GW4869 Sigma-Aldrich, Steinheim, Germany 
HEPES Sigma-Aldrich, Steinheim, Germany 
Hydrogen peroxide 30% Carl Roth, Karlsruhe, Germany 
5-Hydroxy-L-Tryptophan Sigma-Aldrich, Steinheim, Germany 
Insulin (human, recombinant) SAFC/Sigma-Aldrich, Steinheim, Germany 
Isopropyl ȕ-D-1-thiogalactopyranoside (IPTG) MP Biomedicals, Eschwege, Germany 
Kanamycin sulfate Sigma-Aldrich, Steinheim, Germany 
LB Media (Luria/Miller) Carl Roth, Karlsruhe, Germany 
Luminol Sigma-Aldrich, Steinheim, Germany 
Magnesium Chloride Carl Roth, Karlsruhe, Germany 
2-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany 
Methanol AppliChem, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
ML10302 Tocris/R&D Systems, Wiesbaden, Germany 
Monensin Sigma-Aldrich, Steinheim, Germany 
Orange G Santa Cruz, Texas, USA 
Polyethylene glycol (3350, 6000) Sigma-Aldrich, Steinheim, Germany 
Poly-L-lysine-hydrobromide Sigma-Aldrich, Steinheim, Germany 
Ponceau S Carl Roth, Karlsruhe, Germany 
Potassium chloride Carl Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate (KH2PO4) Carl Roth, Karlsruhe, Germany 
2-Propanol/Isopropanol Carl Roth, Karlsruhe, Germany 
Protease inhibitor cocktail (cOmplete™) Roche, Basel, Switzerland 
Protein G - Sepharose® 4B Invitrogen, Karlsruhe, Germany  
Protein A - Sepharose® 4B Invitrogen, Karlsruhe, Germany  
Puromycin InvivoGen, Toulouse, France 
RS127445 Tocris/R&D Systems, Wiesbaden, Germany 
Serotonin creatinine sulfate monohydrate Sigma-Aldrich, Steinheim, Germany 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodium deoxycholat Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
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Sucrose Carl Roth, Karlsruhe, Germany 
TEMED (N,N,N’,N’-Tetramethylethane-1,2-
diamine) 
Carl Roth, Karlsruhe, Germany 
Thapsigargin Invitrogen, Karlsruhe, Germany 
Trichloroacetic acid Carl Roth, Karlsruhe, Germany 
Tricine Carl Roth, Karlsruhe, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Tween® 20 Sigma-Aldrich, Steinheim, Germany 
U73122 Tocris/R&D Systems, Wiesbaden, Germany 
Urea Carl Roth, Karlsruhe, Germany 
X--Gal Takara/Clontech Laboratories Inc., CA, USA 
Table 1. List of chemicals and reagents 
 
1.2 Media and Solutions 
Name Composition, Company 
Amersham ECL Select Western Blotting 
Reagent 
GE Healthcare, Munich, Germany 
Aureobasidin A Takara/Clontech Laboratories Inc., CA, USA 
BamHI buffer Thermo Fisher Scientific, Schwerte, Germany 
Bradford Reagent BioRad, Munich, Germany 
DNase I + 10x DNase I reaction buffer New England BioLabs GmbH, Frankfurt am 
Main, Germany 
Dulbecco’s Modified Eagle Medium (DMEM) 
GlutaMAX™ 
Thermo Fisher Scientific, Schwerte, Germany 
EcoRI buffer Thermo Fisher Scientific, Schwerte, Germany 
Fetal Calf Serum PAN-Biotech GmbH, Aidenbach, Germany 
GelRed™ Nucleic Acid Gel Stains Biotium Inc., California, USA 
GeneRuler 100bp DNA ladder Thermo Fisher Scientific, Schwerte, Germany 
GeneRuler 1kb DNA ladder Thermo Fisher Scientific, Schwerte, Germany 
Gibco® B-27 Supplement Thermo Fisher Scientific, Schwerte, Germany 
Immu-Mount™ Thermo Fisher Scientific, Schwerte, Germany 
Neurobasal® Medium Thermo Fisher Scientific, Schwerte, Germany 
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NuPAGE® MES SDS Running Buffer Thermo Fisher Scientific, Schwerte, Germany 
NuPAGE® LDS sample buffer (4x) Thermo Fisher Scientific, Schwerte, Germany 
NuPAGE® Antioxidant Thermo Fisher Scientific, Schwerte, Germany 
Odyssey® Blocking Buffer (PBS) LI-COR Biosciences, Bad Homburg, Germany 
Opti-MEM® I Reduced Serum Medium Thermo Fisher Scientific, Schwerte, Germany 
Optiprep™ Density Gradient Medium Axis Shield, Dundee, Scotland 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific, Schwerte, Germany 
PBS for cell culture Gibco® PBS tablets dissolved in 500ml  
deionized H2O, autoclaved 
Thermo Fisher Scientific, Schwerte, Germany 
Penicillin/Streptomycin Life Technologies, Darmstadt, Germany 
Restore™ Western Blot Stripping Buffer Thermo Fisher Scientific, Schwerte, Germany 
Rotiphorese® 30 (37.5:1) 30% aqueous solution, 
Acrylamide/Bisacrylamide 37.5:1 
Carl Roth, Karlsruhe, Germany 
See Blue® Pre-stained Protein Standard Thermo Fisher Scientific, Schwerte, Germany 
T4 DNA Ligase + 10x T4 ligase reaction buffer Thermo Fisher Scientific, Schwerte, Germany 
Trypsin 0.05%/EDTA 0.02% in PBS without Ca2+ and 
Mg2+, with Phenol red 
PAN-Biotech GmbH, Aidenbach, Germany 
Table 2. List of media and solutions 
 
1.3 Antibodies 
Primary antibodies: 
 
Antibody Name Company Dilution 
Anti--Actin, mouse mAb, 
A1978 
Sigma-Aldrich, Steinheim, Germany 1:3000 - 1:20000 
Anti-AIF, rabbit mAb, D39D2 
XP® 
Cell Signalling/NEB, Frankfurt, Germany 1:1000 
Anti-Alix, mouse IgG1 mAb, sc-
53540 
Santa Cruz, Texas, USA 1:1000 
Anti-Amyloid- (N), mouse IgG 
mAb 82E1 
Immuno-Biological Laboratories Inc. (IBL 
AMERICA), MN, USA 
1:100 
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Anti-Amyloid- (N), mouse IgG1 
mAb, m3.2 
BioLegend, Fell, Germany 1:1000 
Anti-Amyloid precursor protein 
(C), mouse IgG1 mAb, C1/6.1 
BioLegend, Fell, Germany 1:1000 
Anti-Calnexin, rabbit IgG pAb, 
sc-11397 
Santa Cruz, Texas, USA 1:1000 
Anti-EEA1, rabbit pAb, PM062 MBL/Biozol, Eching, Germany 1:1000 
Anti-Flotillin-1, mouse IgG1 
mAb, 610820 
BD Biosciences, Heidelberg, Germany 1:1000 
Anti-GAPDH, mouse IgG1 mAb, 
sc-47724 
Santa Cruz, Texas, USA 1:500 
Anti-IDE, rabbit pAb, ab25970 abcam, Cambridge, Great Britain 1:1000 
Anti-IDE (C), rabbit pAb, 
ab32216 
abcam, Cambridge, Great Britain 1:1000 
Anti-IDE, mouse IgG1 mAb, 
MAB2496 
R&D Systems, Wiesbaden, Germany 1:100 (ICC) 
Lamp-2, rat IgG2a mAb, ABL-
93-c 
Developmental Studies Hybridoma Bank, 
University of Iowa, USA 
1:2000 
Anti-LC-3, rabbit IgG pAb, 
PM036 
MBL/Biozol, Eching, Germany 1:1000 
Anti-MEK 1/2, rabbit mAb, 
#8727 
Cell Signalling/NEB, Frankfurt, Germany 1:1000 
myc (Wahle, et al., 2005) 1:1000 
Anti-Vps4A, mouse IgG2a mAb, 
sc-133122 
Santa Cruz, Texas, USA 1:500 
Anti-Vps4B, rabbit pAb, 
NBP1-19119 
Novus Biologicals LLC, CO, USA 1:1000 (WB) 
1:250 (ICC) 
Anti-Vps4B, rabbit pAb, 
SAB4200023 
Sigma-Aldrich, Steinheim, Germany 1:1000 (WB) 
Table 3. Primary antibodies 
 
Secondary antibodies and other protein detection reagents: 
 
Antibody/Reagent Company Dilution 
Anti-mouse Alexa Fluor® 488 Life Technologies, Darmstadt, Germany 1:1000 (ICC) 
Anti-mouse-Biotin, goat IgG 
pAb, B7264 
Sigma-Aldrich, Steinheim, Germany 1:5000 
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Anti-mouse-HRP, rabbit IgG 
pAb, A9044 
Sigma-Aldrich, Steinheim, Germany 1:36000 
Anti-mouse-IRDye® 680RD, 
goat IgG 
LI-COR Biosciences, Bad Homburg, 
Germany 
1:10000 
Anti-mouse-IRDye® 800CW, 
goat IgG 
LI-COR Biosciences, Bad Homburg, 
Germany 
1:10000 
Anti-rabbit Alexa Fluor® 546 Life Technologies, Darmstadt, Germany 1:1000 (ICC) 
Anti-rabbit-HRP, goat IgG pAb, 
A9169 
Sigma-Aldrich, Steinheim, Germany 1:36000 
Anti-rabbit-Biotin, goat IgG 
pAb, B8895 
Sigma-Aldrich, Steinheim, Germany 1:20000 
Anti-rabbit-IRDye® 680RD, 
goat IgG 
LI-COR Biosciences, Bad Homburg, 
Germany 
1:10000 
Anti-rabbit-IRDye® 800CW, 
goat IgG 
LI-COR Biosciences, Bad Homburg, 
Germany 
1:10000 
Anti-rat-HRP, goat IgG pAb, 
612-103-120 
Biomol GmbH, Hamburg, Germany 1:36000 
Phalloidin Alexa Fluor® 647 Thermo Scientific, Darmstadt, Germany 1:2000 (ICC) 
Streptavidin-HRP polymer, 
ultrasensitive, S2438 
Sigma-Aldrich, Steinheim, Germany 1:1000 
Table 4. Secondary antibodies and other protein detection reagents 
 
1.4 Commercial Kits 
Kit Company 
Easy Yeast Plasmid Isolation Kit Takara/Clontech Laboratories Inc., CA, USA 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific, Schwerte, Germany 
HiPerFect Transfection Reagent  Qiagen, Venlo, Netherlands 
Matchmaker® Gold Yeast Two-Hybrid System Takara/Clontech Laboratories Inc., CA, USA 
Matchmaker Insert Check PCR Mix 2 Takara/Clontech Laboratories Inc., CA, USA 
NucleoBond® Xtra Maxi Macherey-Nagel, Düren, Germany 
NucleoSpin® Plasmid EasyPure Macherey-Nagel, Düren, Germany 
Pfu DNA Polymerase Promega, Mannheim, Germany 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, Schwerte, Germany 
RNeasy® Mini Kit Qiagen, Venlo, Netherlands 
SuperScript® III First-Strand Synthesis System Thermo Fisher Scientific, Schwerte, Germany 
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Taq 5x Master Mix New England BioLabs GmbH, Frankfurt am Main, 
Germany 
WIZARD® SV Gel and PCR Clean-Up System Promega, Mannheim, Germany 
Yeastmaker® Yeast Transformation System 2 Takara/Clontech Laboratories Inc., CA, USA 
Table 5. Commercial Kits 
 
1.5 Devices and Tools 
Device/Tool Company 
-80°C Freezer Thermo Scientific 
37°C CO2 Incubator Binder 
37°C Incubator VWR 
Analytical Balance (Labstyle 204) Mettler Toledo 
Autoclave H+P 
Beckman Ultracentrifuge Optima™ XPN-80 
Rotor: - SW41Ti 
           - 45Ti 
Beckman Coulter 
Cell Culture Clean Bench Thermo Scientific 
Centrifuges (5415D, 5415R, 5804, 5804R)  Eppendorf 
ChemiDoc™ XRS System with Analysis 
Software Quantity One® Version 4.6.3. 
BioRad 
Cooling System (E100) Lauda 
Glass beads acid-washed (425-600m) G8772 Sigma-Aldrich, Steinheim, Germany 
Magnetic stirrer Velp Scientifica 
MultiSkan RC™ Microplate Reader with 
Ascent™ Software 
Thermo Scientific 
NanoPhotometer® P-class P330 Implen 
Nitrocellulose membrane Amersham 
NuPAGE® 4-12% Bis-Tris Protein Gels Thermo Fisher Scientific 
Odyssey CLx Imager with Analysis Software 
Image Studio™ Lite 5.β 
LI-COR Biosciences 
PCR cycler Eppendorf 
pH meter (MP225) Mettler Toledo 
PVDF membrane GE Healthcare 
Roto Shake Genie Scientific Industries 
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Table 6. Devices and Tools 
 
2. Methods 
2.1 Cell biological techniques 
2.1.1 Cell culture 
BV-2 microglia, Cos-7, HEK293 (all three obtained from ATCC), HEK293FT (kind gift from 
Prof. Oliver Brüstle (University of Bonn)) and N9 microglia cells (kind gift from Prof. Michael 
Heneka (University of Bonn)) were cultured in DMEM GlutaMAX™ supplemented with 10% 
fetal calf serum (v/v) and 100 U/ml penicillin and 100 g/ml streptomycin (DMEM +/+). Cells 
were routinely grown on 10-cm dishes or T75 flasks and incubated at 37°C with 5% CO2 
atmosphere.  
 
2.1.2 Preparation of primary hippocampal neurons, astrocytes and microglia from 
mouse or rat embryonic brain 
Primary mouse or rat neurons, microglia and astrocytes were mainly prepared by Janina Gerth 
and Konstantin Glebov. The cells were obtained by dissection of brains from mouse (C57BL/6) 
or rat (WISTAR) embryos (E18) in dissection medium. Hippocampi were separated for neuron 
isolation, incubated with Trypsin/EDTA for 7 min and after removal of Trypsin mechanically 
dissociated (Pasteur pipette) in chopping medium and centrifuged (1000 g, 5 min). The cells 
were resuspended in Neurobasal® Medium containing 2% B-27 supplement and 3% fetal calf 
serum. The medium was changed after 2 hours of settlement to remove cell debris. Cells were 
seeded to 6-well plates coated with poly-L-lysine and incubated at 37°C with 5% CO2 
atmosphere, changing medium twice a week to Neurobasal® Medium with 2% B-27 
SE 250 Mini-Vertical Gel Electrophoresis Unit  Hoefer 
Sonicator Merck Eurolabs 
TE22 Small Transfer Tank Hoefer 
Thermomixer R 5355 Eppendorf 
TransUV illuminator (GVM 20) Syngene 
Vortex (MS2 Minishaker) IKA 
Water bath Medigen 
XCell SureLock™ Mini-Cell Electrophoresis 
System 
Thermo Fisher Scientific 
XCell4 SureLock™ Midi-Cell Electrophoresis 
System 
Thermo Fisher Scientific 
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supplement (serum free after 3 days and addition of 10 mM AraC to avoid growth of fibroblast 
and other glial cells like astrocytes). For astrocyte and microglia isolation cortices were 
mechanically dissociated (Pasteur pipette) and seeded to poly-L-lysine coated T75 flasks. The 
mixed culture was cultured in DMEM +/+. Primary microglia were received by shaking at 
100 rpm for 2 hours and transferred to a new flask. The now mainly astrocytes-containing 
culture received fresh medium and the procedure of harvesting primary microglia could be 
repeated after 7 days. 
 
2.1.3 Pharmacological treatment and secretion assay 
In order to analyse the secretion of IDE and other exosomal marker proteins an established 
protocol for a secretion assay was carried out, also described earlier (Glebov, et al., 2015; 
Tamboli, et al., 2010). For the secretion assay the same number of cells for each replicate was 
seeded 8 – 24 hours before the assay, cells transfected with siRNA in order to the experimental 
procedure earlier (see 2.1.8). For the secretion assay, the medium was replaced by serum-
free DMEM GlutaMAX™, containing the indicated reagent or equivalent amount of the 
respective carrier solvent in control cells (see Table 7). Cells were washed once with sterile 
PBS to remove serum components, which could interfere with the Western blot analysis (see 
2.2.4). The medium volume was equal for transfected or treated and control cells as well as 
for all replicates. 
 
Pharmacological treatments: 
 
compound concentration 
m-3m3-FBS  5 M 
Brefeldin A (BFA) 5 g/ml 
8-CPT-2ME-cAMP (8-CPT) 5 M 
Altanserin  10 nM 
GR113808  20 nM 
GW4869 1.5 M; 5 M 
5-Hydroxy-L-tryptophan (5-HTP) 500 μM 
ML10302  10 nM 
Monensin 10 M 
RS127445  5 M 
Serotonin creatinine sulfate monohydrate (5-HT)  25 M 
Thapsigargin 1 M 
U73122 10 M 
Table 7. Pharmacological treatments 
Where indicated, a pharmacological pre-treatment with 5-HT receptor antagonists was carried 
out for 6 hours before the assay. After 16 hours (shorter time periods are indicated) the 
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conditioned medium of the cells was collected and centrifuged (1,000xg, 10 min, 4°C) to 
remove dead and detached cells. After the experiment, cells were lysed (see 2.2.1). 
Conditioned media and cell lysates were subsequently analysed by immunoblotting (see 2.2.3 
and 2.2.4). 
 
2.1.4 Co-culture of primary mouse hippocampal neurons and BV-2 microglia cells 
The co-culture for an IDE secretion assay was prepared by preplating primary mouse 
hippocampal neurons into 6-well plates (see 2.1.2). After two weeks the neuronal culture was 
pre-treated with 500 µM 5-HT for 6 hours. Separate cultures of BV-2 cells, where indicated, 
were also pre-treated with 5-HT receptor antagonists for 6 hours. Then BV-2 cells were 
collected by trypsination and added to the neuronal cultures (5x105 per well). After 16 hours, 
conditioned media were collected and cells harvested and subjected to immunoblotting (see 
2.2.3 and 2.2.4). 
 
2.1.5 Co-culture of ES-derived serotonergic neurons and BV-2 microglia cells 
The co-culture of ES-derived serotonergic neurons and BV-2 microglia cells was carried out 
by Thorsten Lau and Konstantin Glebov in the laboratories of Prof. Patrick Schloss at the 
Central Institute of Mental Health in Mannheim. Neuronal stem cell-derived serotonergic 
neurons were generated as described previously (Lau, et al., 2010). Briefly, prior differentiation 
neuronal stem cells were cultured for at least two passages in DMEM supplemented with 
10% (v/v) ES cell-qualified fetal bovine serum, 1x MEM non-essential amino acids, penicillin 
(100 U/ml) and streptomycin (100 µg/ml) and LIF (1000 U/ml). The serotonergic differentiation 
was induced by addition of 1 mM dibutyryl cAMP and 0.05% (v/v) cyclohexane carboxylic acid. 
For the co-culture experiments, 20,000 neuronal stem cells/µm2 were plated on 0.1% (v/v) 
gelatine-coated 24-well dishes and kept in differentiation medium for 7 days to generate stem 
cell-derived serotonergic neurons. Next, 8x104 BV-2 cells were seeded into the wells with 
neurons and a secretion assay was performed (see 2.1.3). After 16 hours conditioned medium 
and cells were harvested. The following analyses by immunoblotting (see 2.2.2 - 2.2.4) were 
performed by me in the laboratories of Prof. Jochen Walter. 
 
2.1.6 Amyloid-β (Aβ) and insulin degradation assay 
In order to analyse the degradation of Aȕ and insulin in the presence of BV-2 microglia cells a 
secretion assay with Aȕ- or insulin-containing medium was carried out. Cells were seeded into 
24-well plate 40 hours before the assay (105 cells per well, in triplicates). After washing the 
cells once with sterile PBS, the medium was replaced by 800 l serum-free DMEM 
GlutaMAX™ containing 1 M Aȕ or 1 M insulin, respectively. A time point 0 sample was taken 
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from extra control cells by harvesting the supernatant of the cells directly after adding the 
medium to the cells. The time point 0 supernatant was centrifuged (1,000xg, 10 min, 4°C) and 
frozen at -20°C. After 7 hours conditioned medium was collected and centrifuged (1,000xg, 
10 min, 4°C). The cells were lysed (see 2.2.1). Supernatant and cell lysates were subjected to 
immunoblotting (see 2.2.2 - 2.2.4). Conditioned medium was either directly loaded onto a 
NuPAGE gel for analysis of Aȕ or first concentrated by TCA precipitation (2.2.2). Insulin in the 
medium was detected by loading TCA-precipitated protein (see 2.2.2) onto a NuPAGE gel (see 
2.2.3) and subsequently staining it by Coomassie staining (see 2.2.5). 
 
2.1.7 Calcium measurements 
Calcium measurements were kindly carried out by Dr. Ronald Jabs from the Institute of Cellular 
Neurosciences in Bonn, assisted by Olaf Merkel, Dr. Konstantin Glebov and me (Glebov, et 
al., 2015). If indicated, the cells were pre-treated with particular receptor antagonists for 16 
hours overnight. Then cells were bulk labelled with Fluo-4 by incubation with cell culture 
medium supplied with 3 µM Fluo-4 AM and 2 mM probenecid for 30 min at 37°C, followed by 
a 30 min washing period. Subsequent time-lapse recordings were performed with a Confocal 
Laserscan Microscope (Leica DMI 6000, SP8, Leica) at an excitation wavelength of 488 nm 
(Haberlandt, et al., 2011). Emission was detected between 500 and 650 nm every 15 sec. 
Changes in [Ca2+]i, measured as change in fluorescence intensity (∆F), were offline related to 
the baseline fluorescence (F0) according to ∆F/F0 = (F - F0)/F0. Ratios were determined in 
separate regions of interest (ROIs) placed in individual BV-2 cells within the field of view. Data 
were corrected for photobleaching by estimation of the rate from unaffected cells and 
subsequent linear compensation. Data analysis was performed with LAS Live Data Mode 
(Leica) and IgorPro 6 software (WaveMetrix Inc.). 
 
2.1.8 Transient protein knockdown by siRNA transfection 
For transient RNA interference the indicated cells were transfected with FlexiTube siRNA (see 
Table 8) and HiPerFect transfection reagent. In general, siRNA transfection was carried out in 
24-well format. Control cells were transfected with an AllStars Negative Control siRNA, a non-
silencing siRNA with no homology to any known mammalian gene. The siRNA stock solution 
(10 M in water) was diluted 1:10 with water and 25 l per well were pipetted into the middle 
of the well. A master mix of 5 l HiPerFect and 95 l OptiMEM® per well for all transfections 
was made and 100 l pipetted onto the siRNA. For complex formation the mix of siRNA and 
HiPerFect were incubated for 5-10 minutes at RT. In the meantime, cells were trypsinised and 
counted. 1x105 cells resuspended in 200 l DMEM +/+ were seeded per well onto the siRNA 
complexes. Cells were incubated for 3 hours followed by the addition of 500 l fresh medium. 
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After incubation overnight the medium was changed and cells were cultured for further 8 or 32 
hours before further analyses. 
In double transfections same siRNA concentration for each siRNA was applied, the amount of 
control siRNA was doubled and parallel single transfections were equalized by adding the 
same amount of negative control siRNA.  
The transfection of cos-7 cells was scaled up to 12-well format. 1x105 cells were seeded per 
well. Primary rat astrocyte siRNA transfection was scaled up to 6-well format and cells were 
seeded to 90-95% confluency. BV-2 siRNA transfections were scaled up to 10 cm dish in 
individual experiments (see 2.2.10).  
 
FlexiTube siRNA Gene Cell line 
AllStars Negative Control - BV-2, cos-7, primary rat astrocytes 
Mm_Pdcd6ip_2 ALIX/Pdcd6ip BV-2 
Mm_Pdcd6ip_6 ALIX/Pdcd6ip BV-2 
Mm_Ide_6 IDE BV-2, primary rat astrocytes 
Hs_Ide_6 IDE Cos-7 
Mm_Vps4a_1 Vps4A BV-2 
Mm_Vps4b_4 Vps4B BV-2, primary rat astrocytes 
Hs_Vps4b_6 Vps4B Cos-7 
Table 8. FlexiTube siRNAs (Qiagen) 
 
2.1.9 shRNA-mediated stable protein knockdown in BV-2 microglia cells 
In order to generate BV-2 cell lines stably expressing IDE- or Vps4B-specific shRNAs to 
achieve a stable RNA silencing, lentiviral particles containing shRNA-encoding plasmids were 
generated for transduction of BV-2 cells. The shRNA-encoding plasmids (see Table 9) were 
generated from The RNAi Consortium (TRC) and purchased from Dharmacon/GE Healthcare 
(Freiburg, Germany) or Sigma-Aldrich (Steinheim, Germany). 
 
shRNA Gene Mature Antisense Vector 
TRCN0000009487 mouse IDE TTTGTCTCTCTAATAGCAAGC pLKO.1-puro 
TRCN0000009488 mouse IDE TAATATGTGGTTTCACGAGGG pLKO.1-puro 
TRCN0000009489 mouse IDE ATAATAGTGCAACTTTCCTGC pLKO.1-puro 
TRCN0000101415 mouse Vps4B AACCTAGTAATTGTTTGCAGG pLKO.1-puro 
TRCN0000101416 mouse Vps4B TACAATGCAGTTAGGATCAGC pLKO.1-puro 
TRCN0000101417 mouse Vps4B ATCCCACATGGAAACAACTGG pLKO.1-puro 
SHC002 non-target shRNA TTGGTGCTCTTCATCTTGTTG pLKO.1-puro 
Table 9. TRC lentiviral shRNA 
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Generation of lentiviral particles 
2.5x106 HEK293 FT cells were seeded to poly-ornithine-coated 15 cm dish (2 per lentiviral 
construct) and cultured for 16 hours. Medium was changed to 13 ml fresh DMEM +/+ 
containing 25 M chloroquine and cells were incubated for 5 min. Then cells were 
co-transfected with the lentiviral plasmid encoding the respective shRNA, the packaging 
plasmid Pax2 and the envelope plasmid pMD2.G using 25 M CaCl2 and 2x HBS buffer as 
transfection reagents. DNA was precipitated by CaCl2 and 2x HBS buffer and then added 
dropwise onto the cells. After 16 hours of incubation medium was changed to fresh DMEM +/+, 
13 ml per dish. After further 24 hours conditioned medium was collected and stored at 4°C 
until the next day, fresh DMEM +/+ was added to the cells, again 13 ml per dish. After further 
24 hours conditioned medium was again collected, combined with the earlier collected medium 
and cells were discarded. The collected medium was centrifuged (1,100 rpm, 5 min, 4°C) and 
the supernatant was filtered through a sterile SFCA membrane (pore size: 0.45 m). The 
filtered supernatant was added to a polyethylene glycol 6,000 (PEG 6,000) buffer that was 
prepared according to Kutner et al. (Kutner, et al., 2009). The suspension was incubated for 
90 min at 4°C mixing it every 20 min. After centrifugation (4,000xg, 30 min, 4°C) the 
supernatant was discarded and the pellet composed of the precipitated lentiviral particles was 
resuspended in 200 l virus freezing medium and kept at -80°C until further use. 
 
2x HBS buffer:  
280 mM NaCl, 10 mM KCL, 1.5 mM Na2HPO4, 50 mM HEPES, 12 mM Glucose, pH 7.00 
PEG 6000 buffer: 
8.5% PEG 6000, 0.3 M NaCl, 7.76% PBS 
Virus freezing medium: 
2x HBS buffer, 1% BSA 
 
 
Transduction of BV-2 cells with lentiviral particles and selection 
For transduction of BV-2 cells 7.5x105 cells per well were seeded into 6-well plate or to a 
3.5-cm dish. After 24 hours the lentiviral particles prepared from two 15-cm dishes (see above) 
were added to the cells and the cells were incubated with the lentiviral particles for 16 hours. 
Then medium was discarded, cells were two times washed with DMEM +/+ and supplied with 
fresh medium. After 5-6 hours selection was started and cells were incubated with DMEM +/+ 
containing 8 g/ml puromycin. Cells were further cultured under selection conditions, 
knockdown was tested by Western immunoblotting (see 2.2.4). 
 
2.1.10 Immunocytochemistry (ICC) 
For fluorescence imaging, cells were seeded onto sterile cover slips in respective culture 
dishes that were coated with poly-L-lysine (poly-L-lysine for 1h at 37°C, three times washed 
with sterile PBS, one time washed with DMEM). After 24 hours, the cells were washed once 
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with pre-warmed (37°C) PBS and then fixed using pre-warmed (37°C) 4% paraformaldehyde 
(PFA) solution for 10 min. Afterwards, the cells were washed two times with PBS to remove 
residual PFA. The cells were then permeabilized with Triton X-100 solution for 2 min and 
thereafter incubated with BSA blocking solution for 1 hour at RT. To stain the proteins of 
interest, the cells were subsequently incubated with the primary antibody (Table 3), which was 
diluted in antibody solution (100 l per cover slip), for 1 hour at RT or over-night at 4°C. The 
cells were washed three times with washing solution and kept in washing solution for 5 min. 
After repeating the washing step twice the cells were incubated with the secondary antibody 
conjugated with a fluorescent dye (Table 4, diluted in antibody solution) for 1 hour at RT in the 
dark. Parallel incubation with DAPI and phalloidin Alexa Fluor® 647 were used to stain the 
nuclei and F-actin, respectively. Residual antibody was removed by the three washing steps 
as described above. Then cells were washed three times with PBS, incubated with PBS for 
5 min and subsequently washed one time with distilled water. The water was removed and the 
cover slips were embedded on a microscope slide using Immu-mount™ and afterwards kept 
in the dark at 4°C. Fluorescence imaging was carried out using a fluorescence microscope 
(Axio Vert 200, Carl Zeiss) with the ZEN analysis software. 
 
PBS: 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4. pH 7.4 
Poly-L-lysine solution: 
100 g/ml sterile poly-L-lysine in PBS 
PFA solution:  
4% paraformaldehyde in PBS (w/v) 
Triton X-100 solution: 
0.25% Triton X-100 in PBS 
Washing solution: 
0.125% Triton X-100 in PBS 
BSA blocking solution: 
2.5% BSA in washing solution 
Antibody solution: 
1.25% BSA in washing solution 
 
2.2 Protein biochemical techniques 
2.2.1 Cell lysis and protein extraction 
Cells were lysed by adding ice-cold RIPA lysis buffer containing 1x-concentrated protease 
inhibitor (PI) cocktail. After 10-15 min incubation on ice, the lysate was homogenised by 
pipetting and then transferred to a micro reaction tube. Insoluble and particulate material was 
removed by centrifugation (13,200xg, 2 min, 4°C). The resulting supernatant was subjected to 
protein estimation with the Pierce™ BCA Protein Assay Kit according to the manufacturer’s 
instructions. Cell lysates were stored at -20°C until further use. 20-35 g protein or the same 
volume of lysate for each condition and replicate was loaded to a polyacrylamide gel for protein 
separation (see 2.2.3). 
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RIPA lysis buffer:  
50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% Na-deoxycholat, pH 7.5 
25x Protease inhibitor cocktail: 
1 cOmplete™ tablet dissolved in 2 ml deionized H2O 
 
 
2.2.2 Protein precipitation by trichloroacetic acid (TCA) 
Conditioned media were collected and centrifuged (1,000xg, 10 min, 4°C) to remove dead and 
detached cells. Then DOC was added to the medium to a final concentration of 0.02% (v/v). 
The solution was mixed by inverting the tube and incubated for 15 min on ice. Thereafter, TCA 
solution was added to a final concentration of 10% (v/v). The solution was mixed by inverting 
the tube and kept on ice. After 60 min the precipitate was pelleted by centrifugation (13,200xg, 
10 min, 4°C) and the supernatant discarded. To collect and remove residual TCA from the 
protein pellet an additional centrifugation step was carried out (13,200xg, 2 min, 4°C). The 
pellet was dried completely at RT or 37°C, dissolved in Tris/SDS buffer and kept at -20°C until 
further use or directly loaded to a gel for protein separation (see 2.2.3). 
 
DOC solution: 
2% sodium deoxycholic acid in deionized water (w/v) 
TCA solution: 
100% TCA in deionized water (w/v) 
Tris/SDS buffer: 
50 mM Tris, 1% SDS in deionized water 
 
 
2.2.3 Protein separation by SDS polyacrylamide gel electrophoresis (SDS-PAGE) / 
NuPAGE 
SDS-PAGE was used to separate proteins according to their molecular weight. For 
polyacrylamide gels, a lower separation gel was casted and allowed to polymerize. Then, the 
upper stacking gel was casted, which is necessary for concentration of the proteins before 
entering the separation gel. In general, the percentage of the acrylamide/bisacrylamide 
determining the pore size of the gel was chosen 10% for the separation gel and 4% for the 
stacking gel (see Table 10). The solution of the separation gel was cast into a gel cassette and 
covered with a layer of 70% ethanol to remove bubbles and to prevent dehydration. After 
polymerization the ethanol was removed and the solution of the stacking gel was added. To 
create wells for later sample loading, a comb was immediately inserted. After complete 
polymerization, the gel-containing cassette was inserted into a gel electrophoresis chamber. 
The chamber is filled with running buffer and the comb is carefully removed from the stacking 
gel and the wells are rinsed with running buffer. Before loading, the samples were denatured 
by boiling with SDS loading buffer at 95°C for 5 min. Additionally to the protein samples, the 
protein standard PageRuler Prestained was loaded into one well of the gel. Electrophoresis 
was performed with constant voltage at 100-120 V.  
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Alternatively, especially for detection of smaller proteins like Aȕ, insulin and proteins in 
conditioned medium, pre-casted NuPAGE® 4-12% Bis-Tris gradient gels were used. The 
samples were prepared according to the manufacturer’s instructions with 4x LDS buffer and 
1 M DTT. As protein standard, here, the SeeBlue® prestained standard was used. 
Electrophoresis was performed with constant voltage at 150-200 V. 
 
 4% stacking gel 10% separation gel 
Deionized H2O 3.25 ml 8.3 ml 
Acrylamide/bisacrylamide 30 (37.5:1) 700 l 6.7 ml 
Upper Tris 1.25 ml - 
Lower Tris - 5 ml 
10% APS 20 l 50 l 
TEMED 20 l 50 l 
Table 10. Composition of SDS-PAGE gels 
 
Stacking gel buffer (4 x) (Upper Tris): 
500 mM Tris, 0.4% SDS, deionized H2O, pH 6.8 
Separation gel buffer (4 x) (Lower Tris): 
1.5 M Tris, 0.4 %SDS, deionized H2O, pH 8.8  
Ammonium persulfate (APS, Sigma): 
10% Ammonium persulfate in deionized H2O 
Running buffer: 
25 mM Tris, 200 mM Glycine, 0.1% SDS in deionized H2O 
SDS Loading dye (5 x):  
25% Upper Tris, 0.34 M SDS, 0.1 M DTT, 50% glycerol, bromphenol blue, with deionized H2O to 10 ml 
 
 
2.2.4 Western immunoblotting (WB) and ECL/Infrared (IR) imaging 
After protein separation by SDS-PAGE or NuPAGE® the gel was usually subjected to WB for 
protein detection. Gels and nitrocellulose or PVDF membrane were equilibrated in transfer 
buffer. PVDF membranes were additionally incubated with methanol. The gel was placed on 
top of the membrane and both were enclosed by two filter papers on each side. This stack was 
tightly clamped together and put into a tank blotting chamber connected to a cooling system. 
The proteins were transferred to the membrane for 1.5-2 hours at constant current of 400 mA. 
After the transfer, the gel was discarded and the membrane was washed once in deionized 
water. Transferred proteins were stained with Ponceau S solution for 1 min followed by 
washing with deionized water. This step was skipped for protein detection by IR imaging. 
For protein detection by ECL imaging the membrane was blocked with 5% milk in PBST for 
1 hour. After washing the membrane shortly several times with PBST it was incubated in 
primary antibody diluted in PBST overnight at 4°C or for 2 hours at RT (for primary antibodies 
and dilution factors see Table 3). Now the membrane was washed three times with PBST for 
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at least 5 min each time followed by incubation with HRP-conjugated secondary antibody 
diluted in PBST for 1 hour at RT (for secondary antibodies and dilution factors see Table 4). 
The membrane was then washed again three times. Where indicated, the incubation with a 
biotinylated instead of HRP-conjugated secondary antibody was carried out to achieve an 
additional signal enhancement. After three washing steps the membrane was then incubated 
with Streptavidin-HRP polymer diluted in PBST for 1 hour at RT, again followed by three 
washing steps. For protein detection the membrane was incubated with ECL solution for 5 min 
and chemiluminescence was detected by an ECL imager from BioRad. In case of weak signals 
the membrane was developed again using ECL SELECT from GE Healthcare according to the 
manufacturer’s instructions to enhance the signal.  
Alternatively, proteins were detected by IR imaging. In comparison to ECL imaging the 
membrane was here blocked with Odyssey® blocking buffer (PBS) 1:1 diluted with PBS and 
incubated with fluorescently IRDye®-labeled instead of HRP-conjugated secondary 
antibodies. IR fluorescence was detected by an IR imager of LI-COR. 
Protein signals were quantified using densitometric analysis using Quantity One® or Image 
Studio™ Lite software. 
 
Transfer buffer:  
5 mM Tris, 200 mM Glycine, 10% methanol, filled up with deionized H2O  
Ponceau S solution: 
2% (w/v) Ponceau S, 30% TCA (w/v) in deionized H2O 
PBS: (2.1.10) 
PBST: 
0.1% Tween-20 in PBS 
Milk blocking solution: 
5% milk powder in PBST 
ECL solution: 
immediately before use mix A and B 1:1 
A: 0.1 M Tris pH 8.5, 0.4 mM cumaric acid, 0.25 mM luminol, filled up with deionized H2O 
B: 0.1 M Tris pH 8.5, 0.018 % H2O2, filled up with deionized H2O 
 
2.2.5 Coomassie staining of polyacrylamide gel and IR imaging 
Alternatively to WB, proteins could also be detected by direct Coomassie staining of the 
polyacrylamide gel after SDS-PAGE or NuPAGE®. The gel was incubated with Coomassie 
staining solution for 30-45 min with gentle shaking. Afterwards the gel was incubated for 
additional 2-4 hours with destaining solution to remove excess Coomassie from the gel. 
Coomassie-stained proteins were detected by using the red channel of the IR imager 
Odyssey® CLx. 
 
Coomassie staining solution: 
0.5% Coomassie brilliant-blue R-250 (w/v), 45% isopropanol (v/v), 10% acetic acid (v/v), filled up with 
deionized H2O 
Destaining solution: 
45% methanol (v/v), 10% acetic acid, filled up with deionized H2O 
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2.2.6 Co-immunoprecipitation (Co-IP) 
After washing once with ice-cold PBS, cells were lysed directly in the cell culture dish with 1 ml 
IP lysis buffer supplemented with 1x-concentrated protease inhibitor cocktail (see earlier) per 
10cm-dish. After 30 min incubation on ice, the cell lysate was homogenised by pipetting and 
transferred to a micro reaction tube. Using the Pierce™ BCA protein assay kit the protein 
amount of the cell lysates was determined. An aliquot containing 1 mg protein was incubated 
with 1-3 g of the specific antibody and 50 l of a slurry containing protein A or G sepharose 
beads overnight at 4°C constantly being inverted. Protein A sepharose was used in 
combination with rabbit IgG and protein G sepharose in combination with mouse IgG. A control 
containing only cell lysate and sepharose beads without specific antibody was run in parallel. 
Subsequently, the beads were pelleted by centrifugation (6,000xg, 2 min, 4°C). The 
supernatant was discarded and the beads were sucked dry with a syringe needle. The beads 
were washed by adding 400 l ice-cold IP lysis buffer and inverting the tube for 5 min at 4°C. 
Then the beads were pelleted again by centrifugation (6,000xg, 2 min, 4°C) and the 
supernatant was discarded and the beads sucked dry with a syringe needle. That washing 
step was repeated twice. The samples were boiled for 10 min with 15 l of 2x NuPAGE® LDS 
sample buffer and 1.5 l 1 M DTT at 70°C and loaded on a NuPAGE® 4-12% Bis-Tris gel for 
protein separation and subsequent WB analysis (see 2.2.3 and 2.2.4). 
 
IP lysis buffer: 
150 mM NaCl, 20 m NaF, 10 mM Tris, 1 mM EDTA, 1 mM EGTA, 200 M Na3VO4, 1% Triton X-100, 
0.5% Igepal CA-B30, pH 7.4 
PBS: (2.1.10) 
 
2.2.7 Expression and purification of Maltose-binding protein (MBP) fusion proteins 
For the expression of the Vps4B-MBP fusion protein in E. coli, 400 ml LB medium containing 
100 g/ml ampicillin were inoculated with an 20 ml-overnight culture of bacteria transformed 
with a Vps4B-MBP construct (see Table 14). The culture was grown at 37°C to an OD600 of 
0.5-0.6. Before addition of 0.5 mM IPTG to induce the expression of the fusion protein, an 
aliquot of 200 l was taken, pelleted and stored at -20°C until further use. After 4 hours of 
shaking a further aliquot was taken (see above) and the cells were pelleted by centrifugation 
(3,220xg, 15 min, 4°C). The pellet was resuspended in 10 ml column buffer and incubated for 
30 min on ice after addition of lysozyme (5 mg/ml). The suspension was transferred to 
centrifuge tubes and sonicated 5 times with a pulse at an intensity of 50% for 30 sec. After 
taking another aliquot (see above) cell debris and insoluble fragments were removed by 
centrifugation (10,000xg, 30 min, 4°C). The pellet was stored at -20°C and the supernatant 
containing the fusion protein was transferred to a new tube. Another aliquot was taken (see 
above) and then the solution was filled up to 45 ml using column buffer. Amylose resin (2 ml 
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slurry) that binds to MBP was washed 3-4 times with 10 ml column buffer and resuspended in 
5 ml fresh column buffer before addition to the protein solution. Both were incubated under 
constant inversion for 1 hour at 4°C. The amylose resin was pelleted by centrifugation 
(2,000xg, 5 min, 4°C) and the supernatant was discarded after taking a further aliquot (see 
above). The amylose resin was resuspended in column buffer and washed 5 times with the 
just described procedure. The amylose resin was resuspended in 5 ml column buffer and 
carefully added to a poly-prep chromatography column. The resin was again washed with 5 ml 
column buffer on the column, taking an aliquot of the flow-through in-between. Finally, the 
fusion protein was eluted from the resin beads by adding 10 ml elution buffer to the column 
and collecting 10 fractions of 1 ml each. The protein concentration of the fractions was 
determined using the Bradford assay (20 l sample or standard, Bradford Reagent 1:5 diluted 
– 200 l per well, extinction at 595 nm) and the purity was controlled by Coomassie staining 
(see 2.2.5). 
 
Column buffer: 
20 mM tris, 200 mM NaCl, 1 mM EDTA, pH 7.4 
Elution buffer: 
10 mM maltose in column buffer 
 
 
2.2.8 Blue Native (BN) PAGE and subsequent SDS/Urea PAGE in the 2nd dimension 
In order to detect protein complexes, blue native (BN) PAGE was performed to separate 
proteins according to their molecular weight under non-denaturing and non-reduced 
conditions. Cells were harvested by trypsination, pelleted and washed once with PBS. Cell 
pellets were then resuspended in sucrose buffer supplemented with 1x-concentrated PI 
cocktail adding 2 l sucrose buffer / mg cells (wet weight). The cells were subjected to 
ultrasonic for lysis constantly kept on ice: one pulse at an intensity of 50% for 5 sec and two 
pulses at an intensity of 30% for 5 sec. The lysates were then centrifuged (13,200xg, 30 min, 
4°C) and the pellets discarded. After BCA protein estimation, the supernatant was 
supplemented with ACA buffer and loading buffer and kept on ice or at 4°C. Depending on the 
sample volume, one volume of ACA buffer is added to two volumes of the sample, completed 
by addition of one tenth of the final volume of loading buffer. 80 g of protein were loaded on 
a BN PAGE described by Wittig and colleagues (Wittig, et al., 2006) consisting of a 4% stacking 
gel on top of a 5 or 7.5% separation gel. The gels were casted as described earlier (see 2.2.3) 
with the BN PAGE-specific buffers listed in Table 11. Parallel to the samples 5-8 l Native Mark 
Unstained protein standard were loaded. Gel electrophoresis was started with dark blue 
cathode buffer in the inner chamber and anode buffer in the outer chamber using the following 
settings: constant 10 mA, 500 V. After the running front had passed the lower edge of the wells 
and the samples completely entered the separation gel of the stacking gel (circa after 20 min) 
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the cathode buffer was changed completely to clear cathode buffer without Coomassie G-250 
and run further until the blue dye front left the separation gel. Subsequently, the gel was 
reduced slowly shaking in reducing buffer for 15 min and washed afterwards four times with 
transfer buffer. Then the gel was subjected to WB (see 2.2.4). For the transfer exclusively 
PVDF membranes were used. After the transfer the membranes were destained with methanol 
for 1-2 minutes to get rid of Coomassie. The protein standard can be stained via Ponceau S 
staining (see 2.2.4). Protein detection was carried out via ECL imaging (see 2.2.4). 
 stacking gel separation gel 
 
4% 5% 7.5% 
Deionized H2O 3.23 ml 12.83 ml 10.5 ml 
Acrylamide/bisacrylamide 30 (37.5:1) 887 l 4.67 ml 7 ml 
6x Gel buffer 833 l 3.5 ml 3.5 ml 
10% APS 50 l 80 l 80 l 
TEMED 5 l 20 l 20 l 
Table 11. Composition of BN PAGE gels 
Instead of WB additionally a subsequent SDS/Urea PAGE in the 2nd dimension was run from 
single lanes of the native PAGE. After reducing the gel (see above) it was washed several 
times with equilibration buffer instead of transfer buffer to remove -mercapto ethanol. Now 
single lanes were cut from the gel and marked for their orientation. If not used immediately the 
gel lane could be frozen at -20°C at this point. The single gel lane was put into a gel cassette 
in horizontal orientation with decreasing protein size from left to right. A 10% SDS/urea 
separating gel was cast into the cassette underneath the gel lane. After polymerization a 4% 
SDS/urea stacking gel was cast around the gel lane also leaving a well to load a protein 
standard (PageRuler prestained). The gel recipe is given in Table 12. Gel electrophoresis was 
performed at constant voltage of 100-120 V until the blue running front left the gel and followed 
by WB (see 2.2.4). 
 
 4% stacking gel 10% separation gel 
8 M Urea 3.25 ml 8.3 ml 
Acrylamide/bisacrylamide 30 (37.5:1) 700 l 6.7 ml 
Lower Tris  - 5 ml 
Upper Tris 1.25 ml - 
10% APS 20 l 50 l 
TEMED 20 l 50 l 
Table 12. Composition of SDS/urea PAGE gels. 
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Sucrose buffer: 
250 mM sucrose, 10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, pH 7.0 
25x PI cocktail: 
(2.2.1) 
ACA buffer: 
750 mM -amino-caproic acid, 50 mM bis-tris, 0.5 mM EDTA, pH 7.0 
Loading buffer:  
750 mM -amino-caproic acid, 5% Coomassie G-250 
6x Gel buffer: 
3 M -amino-caproic acid, 0.3 M bis-tris 
Cathode buffer:  
50 mM tricine, 15 mM bis-tris, pH 7.0 
Dark blue cathode buffer: 
0.2% Coomassie G-250 in cathode buffer 
Anode buffer: 
50mM bis-tris, pH 7.0 
Reducing buffer:  
1% SDS (v/v), 1% -mercapto ethanol (v/v) in deionized H2O 
Transfer buffer: 
(2.2.4) 
Lower and Upper Tris: 
(2.2.3) 
Equilibration buffer: 
50 mM tris, 1% SDS (w/v), pH 6.8 
 
 
2.2.9 Exosome preparation by differential centrifugation and fractionation by density 
gradient centrifugation 
Exosomes from conditioned medium of cells were isolated by differential centrifugation, 
according to Théry and colleagues (Théry, et al., 2006) and Xu and colleagues (Xu, et al., 
2015). To remove detached cells the medium was centrifuged at 300xg for 10 min. The 
supernatant was then centrifuged at 2,000xg and 4°C for 20 min to get rid of dead cells and 
cell debris. Subsequently the supernatant was centrifuged at 10,000xg for 30 min. The 
resultant pellet (P10) containing microvesicles was kept and resuspended in RIPA lysis buffer. 
As a final step the supernatant was now subjected to ultracentrifugation at 100,000xg for 1 hour 
to sediment exosomes. The resultant pellet (P100) was resuspended in RIPA lysis buffer. All 
centrifugation steps were carried out at 4°C and after every centrifugation step a 1.4 ml aliquot 
of the supernatant was taken (S03, S2, S10 and S100) and subjected to TCA precipitation 
(see 2.2.2). Pellets, medium aliquots and cell lysates were analysed by subsequent WB 
analysis (see 2.2.3 - 2.2.4). 
For further fractionation, the exosome-containing P100 pellet was resuspended in 100 l 6% 
OptiPrep™/DMEM GlutaMAX™ and subjected to density gradient centrifugation. The density 
gradient was prepared using OptiPrep™, a 60% iodixanol solution, and DMEM GlutaMAX™ 
as diluent. The following solutions were layered one on top of the next with decreasing density 
from bottom to top, each of 1 ml volume: 6; 9.8; 13.6; 17.4; 21.2; 25; 28.8; 32.6; 36.4; 40.2 (v/v 
iodixanol). The exosome pellet was loaded on top of the gradient and centrifugation was 
carried out for 16 hours at 100,000xg at 4°C. Fractions of 1 ml each were collected after 
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centrifugation and proteins precipitated with TCA (see 2.2.2) before WB analysis (see 2.2.3 - 
2.2.4). Centrifugation and ultracentrifugation at 10,000xg and 100,000xg was carried out using 
an Optima™ XPN-80 with the swinging bucket rotor SW41Ti for volumes till 11 ml and the 
fixed angle rotor 45Ti for volumes of 35-70 ml. 
 
2.2.10 Cell fractionation by differential centrifugation 
Cytosolic, membrane and nuclear fractions were separated by differential centrifugation. Cells 
were subjected to osmotic lysis by adding 500 l hypotonic buffer supplemented with 1x-
concentrated PI cocktail. After 15-20 min incubation on ice, the cell lysate was transferred to 
a micro reaction tube and homogenised by passing the lysate 15 times through a 1-ml syringe 
needle (23G). After centrifugation at 1,000xg and 4°C for 5 min, the pellet containing the 
nuclear fraction was frozen at -20°C until further use for preparation of the nuclear fraction. 
The resultant post nuclear supernatant (PNS) was centrifuged at 13,200xg and 4°C for 1 hour 
to obtain the membrane pellet. The supernatant was transferred to a new tube and kept as the 
cytosolic fraction. The membrane pellet was resuspended in 50 l RIPA lysis buffer, incubated 
on ice for 10 min and then centrifuged at 13,200xg and 4°C for 15 min. The resultant 
supernatant was kept as the membrane fraction. The nuclear pellet (see above) could now be 
resuspended in 100 l buffer C, incubated on ice for 20 min, mixed from time to time, and then 
centrifuged at 13,200xg and 4°C for 15 min. The resultant supernatant was kept as nuclear 
fraction. Using the Pierce™ BCA protein assay kit the protein in cytosolic and membrane 
fraction were determined and 20 g of each fraction and corresponding volumes of the nuclear 
fraction were loaded on a SDS PAGE gel and subjected to WB analysis (see 2.2.3 - 2.2.4). 
 
Hypotonic buffer:  
10 mM tris (pH 7.5), 10 mM NaCl, 0.1 mM EGTA  
25x PI cocktail: (2.2.1) 
RIPA lysis buffer: (2.2.1) 
Buffer C:  
25 % glycerol (v/v), 20 mM HEPES (pH 7.9), 0.5 M NaCl, 1 mM EGTA, 1 mM EDTA (pH 8.0), 25 mM 
ȕ-glycerophosphate 
 
 
2.2.11 Subcellular fractionation of intracellular vesicles by density gradient 
centrifugation 
In order to analyse the subcellular distribution of proteins in more detail, the PNS of cell lysates 
(see above) was subjected to density gradient centrifugation to fractionate intracellular vesicles 
and organelles. BV-2 cells were lysed with 750 l hypotonic buffer as described earlier (see 
2.2.10). A density gradient was prepared using OptiPrep™, a 60% iodixanol solution, and 
diluent buffer. The following percentage solutions (%, v/v) were carefully layered one on top of 
the next with decreasing density from bottom to top, each of 1.2 ml volume: 
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siRNA experiments: 2.5 5.0 7.5 12.5 15.0 17.5 20.0 30.0 50.0 
shRNA experiments: 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 30.0 
  
500 l of the PNS were loaded on top of the gradient and centrifugation at 100,000xg and 4°C 
for 16 hours was carried out using an Optima™ XPN-80 with the swing bucket rotor SW41Ti. 
After centrifugation, 13 fractions of 750 l each and a 14th last fraction of 1.5 ml were collected 
from top to bottom of the gradient. Proteins were concentrated via TCA precipitation (see 2.2.2) 
before the fractions were subjected to WB analysis (see 2.2.3 - 2.2.4). 
 
Diluent buffer: 
0.25 mM sucrose, 6 mM EDTA, 60 mM HEPES, pH 7.4 
 
2.3 Molecular biological techniques 
2.3.1 RNA isolation from eukaryotic cells and cDNA synthesis by reverse 
transcription (RT) 
Total RNA was extracted from BV-2 cells using the RNeasy® Mini Kit according to the 
manufacturer´s instructions. The cells were harvested by trypsination or by scraping in PBS 
using a cell scraper. The pelleted cells were either frozen at -80°C until further use or directly 
lysed by adding appropriate amount of a guanidine thiocyanate-containing buffer 
supplemented with -mercapto ethanol. Homogenisation was carried out by passing the cell 
suspension 5 times through a syringe needle (20G) and the RNA was isolated using an RNA-
binding silica-based membrane. The membrane specifically binds RNA of more than 200 
nucleotides in length thereby allowing the enrichment of mRNAs. RNA was eluted with 
deionized RNAse-free water and stored at -80°C. 
Before reverse transcription of RNA samples to get cDNA, endogenous genomic DNA was 
removed by digestion with DNase I. 2 g RNA were incubated with 1 U DNase I in 1x-
concentrated DNase reaction buffer for 20 min at 37°C. The reaction was stopped by heat 
inactivation at 75°C for 10 min. Subsequently, the RNA was reverse-transcribed with the 
SuperScript® III First-Strand Synthesis System using random hexamer primers according to 
the manufacturer´s instructions in a volume of 25 l. The RNA was incubated with hexameric 
primers at 25°C for 10 min. Then mixed deoxyribose nucleoside triphosphates (dNTPs), 
MgCl2, DTT, RNase inhibitor and the SuperScript III were added and cDNA synthesis reaction 
was carried out at 50°C for 50 min and terminated by heat inactivation of the reverse 
transcriptase at 85°C for 5 min. cDNA was stored at -20°C and aliquots of 1 l cDNA were 
subjected to PCR as template DNA for cloning or expression analysis (see 2.3.2). 
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2.3.2 Polymerase chain reaction (PCR) 
DNA sequences were amplified by polymerase chain reaction (PCR). In order to subclone 
certain DNA sequences obtained by reverse transcription of mRNA from eukaryotic cells (see 
2.3.1), Pfu DNA polymerase was as added together with appropriate primers (see Table 13) 
that contain the respective restriction sites. A PCR master mix solution containing dNTPs, 
forward (fw) and reverse (rev) primer, cDNA as template and Pfu polymerase was prepared: 
 
10x Pfu buffer (with MgSO4) 5 l cDNA (~80 ng) 1 l 
dNTPs (0.2 mM each) 5 l Pfu polymerase (2-3 U/l) 1 l 
fw primer (0.1 M) 1 l DNase-free H2O to 50 l 
rev primer (0.1 M) 1 l   
 
Basic PCR program: 
 
1. Initial denaturation 95°C, 3 min 
2. Denaturation 95°C, 30 sec 
3. Annealing variable, 30 sec 
4. Elongation 72°C, 2 min/kbp 
5. Final elongation 72°C, 5 min 
repetition step 2-4  25-30 times 
 
The PCR program varied according to the melting temperature of the primers and the length 
of the target DNA that is to be amplified. Briefly, the DNA strands were denatured, fw and rev 
primer were annealed to the DNA according to the annealing temperatures listed in Table 13 
and elongated (2 min/kilo base pair (kbp)) by the Pfu polymerase to create a new DNA strand. 
Denaturation, annealing and elongation were repeated for 25-30 times to amplify the DNA 
fragment. 
PCR products were separated by agarose gel electrophoresis. PCR samples were mixed with 
OrangeG loading dye and loaded on gels (1-1.5% agarose in TBE buffer) containing GelRed™ 
(2 l/100 ml). After electrophoresis, DNA was visualised using UV light which induces 
fluorescence of the DNA-intercalating GelRed™. The fluorescence was detected by an imager 
from BioRad. 
Other PCR applications, including a colony screen after cloning or expression analysis were 
carried out using Taq DNA polymerase and a 5x master mix from NEB. For colony screen 
PCR, a 12.5 l PCR master mix was prepared containing 1x-concentrated NEB Taq master 
mix and 0.1 M of each fw and rev primers. As DNA template 1 l of bacterial culture for each 
tested colony (see 2.3.3) was used. The program described above was varied for elongation 
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time to 1 min/kbp for Taq polymerase in comparison to Pfu polymerase. For expression 
analysis a 25 l PCR master mix was prepared and cDNA transcribed from isolated RNA (see 
2.3.1) of BV-2 cells was used as template for the reaction. 
 
TBE buffer:  
89 mM tris, 89 mM boric acid, 2 mM EDTA, pH 8.0  
6x OrangeG loading dye:  
60% glycerin, 0.15 % OrangeG, 60 mM EDTA, 10 mM tris, pH 7.6 
 
Name Primer Sequence 
Annealing 
temperature 
IDE Bait 
fw: AAA GAA TTC TTC ATC ATC CAG TCA GAA AAA CC 
rev: TTT GGA TCC GAG TTT TGC AGC CAT GAA GTT 
59°C 
Vps4B-Flag 
fw: AAA GAA TTC ATG GCG TCC ACG AAC ACC AAC CTG CAG AAA 
rev: TTT GGA TCC TTA CTT ATC GTC ATC GTC TTT GTA ATC GCC TTC 
CTG GCC AAA 
55°C 
Vps4B-
MBP 
fw: AAA GAA TTC ATG GCG TCC ACG AAC ACC 
rev: GGA TCC TTA GCC TTC CTG GCC AAA ATC 
55°C 
Vps4B-
mCherry 
fw: AAA GAA TTC ATG GCG TCC ACG AAC ACC 
rev: TTT GGA TCC TTG CCT TCC TGG CCA AAA TC 
60°C 
Table 13. Cloning primers and primers for expression analysis 
 
2.3.3 Cloning of expression plasmids 
PCR products, further referred to as insert, and the respective vector were digested with the 
restriction enzymes EcoRI and BamHI for 2 hours at 37°C (2 U each enzyme/1 g DNA in 1x 
EcoRI buffer or 2 U BamHI + 4 U EcoRI/1 g DNA in BamHI buffer). In parallel a positive 
control digestion was carried out to check for successful restriction. Following restriction, 
vectors were dephosphorylated by addition of 1 U of FastAP thermosensitive alkaline 
phosphatase for 10 min at 37°C. Insert, vector and positive control were separated on an 
agarose gel and visualised by UV light. The restricted vector and insert were cut out of the gel 
and purified with the WIZARD® SV Gel and PCR Clean Up System according to the 
manufacturer’s instructions. The purified insert and vector were mixed in a molar ratio of γ:1 
to 8:1 and ligated by T4 DNA ligase (50-100 ng vector, respective amount of insert, 1x T4 
ligase buffer, 2 U T4 ligase) for 30 min at RT. A ligation control was performed in parallel 
containing only vector (without insert DNA). Directly after ligation, chemically competent E.coli 
(TOP10) cells were transformed. The bacteria were thawed and then incubated with the ligated 
DNA for 20 min on ice. To allow efficient DNA uptake, a heat shock at 42°C for 45 sec was 
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performed followed by incubation on ice for 2 min. 950 l SOC medium was added to the 
bacteria and they were shaken for 1-1.5 hour at 37°C. After pelleting the bacteria for 1 min at 
3,000xg they were resuspended in 30-50 l SOC medium and spread to an LB agar plate 
containing the appropriate antibiotics.  
The plates were incubated at 37°C overnight and growing colonies were subsequently tested 
for the particular DNA fragment using colony screen PCR. For this the colonies were picked 
into 200 l antibiotics-containing SOC medium and shaken for 3-5 hours at 37°C. 1 µl of these 
bacterial cultures was used as template for colony screen PCR (see 2.3.2). In parallel a positive 
and negative control were run. Positive clones showing a signal in the PCR were sequenced 
by an external company to control for mutations and exact sequence. In some cases, an 
additional control digestion with the appropriate restriction enzymes was performed before the 
DNA sequencing.  
 
Name of construct NCBI accession number Vector Restriction enzymes 
IDE Bait 
NM_031156.3 
CDS position (bp): 2568-3083 
pGBKT7 EcoRI/BamHI 
Vps4B-Flag NM_009190.2 pcDNA 3.1 (-) EcoRI/BamHI 
Vps4B-MBP NM_009190.2 pMal-c2 EcoRI/BamHI 
Vps4B-mCherry NM_009190.2 pmCherry-N1 EcoRI/BamHI 
Table 14. Generated constructs. 
 
2.3.4 Purification of plasmid DNA from E. coli 
Purification of small amounts of plasmid DNA (< 40 g) from E.coli was carried out using the 
NucleoSpin® Plasmid EasyPure kit according to the manufacturer’s instructions taking 
bacteria of a 2 ml overnight culture in LB medium with the appropriate antibiotics. For isolation 
of higher amounts of plasmid DNA (0.5-1.5 mg) the NucleoBond® Xtra Maxi kit was used 
according to the manufacturer’s instructions taking bacteria of a β50 ml overnight culture in LB 
medium with the appropriate antibiotics. In both kits the pelleted bacteria were resuspended 
and incubated with lysis and neutralisation buffer. Subsequently, the suspension was cleared 
from precipitated proteins and cell debris by centrifugation and loaded onto a DNA-binding 
column. After elution from the column the DNA was either ready to use (NucleoSpin® Plasmid 
EasyPure kit) or was once again precipitated by isopropanol and washed with 70% ethanol to 
get a higher purity (NucleoBond® Xtra Maxi kit). 
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2.3.5 Yeast two-hybrid (Y2H) – protein interaction studies 
All YβH experiments were carried out using Matchmaker™ Gold Yeast Two-Hybrid System, 
Yeastmaker™ Yeast Transformation System β and the Easy Yeast Plasmid Isolation kit. The 
bacterial and yeast strains as well as plasmids used in this study are listed in Table 15. 
 
Strain or plasmid relevant characteristics 
S. cerevisiae 
Y2H Gold HIS3, ADE2, AUR1-C, MEL1 
Y187 MEL1, lacZ 
E. coli 
TOP10 chemically competent cells 
Plasmids 
pGBKT7 Gal4-DBD, TRP1, Kanr 
pGADT7 Gal4-AD, LEU2, Ampr 
pGBKT7-p53 pGBKT7 derivative containing DBD-p53 
pGBKT7-Lam pGBKT7 derivative containing DBD-Laminin 
pGADT7-T pGADT7 derivative containing AD-SV40 large T-antigen 
IDE bait pGBKT7 derivative containing DBD-IDE bait 
Table 15. Yeast strains and plasmids used in Y2H studies 
 
Principle: 
The bait protein is expressed as a fusion protein with the Gal4 DNA-binding domain (DNA-BD) 
by cloning into the plasmid pGBKT7, the prey proteins are fused to the Gal4 activation domain 
(AD) by cloning into pGADT7. The general principle was described by Stanley Fields and 
colleagues (Fields & Song, 1989; Chien, et al., 1991). Interaction of bait and prey protein leads 
to transcription activation of four reporter genes (shown in Figure 5) enabling the yeast to grow 
in the respective selection medium (see also Figure 5).  
 
AUR1-C AUR1-C expression provides resistance to Aureobasidin A. 
HIS3 HIS3 expression enables the cell to synthesize the essential amino acid histidine. 
ADE2 Ade2 expression enables the cell to synthesize the essential adenine. 
MEL1 Enables the cell to hydrolyse X--Gal and produce a blue precipitate. 
 
Furthermore, the used plasmids also encode for TRP1 (pGBKT7) and LEU2 (pGADT7) 
enabling the cell transformed with the respective vector to synthesize tryptophan or leucine 
and grow in the respective selection medium.  
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Figure 5. Principle of Matchmaker™ Gold YβH System: General principle of YβH (left), reporter gene constructs 
in Matchmaker yeast strains Y2H Gold and Y187 (right). Source: Matchmaker™ Gold YβH System User Manual. 
cDNA library screen:  
A mouse brain Mate & Plate™ cDNA library was purchased from Takara Clontech. The library 
is cloned into a Gal4 AD vector and transformed into the yeast strain Y187, furthermore, it is 
normalized by selectively removing transcripts with high frequency to increase the proportion 
of low abundant transcripts. Y2H Gold transformed with the created IDE bait construct (see 
Table 14) were generated using the Yeast 
Transformation System 2 following the 
manufacturer’s instructions. Y187 expressing 
the cDNA library and the IDE bait-expressing 
Y2H Gold were mated following the 
instructions of the Matchmaker™ YβH Gold 
kit. Briefly, the IDE bait-containing Y2H Gold 
and the cDNA library-containing Y187 were 
cultured together under rich medium 
condition, which induces spontaneous mating (Merlini, et al., 2013) traceable by the formation 
of diploid zygotes with a typical 3-lobed shape (see Figure 6). Subsequently a dilution of the 
mated cells was streaked out on single (SD) and double dropout (DDO) agar plates lacking 
the essential amino acids leucine and tryptophan, respectively, to determine the mating 
efficiency. The rest of the mating culture was plated on DDO agar plates additionally containing 
X--Gal and Aureobasidin A (DDO/X/A). Blue colonies were picked, plated on quadruple 
dropout agar plates (QDO/-Trp/-Leu/-His/-Ade) containing X--Gal and Aureobasidin A 
(QDO/X/A) to select for positive interaction partners. Two screens were carried out. For both 
a sufficient number of screened diploid clones after the mating procedure could be achieved 
(screen 1: 4.72x106; screen 2: 5.85x106), a minimum of 1 million screened clones is 
recommended for efficient detection of genuine interactions. The calculated mating efficiencies 
exceeded the minimum value given of 2% (screen 1: 11.7%; screen 2: 15.1%). After growing 
on QDO/X/A colony PCR was performed using the Matchmaker® Insert Check PCR Mix 2 
Figure 6. Typical 3-lobed „Mickey mouse“-shaped zygote 
during mating of the strains Y2H Gold and Y187. 
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following the manufacturer’s instructions. The PCR fragments were sequenced via an external 
company. 
 
Plasmid rescue and co-transformation:  
Plasmids of the respective clones were isolated following the instructions of the Easy Yeast 
Plasmid Isolation kit. TOP10 competent cells were transformed with these plasmids which then 
were again sequenced. Co-transformation of bait and the respective prey plasmids were 
carried out following the instructions of the Matchmaker™ YβH Gold Kit and the Yeastmaker™ 
Transformation System 2. This served to distinguish genuine positive which can activate 
reporter gene expression only by interaction with the bait protein and false positive clones, 
which can autoactivate it without bait presence. 
 
2.4 Statistical analysis 
Statistical analysis of experiments comparing two different individual groups was carried out 
using the student’s t-test (unpaired, two-sided). In experiments comparing more than two 
individual groups with each other a One-Way ANOVA was carried out (with Dunnett’s or 
Sidak’s post hoc test). Confidence level: 95%. The number of independently performed 
experiments is displayed by n. If not indicated differently the diagrams show the mean value 
and the corresponding standard deviation (SD). The P values used for classification of 
statistical significance were the following: p < 0.05, *; p < 0.01, **; p < 0.001, ***. No further 
indication or the abbreviation ns stands for a statistically non-significant difference. 
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C Results 
1. Stimulation of IDE secretion by serotonin in microglia 
1.1 Serotonin increases IDE release from microglial cells. 
Previous studies showed that different cell lines, including BV-2 microglial cells (Tamboli, et 
al., 2010), secrete IDE via an unconventional secretory pathway (Zhao, et al., 2009; Bulloj, et 
al., 2010). To assess whether serotonin (5-HT) affects the release of IDE, BV-2 cells or primary 
mouse microglia were incubated for 16 hours with 25 M 5-HT and IDE was detected in 
conditioned media and cell lysates by WB. An almost 2-fold increase in IDE levels in 
conditioned media is detected in comparison to control cells for BV-2 (197.7  92.8% vs. NTC, 
Figure 7A) and primary mouse microglia (191.5  44.6% vs. NTC, Figure 7B), suggesting that 
5-HT can stimulate the release of IDE from microglial cells. 
 
Figure 7. Serotonin increases the release of IDE from BV-2 and primary microglial cells. Western blot analysis 
of IDE protein levels in conditioned media and lysates of BV-2 cells (A, n=7; 4 in triplicates, 3 in duplicates) and 
primary mouse microglia (B, n=1 in triplicates) upon administration of 25 M 5-HT for 16 hours. Relative secretion 
is expressed as ratio of secreted to intracellular IDE protein levels. Statistical analysis was done using a two-sided 
unpaired student’s t-test (A) and One-Way ANOVA (Dunnett’s post hoc test, B, see also Figure 11B+E). Values 
represent means  SD. 
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1.2 Expression of 5-HT receptors in BV-2 cells and in primary mouse microglia. 
Since it was shown that some 5-HT receptors (5-HTRs) are found in microglial cells (Krabbe, 
et al., 2012), it was tested which 5-HTRs were expressed in the microglia cell line BV-2 in 
comparison to primary mouse microglia. Performing reverse transcription PCR of several 
5-HTRs using cDNA synthesized from isolated RNA revealed that BV-2 microglial cells 
express the 5-HTRs 1b, 2a, 2b, 3 and 4. Primary mouse microglia also express the 5-HTRs 
2b, 3 and 4, while the receptors 1b and 2a were not detected. The receptors 2b and 3 show 
semiquantitatively the highest expression (Figure 8). These results first indicate that BV-2 cells 
and primary mouse microglia are similar but different in the 5-HTR expression pattern, and 
second, that 5-HT might activate several G-proteins and related pathways in BV-2 and 
microglial cells. Furthermore these results are comparable to the expression pattern in primary 
microglia found by Krabbe and colleagues (Krabbe, et al., 2012). 
 
Figure 8. Expression analysis of 5-HTRs in BV-2 cells and primary mouse microglia. Expression analysis by 
PCR was carried out using specific primers for the 5-HTRs 1a, b, d; 2a, b, c; 3; 4; 5a; 6 and 7 upon RNA isolation 
and subsequent cDNA synthesis from BV-2 and primary mouse microglial cells. The expression pattern is presented 
in the table (right). 
 
1.3 Involvement of 5-HT2a, 5-HT2b and 5-HT4 receptors in the regulation of IDE 
release. 
To test if the expressed 5-HTRs 2a, 2b and 4 are involved in the stimulation of IDE release, 
cells were simultaneously treated with 5-HT and specific antagonists for the three receptors. 
Altanserine was used as selective 5-HT2aR antagonist, RS127445 as selective antagonist for 
5-HT2bR and GR113808 as selective antagonist for the 5-HT4R. While 5-HT alone stimulates 
the release of IDE, co-treatment with the three antagonists reduces the effect (Figure 9). 
Altanserine and GR113808 treatment shows a reduction of IDE secretion to the basal level of 
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control cells (100.13  11.4% and 86.2  42.8% respectively vs. NTC). RS127445 diminishes 
the release of IDE even stronger to approximately 40% of the basal secretion level 
(36.7  6.5% vs. NTC). These results suggest the involvement of all three G protein-coupled 
receptors in triggering IDE release by 5-HT treatment in BV-2 cells. 
 
Figure 9. The 5-HT receptors 2a, 2b and 4 are involved in the regulation of IDE release. Western blot analysis 
of IDE protein levels in conditioned media and lysates of BV-2 cells after treatment with 25 M 5-HT and the 
selective 5-HTR antagonists Altanserine (10 nM, 5-HT2aR), RS127445 (5 M, 5-HT2bR) and GR113808 (20 nM, 
5-HT4R) for 16 hours, additional antagonist pre-treatment for 6 hours (n=7 for 5-HT see also Figure 7; n=3 in 2x 
triplicates, 1x duplicates for 5-HT+antagonists). Relative secretion is expressed as ratio of secreted to intracellular 
IDE protein levels. Statistical analysis was done using a One-Way ANOVA (Sidak’s post hoc test). Values represent 
means  SD. 
 
1.4 Activation of 5-HT4R promotes the release of IDE via PLC-dependent Ca2+ 
mobilization. 
IDE is released associated to exosomes (Bulloj, et al., 2010; Tamboli, et al., 2010) and several 
previous studies showed already that exosome secretion is regulated by the level of [Ca2+]i 
(Savina, et al., 2003; Raposo, et al., 1997). The 5-HTRs 2a and 2b are Gq/11 protein-coupled 
receptors that mediate activation of phospholipase C (PLC) leading to an increase in [Ca2+]i 
(Raymond, et al., 2001; Bockaert, et al., 2006; Peroutka, 1995). Only little is known about the 
role of 5-HT4R in the regulation of [Ca2+]i. Rather, 5-HT4R is known to couple with Gs protein 
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and to increase intracellular levels of cAMP by activation of the adenylate cyclase (AC) (Fagni, 
et al., 1992). However, additional studies showed that cAMP can directly activate the guanine-
exchange factor (GEF) Epac that can activate PLC via the Rap GTPases Rap1 or Rap2B (de 
Rooij, et al., 1998; Schmidt, et al., 2001; Oestreich, et al., 2007). Several pharmacological 
treatments were carried out to test whether these PLC-activating pathways are also triggered 
by 5-HT4R in BV-2 cells. First, BV-2 cells were treated with the partial 5-HT4R agonist 
ML10302. Treatment of BV-2 cells with ML10302 significantly increases the release of IDE 
(151.9  57.9% vs. NTC, Figure 10A). This effect is diminished by the 5-HT4R antagonist 
GR113808 (133.0  62.4% vs. NTC, Figure 10A). 
Treatment of BV-2 cells with the pertussis toxin (PTX) results in an elevated IDE secretion as 
well, indicating that an increase in intracellular cAMP (Burns, 1988) indeed stimulates release 
of IDE (Glebov, et al., 2015). 
 
Figure 10. Activation of 5-HT4R stimulates IDE release via an increase in intracellular cAMP levels. (A) 
Western blot analysis of IDE protein levels in conditioned media and lysates of BV-2 cells upon treatment with 
ML10302 (10 nM, n=4 in triplicates) and ML10302 + GR113808 (20 nM, n=2 in triplicates) for 16 hours, additional 
pre-treatment with GR113808 for 6 hours. Relative secretion is expressed as ratio of secreted to intracellular IDE 
protein levels. Statistical analysis was done using a One-Way ANOVA (Dunnett’s post hoc test). Values represent 
means  SD. (B) Western blot analysis of IDE protein levels in conditioned media and lysates of BV-2 cells after 
treatment with Pertussis toxin (PTX) carried out by Olaf Merkel (published in (Glebov, et al., 2015)). 
8-CPT-2Me-cAMP (8-CPT) is a selective activator of Epac and was used to examine the 
potential influence of Epac on IDE release without prior stimulation of 5-HT. Administration of 
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8-CPT results in an increase of IDE release from BV-2 cells (201.4  79.1% vs. NTC, Figure 
11A+D) as well as from primary mouse microglia (149.9  13.6% vs. NTC, Figure 11B+E). Also 
direct stimulation of PLC by treatment of BV-2 cells with the activator m-3m3FBS (3m3FBS) 
leads to an increase in IDE release (126.6  16.6% vs. NTC, Figure 11C+F) and is reduced to 
almost basal levels of control cells by the PLC inhibitor U73122 (103.2  17.0% vs. NTC, 
Figure 11C+F). 
These results suggest that 5-HT4R might also contribute to the stimulation of IDE release via 
an increase in cAMP which leads to activation of Epac and PLC. 
 
Figure 11. Activation of Epac and PLC promotes the release of IDE. Western blot analysis of IDE protein levels 
in conditioned media and lysates of BV-2 cells (A+D, n=3 in triplicates) or primary mouse microglia (B+E, n=1 in 
triplicates) after treatment with the Epac activator 8-CPT (5 µM) for 16 hours. (C+F) IDE protein levels in conditioned 
media and lysates of BV-2 cells after treatment with 3m3FBS (5 µM) and U73122 (10 M) for 3 hours (n=2 in 
triplicates), additional pre-treatment with U73122 for 16 hours. Relative secretion is expressed as ratio of secreted 
to intracellular IDE protein levels. Statistical analysis was done using a two-sided unpaired student’s t-test (D) and 
a One-Way ANOVA (Dunnett’s post hoc test; F; E + Figure 7B). Values represent means  SD. 
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1.5 5-HT increases cytosolic Ca2+ that stimulates IDE release. 
The experiments addressing the stimulatory effect of 5-HT on IDE secretion in BV-2 and 
primary microglial cells so far revealed the involvement of PLC. PLC induces an increase in 
[Ca2+]i by formation of inositol 1,4,5-triphosphate (IP3). IP3 activates IP3 receptors acting as 
Ca2+ channels in the ER and this way opens intracellular calcium stores causing an elevation 
of [Ca2+]i. This increased [Ca2+]i can stimulate the fusion of MVBs with the plasma membrane 
leading to the release of exosomes (Raposo, et al., 1997; Savina, et al., 2003). Several studies 
already showed that 5-HT leads to an increased formation of IP3 and elevated [Ca2+]i mainly 
attributed to the signalling of 5-HT2Rs (Schmuck, et al., 1994; Saini, et al., 2003; Bonhaus, et 
al., 1999). 
 
Figure 12. 5-HT-stimulated increase in [Ca2+]I triggers IDE release in BV-2 microglial cells. (A) Western blot 
analysis of IDE protein levels in conditioned media and lysates of BV-2 cells after treatment with 1 M Thapsigargin 
for 2 hours (n=1 in triplicates). Relative secretion is expressed as ratio of secreted to intracellular IDE protein levels. 
Statistical analysis was done using a two-sided unpaired student’s t-test. Values represent means  SD. (B) Time 
lapse recordings of BV-2 cells, that were bulk-labelled with the Ca2+ indicator Fluo-4, before and after application 
of 25 M 5-HT (grey background) with or without 16 hours pre-treatment of the 5-HTR antagonists Altanserine 
(10 nM), RS127445 (5 µM) and GR113808 (20 nM) to monitor [Ca2+]i (source: (Glebov, et al., 2015), Figure 4B). 
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To test whether 5-HT stimulates the secretion of IDE associated with exosomes via increasing 
the [Ca2+]i, first, the effect of Thapsigargin that raises the [Ca2+]i (Lytton, et al., 1991) was 
examined. IDE secretion slightly elevates upon cell treatment with Thapsigargin 
(127.5  11.9% vs. NTC, Figure 12A) suggesting that an increase of [Ca2+]i stimulates the 
release of IDE. This assumption is further supported by the observation that Monensin also 
increased IDE release from BV-2 cells (see below, 2.3). Monensin induces an elevation in 
[Ca2+]i and this way increases the release of exosomes (Savina, et al., 2003). Next, Ca2+ 
measurements were kindly carried out by Dr. Ronald Jabs to examine the effect of 5-HT and 
5-HTR modulators on [Ca2+]i. Application of 5-HT to BV-2 cells significantly increases [Ca2+]i. 
This effect is attenuated by pre-treatment of cells with the 5-HTR antagonists Altanserine, 
RS127445 or GR113808 (see Figure 12B). The strongest reduction is observed when cells 
are pre-treated with all three antagonists simultaneously.  
These results indicate that 5-HT stimulates IDE release from BV-2 cells by elevation of [Ca2+]i 
which leads to the fusion of MVBs with the plasma membrane and release of IDE-loaded 
exosomes into the extracellular media. 
 
1.6 5-HT stimulates the release of exosome-associated IDE. 
Recent studies showed that statins promote degradation of extracellular Aȕ due to the 
stimulation of exosome-associated secretion of IDE (Tamboli, et al., 2010). To examine if the 
5-HT-induced elevation of IDE release is also linked to an increase in exosome secretion, 
exosomes were isolated from conditioned media of BV-2 cells by differential centrifugation.  
Treatment with 5-HT indeed increases IDE levels in the exosome fraction (P100) 
(142.7 ± 11.6% vs. NTC, Figure 13A). Also other exosomal marker proteins like Flotillin-1 
(213.5 ± 6.8% vs. NTC), Alix (120.7 ± 17.6% vs. NTC) and Actin (120.7 ± 17.9% vs. NTC) 
show a significant (Flotillin-1) or non-significant elevation in the exosome fraction P100 (see 
Figure 13A). Subsequent density gradient centrifugation of the isolated exosomes by loading 
the P100 fraction onto a density gradient shows a co-fractionation of IDE with the exosomal 
markers Alix, Flotillin-1 and Actin. In comparison to the typical exosomal marker proteins, IDE 
shows a broader distribution across the fractions including also fractions of lower density. 
However, the majority of IDE co-fractionized with Alix, Flotillin-1 and Actin (see Figure 13B). 
Furthermore, levels of IDE that co-fractionate with the common exosome marker Alix are 
elevated upon the treatment with 5-HT (highlighted by the black boxes in Figure 13B). 
Microvesicle-associated IDE, however, is rather decreased upon treatment with 5-HT. Similar 
effects are observed for Flotillin-1 and Actin in the microvesicle fraction P10 (Figure 13A). 
These findings indeed suggest that the elevation in IDE secretion in BV-2 cells stimulated by 
5-HT can be attributed to an increased release of exosomes.  
Results  58 
 
Figure 13. 5-HT stimulates the release of exosomes from BV-2 cells. (A) Western blot analysis of IDE, Flotillin-1, 
Alix and Actin in P10 and P100 fractions and lysates of BV-2 cells upon treatment with 25 µM 5-HT for 16 hours 
(n=2 in single replicate for P10 and P100). P10 and P100 were prepared by differential centrifugation from 
conditioned media. Relative protein levels are expressed as the ratio of signals in the P100 fraction to that in cell 
lysates. Statistical analysis was carried out using a two-sided unpaired student’s t-test. Values (5-HT treatment) 
represent means  SD. (B) Western blot analysis of IDE, Flotillin-1, Alix and Actin after fractionation of the exosome 
fraction P100 through density gradient centrifugation. The density gradient was prepared by OptiPrep® solutions. 
The exosome fraction is represented by the exosomal marker Alix (black boxes). 
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1.7 Neurons can stimulate IDE secretion from BV-2 microglial cells. 
The communication between neurons and microglia in the brain plays an essential role in 
neuroinflammation as well as for neurogenesis and neuroprotection (Gemma, et al., 2010). 
Neuron-derived signals, for example, can regulate microglial activity (Biber, et al., 2007; Eyo 
& Wu, 2013). Thus, it was tested whether neurons can stimulate the secretion of IDE from 
microglia by release of 5-HT. Co-culture of BV-2 cells with primary mouse neurons indeed 
causes a significant increase in IDE release from BV-2 cells (284.2 ± 14.4% vs. BV-2 alone, 
233.3 ± 42.3% in the presence of the 5-HT precursor 5-hydroxy tryptophan (5-HTP), Figure 
14A+B). The neurons themselves secrete only low quantities of IDE (Figure 14A). Addition of 
5-HTP should assure neuronal 5-HT production in case neurons would not express the 
tryptophan hydroxylase. 5-HTP addition shows a moderate decrease in the effect observed for 
IDE secretion which, however, is not significant. 
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Figure 14. Neurons can stimulate IDE secretion from BV-2 microglial cells. Western blot analysis of IDE protein 
levels in conditioned media and lysates of BV-2 cells upon co-culture with primary mouse neurons (A+B, n=1, BV-2 
in triplicate, neurons in duplicate, BV-2 + neurons in duplicate, BV-2 + 5-HTP + neurons in septuplicate) or co-culture 
with ES-derived serotonergic neurons (ESN) (C-F, n=3 in triplicate). IDE secretion from BV-2 cells is increased in 
the presence of neuronal cells (B+D). Co-treatment of co-cultured BV-2 and ESN with the 5-HTR antagonists 
Altanserine (10 nM), RS127445 (5 µM) and GR113808 (20 nM) leads to a significant diminished effect but also 
decreases IDE secretion in BV-2 cells alone (C+D). Upon co-culture with ESN absolute levels of secreted IDE from 
BV-2 cells (E) are stronger increased than relative IDE secretion (D) and accompanied by an elevated IDE 
expression (F). Relative secretion is expressed as ratio of secreted to intracellular IDE protein levels, relative 
expression as normalization of intracellular IDE to Actin protein level. Statistical analysis was done using a One-
Way ANOVA (Sidak’s post hoc test). Values represent means  SD. 
To determine in more detail if neuronal 5-HT release stimulates IDE release, a co-culture 
approach of BV-2 cells with ES-derived serotonergic neurons (ESN) was carried out. 90% of 
the ES-derived neurons exhibit a serotonergic phenotype and release 0.24 ± 0.03 pmol 
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5-HT/well/min (Lau, et al., 2010). Co-culture of BV-2 cells with these ESN results in an 
increased IDE release by BV-2 cells (140.1 ± 31.2% vs. BV-2 alone, Figure 14C+D). This effect 
is reduced to basal levels of BV-2 cells alone by co-treatment with the 5-HTR antagonists 
Altanserine, RS127445 and GR113808 (102.6 ± 33.1% vs. BV-2 alone, Figure 14C+D). ESN 
themselves secrete only low quantities of IDE (see Figure 14C). However, also treatment of 
BV-2 cells alone with the three antagonists leads to a significant decrease of IDE release 
(65.3 ± 12.7% vs. BV-2 alone), similar in magnitude as observed for co-cultured BV-2 cells and 
ESN. This rather suggests an at least partial independency of 5-HT stimulation for the 
observed effect. 
The absolute amount of secreted IDE by BV-2 cells is even more elevated by co-culture with 
ESN (230.4 ± 81.3% vs. BV-2 alone, Figure 14E) in comparison to the approximately 1.5-fold 
increase in relative IDE secretion (secreted/intracellular IDE). Also here a significant reduction 
by co-treatment with the three antagonists can be detected (128.6 ± 61.0% vs. BV-2 alone, 
Figure 14E). The increase of secreted IDE is accompanied by an increased IDE expression in 
BV-2 cells after co-culture with ESN (174.1 ± 47.5% vs. BV-2 alone, Figure 14F), which is 
partially diminished in the presence of the three 5-HTR antagonists (131.9 ± 41.2% vs. BV-2 
alone, Figure 14F). 
These results suggest that serotonergic neurons not only stimulate the secretion of IDE from 
BV-2 microglial cells, but also induce an increase in IDE expression. The underlying 
mechanisms leading to an increase in IDE expression need to be elucidated. Also the actual 
proportion of neuronal 5-HT-mediated stimulation of IDE secretion in BV-2 cells needs further 
examinations. 
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2. Molecular mechanisms in IDE secretion 
2.1 Differential effects of nSMase2 and ceramide in the release of exosomal 
proteins in distinct cell types 
The mechanisms for protein sorting to MVBs during inward budding of intraluminal vesicles 
are not fully understood. ESCRT- dependent (Babst, et al., 1998; Baietti, et al., 2012; Gan & 
Gould, 2011) and ESCRT-independent (Trajkovic, et al., 2008; van Niel, et al., 2011; Alonso, 
et al., 2011) mechanisms have been identified. Trajkovic and colleagues showed that inward 
budding is triggered by raft-based microdomains enriched in ceramides. To decrease ceramide 
levels they treated cells with GW4869, an inhibitor for the neutral sphingomyelinase 2 
(nSMase2), that catalyses the conversion of sphingomyelin to ceramide. 
In order to examine the effect of nSMase2 inhibition on exosome release, and in particular on 
the secretion of IDE, BV-2 cells were treated with 1.5 and 5 µM GW4869. Inhibition of nSMase2 
with GW4869 causes a significant increase in IDE release in BV-2 microglial cells (1.5 µM: 
173.8 ± 34.4% vs. NTC; 5 µM: 256.6 ± 50.2% vs. NTC; Figure 15A). 
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Figure 15. Inhibition of nSMase2 stimulates release of IDE in the microglia cell lines BV-2 and N9. Western 
blot analysis of IDE, Alix and Flotillin-1 protein levels in conditioned media and lysates of BV2 (A) and N9 cells (B) 
upon treatment with 1.5 M (n=1 in triplicates) and 5 M GW4869 (n=2 in triplicates for BV-2, n=1 in triplicates for 
N9) for 16 hours. Relative secretion is expressed as ratio of secreted to intracellular protein levels. Statistical 
analysis was done using a One-Way ANOVA (Dunnett’s post hoc test). Values represent means  SD. 
In comparison, the secretion of the exosome markers Alix (1.5 M: 94.9 ± 14.4% vs. NTC; 
5 M: 86.1 ± 5.1% vs. NTC) and Flotillin-1 (1.5 M: 111.5 ± 19.9% vs. NTC; 5 M: 
81.0 ± 19.8% vs. NTC) are rather unaffected by GW4869 treatment (Figure 15A). These 
results contradict the findings by Trajkovic and colleagues showing a decreased release of the 
exosome-associated proteins PLP and CD63 in Oli-neu cells upon GW4869 treatment 
(Trajkovic, et al., 2008). In addition to BV-2 cells, another mouse microglial cell line, N9, was 
analysed. GW4869 treatment also here increases IDE secretion in N9 cells at 5 M 
(183.7 ± 22.9% vs. NTC, Figure 15B), whereas 1.5 M shows no significant effect 
(82.7 ± 2.7% vs. NTC, Figure 15B). However, secretion of Alix and Flotillin-1 is significantly 
decreased after inhibition of nSMase2 (1.5 M: Alix 47.3 ± 1.9% vs. NTC, Flotillin-1 
42.6 ± 4.6% vs. NTC; 5 M: Alix 49.8 ± 1.3% vs. NTC, Flotillin-1 63.5 ± 0.8% vs. NTC). These 
results demonstrate differential effects of GW4869 on different exosomal proteins in microglial 
cells, suggesting the involvement of ESCRT-dependent and -independent mechanisms in the 
release of the different exosomal proteins. 
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A recent study showed involvement of astrocyte-derived exosomes in the aggregation of Aȕ. 
Inhibition of nSMase2 by GW4869 treatment significantly decreased exosome release by 
primary astrocytes of a transgenic mouse model and reduced Aȕ plaque formation (Dinkins, 
et al., 2014). Thus, the study on IDE secretion was extended to primary rat astrocytes. 
Inhibition of nSMase2 by GW4869 strongly decreases the release of Alix (1.5 M: 8.1 ± 2.4% 
vs. NTC; 5 M: 1.0 ± 1.3% vs. NTC; Figure 16) and Flotillin-1 (1.5 M: 14.7 ± 6.7% vs. NTC; 
5 M: 13.8 ± 7.5% vs. NTC; Figure 16). Also IDE secretion is strongly decreased by GW4869 
treatment in primary rat astrocytes (1.5 M: 16.8 ± 5.2% vs. NTC; 5 M: 18.5 ± 7.7% vs. NTC; 
Figure 16) suggesting a cell type-specific regulation of IDE secretion in microglia and 
astrocytes. 
 
Figure 16. Inhibition of nSMase2 strongly decreases the release of exosomal marker proteins in primary rat 
astrocytes. Western blot analysis of IDE, Alix and Flotillin-1 protein levels in conditioned media and lysates of 
primary rat astrocytes upon treatment with 1.5 M and 5 M GW4869 for 16 hours (n=2 in triplicates). Relative 
secretion is expressed as ratio of secreted to intracellular protein levels. Statistical analysis was done using a One-
Way ANOVA (Dunnett’s post hoc test). Values represent means  SD. 
 
These results again emphasise that the regulation of exosome release, which might be also 
coupled to the composition of exosomes, seems to vary not only for different exosome cargo 
proteins but also between different cell types. 
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2.2 Role of the ESCRT machinery and IDE in the regulation of exosome biogenesis 
2.2.1 Minor effects of Alix knockdown on the release of IDE in BV-2 cells 
Alix is an accessory protein of the ESCRT machinery and modulates vesicle budding and 
cytokinesis (Odorizzi, 2006; Morita, et al., 2007). The involvement of Alix in the sorting and 
secretion of exosomal cargo and possibly also the formation process of exosomes as ILVs at 
endosomal membranes was demonstrated recently by Baietti and colleagues (Baietti, et al., 
2012). They showed a strong decrease in the release of exosomal marker proteins after 
knockdown of Alix by RNAi. To test whether Alix is functionally involved in IDE release, BV-2 
cells were transfected with Alix-specific siRNA. Two independent siRNAs efficiently decrease 
protein levels of Alix by ~90% (Alix: 10.3 ± 7.3% for siRNA 2 and 4.7 ± 4.3% for siRNA 6 vs. 
neg. ctrl. siRNA; Figure 17), but do not significantly change the secretion of IDE (121.1 ± 24.1% 
for siRNA 2 and 117.9 ± 36.5% for siRNA 6 both vs. neg. ctrl. siRNA; Figure 17). The amount 
of secreted IDE tends to be increased, in particular for siRNA 2, which is associated with a 
moderate increase in IDE expression, being significant only for siRNA 2 (122.7 ± 7.9% for 
siRNA 2 and 109.6 ± 13.5% for siRNA 6 vs. neg. ctrl. siRNA; Figure 17). 
  
Figure 17. Downregulation of Alix does not significantly influence IDE secretion in BV-2 cells, but does 
slightly affect IDE expression. Western blot analysis of IDE protein levels in conditioned media and lysates of 
BV-2 cells after siRNA-mediated knockdown of Alix 48 hours after transfection (n=2 in triplicates). Relative secretion 
is expressed as ratio of secreted to intracellular IDE protein levels, relative expression as normalization of 
intracellular IDE to Actin protein level. Statistical analysis was done using a One-Way ANOVA (Dunnett’s post hoc 
test). Values represent means  SD. 
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These observations suggest that Alix could affect IDE secretion, but rather cellular IDE 
expression or metabolism. Whether sorting of IDE into exosomes is affected by Alix remains 
to be determined in more detail. 
 
2.2.2 IDE secretion is significantly increased upon siRNA-mediated knockdown of 
Vps4B. 
The AAA ATPase Vps4B is also an ESCRT-accessory protein (Hanson & Cashikar, 2012; 
Babst, et al., 1998). It plays a role in the formation of ILVs that are released as exosomes upon 
fusion of MVBs with the plasma membrane (Baietti, et al., 2012; Kunadt, et al., 2015; Colombo, 
et al., 2013), although that role of Vps4B is controversial (Trajkovic, et al., 2008). To assess 
whether IDE secretion is dependent on Vps4B, its expression was knocked down by transient 
transfection with Vps4B-specific siRNA in BV-2 cells. 
The yielded knockdown is 55% on average (Vps4B: 44.9 ± 17.0% vs. neg. ctrl siRNA, Figure 
18A) and varies from 32-77% between the different experiments. Knockdown of Vps4B 
significantly increases the release of IDE (244.3 ± 120.3% vs. neg. ctrl. siRNA, Figure 18A). 
The high standard deviation values result from a varying effect strength between the individual 
experiments, while the variations between biological replicates within one experiment are 
rather small. The effect of siRNA-mediated Vps4B knockdown on IDE secretion in BV-2 cells 
ranges from 53 to 313% increase. 
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Figure 18. Effects of RNAi-mediated knockdown of Vps4A and 4B on the release of IDE and exosomal 
marker proteins from BV-2 cells. Western blot analysis of IDE, Alix, Flotillin-1, Vps4A and Vps4B protein levels 
in conditioned media and/or lysates of BV-2 cells after siRNA-mediated knockdown of Vps4B alone (A, n=4 in 
triplicates, Flotillin-1: n=3 in triplicates) or Vps4A and 4B (B, n=3 in triplicates) 48 hours after transfection. Relative 
secretion is expressed as ratio of secreted to intracellular protein levels, relative expression as normalization of 
intracellular IDE, Alix, Flotillin-1, Vps4A or Vps4B to Actin levels. Statistical analysis was done using a One-Way 
ANOVA (Dunnett’s post hoc test, for A see also Figure 23A). Values represent means  SD. 
In comparison to IDE release the secretion of the exosomal marker proteins Alix 
(109.4 ± 30.7% vs. neg. ctrl. siRNA, Figure 18A) and Flotillin-1 (110.0 ± 30.1% vs. neg. ctrl. 
siRNA, Figure 18A) is not significantly affected but shows interexperimental variations as well. 
To test potential compensating effects of the Vps4B paralogue Vps4A, both paralogues were 
targeted by RNAi. However, combined knockdown of Vps4A and Vps4B does not further 
stimulate IDE secretion (189.2 ± 84.3% vs. neg. ctrl. siRNA, Figure 18B) as compared to the 
knockdown of Vps4B alone (216.5 ± 158.7% vs. neg. ctrl. siRNA, Figure 18B). The knockdown 
of Vps4A alone has no significant effect on IDE secretion. As observed before for Vps4B alone, 
neither single nor double knockdown of both paralogues affects the release of the exosomal 
marker proteins Alix and Flotillin-1 (see Figure 18B). These data suggest that Vps4A could not 
compensate the suppression of Vps4B. In line with this, the protein levels of Vps4A are not 
changed upon knockdown of Vps4B. 
Interestingly, Vps4A and 4B double knockdown cells show slight changes in intracellular levels 
of IDE and Flotillin-1. Whereas intracellular Flotillin-1 is slightly increased (131.3 ± 18.5% vs. 
neg. ctrl. siRNA, Figure 18B), IDE levels appear to be decreased (70.2 ± 27.3% vs. neg. ctrl. 
siRNA, Figure 18B) indicating an influence of the double knockdown on the expression or 
metabolism of both proteins, which, however, was not further determined. 
The combined data indicate that the release of IDE from BV-2 cells is negatively regulated by 
Vps4B. However, the secretion of the exosome marker proteins Alix and Flotillin-1 is not 
significantly affected by Vps4B knockdown. The findings support that there is a “heterogeneity 
of extracellular vesicles” (Colombo, et al., 2013), and also suggest the existence of different 
exosome pools harbouring a distinct set of cargo proteins. 
 
2.2.3 Generation of BV-2 clones with stable knockdown of Vps4B and IDE by 
expression of specific shRNA 
To achieve a stable knockdown for Vps4B and IDE for further biochemical analyses at larger 
scale, BV-2 cells with stable expression of shRNA should be generated. Approaches to 
transfect BV-2 cells with DNA plasmids were inefficient. Inefficient transfection of microglial 
cells or the related macrophages in general was already observed in several other studies 
(Balcaitis, et al., 2005; Smolny, et al., 2014; Burke, et al., 2002). Therefore BV-2 cells were 
transduced with lentiviral particles containing constructs with a Vps4B- or IDE-specific shRNA 
or non-targeting shRNA (referred to as neg. ctrl. shRNA from now on), respectively (see Figure 
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19A+B). Selection of transduced clones was achieved by treatment with 8 g/ml puromycin. 
Successful knockdown of IDE or Vps4B, respectively, was tested by Western immunoblotting. 
Different passages of the cells were analysed to test for potential loss of knockdown efficiency 
(see Figure 19C). An efficient and persistent IDE knockdown for all three used shRNA 
constructs is detected. shRNA 9488 shows weaker suppression of IDE as compared to 
shRNAs 9487 and 9489 (see Figure 19C). For further experiments, cells expressing shRNA 
9489 are used. 
 
Figure 19. Generation of BV-2 cells stably expressing Vps4B- and IDE-specific shRNA by transduction with 
lentiviral particles. (A) shRNA constructs with the vector backbone of pLKO.1-puro containing Vps4B- and IDE-
specific shRNAs or a non-target shRNA generated by The RNAi Consortium (TRC) were purchased from 
Dharmacon and Sigma. Scheme from TRC manual. (B) mRNA domain map and nucleotide numbering scheme for 
mouse Vps4B and IDE. The location of shRNA sequences inside the coding sequences (CDS) are indicated by 
black boxes. IDE-specific shRNA 9487 is encoded in the γ’UTR and not marked here. Map of Vps4B is based on 
(Scott, et al., 2005). MIT – microtubule interacting and trafficking. Map of IDE is based on (Glebov, et al., 2011). 
NLS – nuclear localisation sequence, PTS – peroxisome target signal (C) Western blot analysis of IDE, Vps4B, Alix, 
and Actin protein levels in cell lysates of transduced BV-2 cells after selection procedure with puromycin. Different 
passages (P) were analysed to test for potential loss of knockdown efficiency.  
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Vps4B is also efficiently knocked-down by shRNAs 101416 and 101417 in BV-2 cells (see 
Figure 19C).Here 101417-expressing cells are used for further experiments. shRNA 101416-
expressing cells show reduced growth/proliferation rates in comparison to the other shRNA-
transduced BV-2 cells. 
 
2.2.4 shRNA-mediated stable knockdown of Vps4B in BV-2 causes changes in IDE 
and Flotillin-1 but not Alix release. 
Stable expression of the Vps4B-specific shRNA 101417 decreases Vps4B expression by 75% 
(Vps4B: 24.8 ± 8.7% vs. neg. ctrl. shRNA cells, Figure 20A). In contrast to the siRNA-
transfected cells here only a rather small variation of the knockdown efficiency between the 
experiments could be observed ranging from 62-82%. Nevertheless also here strong 
interexperimental fluctuations are detected regarding the analysis of the release of exosome-
associated proteins. Despite high variations in the effect size, an increased IDE secretion upon 
stable knockdown of Vps4B in BV-2 cells can be determined (238.3 ± 222.2% vs. neg. ctrl. 
shRNA cells, Figure 20A) supporting the earlier observations after transient siRNA transfection 
(see 2.2.2). In two experiments also Flotillin-1 release is significantly enhanced, but two further 
experiments show no effect (182.9 ± 144.9% vs. neg. ctrl. shRNA cells, Figure 20A). The 
release of Alix appears to be unaffected by knockdown of Vps4B also underlining the 
observations made with siRNA transfection (see 2.2.2). 
Subsequently, microvesicles and exosomes were isolated from conditioned media using 
differential centrifugation. In the microvesicle fraction, IDE, Alix and Flotillin-1 tend to be 
increased. However, this effect varies in three independent experiments, and is not statistically 
significant. The levels of these proteins in the exosome fraction are rather unchanged upon 
knockdown of Vps4B (see Figure 20B). 
These results suggest a potential role for Vps4B in the formation or release of microvesicles 
rather than of exosomes. Thus, the observed increase in the secretion of IDE and partly of 
Flotillin-1 into conditioned medium (see Figure 20A) seems to be rather attributable to an 
increased release of microvesicles than of exosomes. Only a small proportion of Alix is 
released via microvesicles in comparison to that in exosomes, why the elevated Alix levels in 
the microvesicle fraction upon Vps4B knockdown have no impact on its overall secretion. By 
contrast, a much higher proportion of IDE and Flotillin-1 are also found in the microvesicle 
fraction. However, additional experiments would be required to substantiate the conclusions. 
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Figure 20. Influences of stable Vps4B knockdown on the secretion of IDE and Flotillin-1 are rather 
attributable to the regulation of microvesicle than exosome release. (A) Western blot analysis of IDE, Alix, 
Flotillin-1 and Vps4B protein levels in conditioned media and/or cell lysates of BV-2 cells after shRNA-mediated 
stable knockdown of Vps4B (n=4 in triplicates). Relative secretion is expressed as ratio of secreted to intracellular 
protein levels, relative expression as normalization of intracellular IDE/Vps4B to Actin levels. Statistical analysis 
was done using a One-Way ANOVA (Dunnett’s post hoc test, see also Figure 24A). Values represent means  SD. 
(B) Preparation of microvesicles (P10) and exosomes (P100) by differential centrifugation from conditioned media 
of BV-2 cells (n=3 in single replicates for P10 and P100). Relative protein levels are expressed as ratio of P10/P100 
protein to intracellular protein levels. 
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2.2.5 Knockdown of Vps4B in BV-2 microglial cells does not alter the subcellular 
distribution of IDE. 
As a member of the ESCRT machinery Vps4B was already shown to play a role in endocytic 
protein trafficking (Bishop & Woodman, 2000; Lin, et al., 2012; Hislop, et al., 2004). Thus, the 
subcellular distribution of IDE was analysed upon siRNA- and shRNA-mediated knockdown of 
Vps4B. Subcellular fractionation reveals predominant localisation of IDE in the cytosol, 
 
Figure 21. Distribution of IDE, Alix and Flotillin-1 between the cytosolic and the membrane-associated 
fraction in Vps4B-knockdown cells. Western Blot analysis of IDE, Alix, Flotillin-1, AIF and MEK1/2 protein in the 
cytosolic (CYT) and the membrane (MEM) fraction of BV-2 cell lysates after cell fractionation (n=3 in triplicates). 
Cytosolic MEK1/2 (mitogen-activated kinase kinases) and mitochondrial-intermembrane space-localised AIF 
(apoptosis-inducing factor) are used as marker proteins for successful separation of cytosolic and membrane 
fraction. Relative protein levels are expressed as ratio to Actin protein level. Statistical analysis using One-Way 
ANOVA (Dunnett’s post hoc test) does not show statistical difference. Values represent means  SD. 
although readily detectable association of IDE with the cellular membranes is evident. A similar 
distribution is also found for Alix. Flotillin-1, as expected for an integral membrane protein (Otto 
& Nichols, 2011), is detected in the membrane fraction. Stable knockdown of Vps4B does not 
cause obvious changes in the distribution of all three proteins (Figure 21). 
To gain further insight into the vesicular distribution of IDE, a density gradient centrifugation of 
the post nuclear supernatant (PNS) was performed. Individual fractions were characterised by 
the detection of marker proteins for distinct vesicular compartments. Alix, a known exosome 
cargo protein (Théry, et al., 2001; Géminard, et al., 2004), can be expected in MVBs, apart 
from its predominantly cytosolic localisation. 
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Figure 22. Subcellular distribution of IDE, Flotillin-1 and Alix. Detection of IDE and other proteins by Western 
immunoblotting after fractionation of intracellular vesicles and organelles by density gradient centrifugation of PNS 
from BV-2 cells. After centrifugation, the gradient was divided by taking off 12 (siRNA experiments, A) or 14 (shRNA 
experiments, B) fractions of increasing density. Specific marker proteins were used to discriminate endosomal 
(EEA1), lysosomal (Lamp2), MVB (Alix) and ER (Calnexin) fractions. Neither transient Vps4B knockdown by siRNA 
(A, n=2) nor stable knockdown by shRNA (B, n=3) does affect the subcellular distribution of IDE especially 
concerning its localisation to the MVB fractions (A: 7-10; B: 10-12). Statistical analysis using a One-Way ANOVA 
(Dunnett’s post hoc test, A) and an unpaired two-sided t-test (B) does not show significant differences in the 
distribution of the tested marker proteins. All values represent means, partly ± SD. 
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It can be assumed that MVBs show a similar density as lysosomes and thus co-migrate with 
lysosomal marker proteins in the applied gradient. Co-fractionation of MVBs and lysosomes 
was already shown by Alonso and colleagues using Percoll density gradient centrifugation 
(Alonso, et al., 2011). Therefore Alix found in fractions of higher density is likely associated 
with MVBs and can be used as MVB marker in these gradients (gradient in siRNA experiments: 
fraction 7-10; gradient in shRNA experiments: fraction 10-12, see Figure 22). IDE is 
predominantly found in fractions of lower density representing cytosol and early endosomes 
and only a small proportion is found in fractions of higher density that are associated to 
compartments surrounded by membranes (fraction 6-12/14, see Figure 22). Knockdown of 
Vps4B does not significantly change the subcellular distribution of IDE, especially its 
association with MVB containing fractions is unaffected (see Figure 22). This indicates that 
neither transient nor stable knockdown of Vps4B does influence the trafficking of IDE. 
Taken together the results do not support a major role of Vps4B in sorting of IDE to MVBs. All 
in all within the framework of the performed techniques it can be assumed that the observed 
changes in IDE secretion upon knockdown of Vps4B are not a consequence of an altered IDE 
intracellular transport or a shift from cytosolic to membrane-associated IDE. 
 
2.2.6 IDE knockdown in BV-2 cells alters subcellular distribution and secretion of 
Alix. 
Several previous studies showed that IDE is released via unconventional secretion associated 
to exosomes (Bulloj, et al., 2010; Tamboli, et al., 2010; Glebov, et al., 2015). To test whether 
IDE could also exert a functional role in the biogenesis and secretion of exosomes IDE was 
downregulated by transient transfection with IDE-specific siRNA in BV-2 cells.  
In the individual experiments expression of IDE is decreased by 45 to 78% upon RNAi 
(IDE: 43.2 ± 16.5% vs. neg. ctrl. siRNA, Figure 23A). Interestingly, knockdown of IDE causes 
a significant increase of Alix release (146.3 ± 48.8% vs. neg. ctrl. siRNA, Figure 23A) in BV-2 
cells whereas Flotillin-1 secretion is not significantly affected (106.2 ± 10.0% vs. neg. ctrl. 
siRNA, Figure 23A). Also here, like already observed analysing secretion upon knockdown of 
Vps4B (2.2.2) the interexperimental fluctuations are high and the increasing effect on Alix 
release by knockdown of IDE is detectable only in 3 out of 4 experiments. 
Density gradient centrifugation revealed that the main proportion of Alix protein (about 90%) is 
found in fractions of lower density containing cytosolic ( LC3-I) and early endosome-associated 
proteins (EEA1) (fraction 1-4/5, Figure 23B). Only a small proportion of Alix is detectable in 
fractions of higher density containing Lamp2-positive compartments (fraction 7-10, Figure 
23B). The knockdown of IDE causes a slight but significant change of Alix distribution. In 
comparison to control cells IDE knockdown shows an increase in MVB-associated Alix protein  
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Figure 23. siRNA-mediated knockdown of IDE leads to an increase in Alix release and influences its 
subcellular distribution. Western blot analysis of IDE, Alix and Flotillin-1 protein levels in conditioned media and 
lysates of BV-2 cells after siRNA-mediated knockdown of IDE, 48 hours after transfection (A, n=4 in triplicates). An 
increased release of Alix is accompanied by a significant increase of Alix in the MVB fractions (9 +10) after density 
gradient centrifugation of PNS (B, n=2). Relative secretion is expressed as ratio of secreted to intracellular protein 
levels, relative expression as normalization of intracellular IDE and Alix to Actin levels. Statistical analysis was done 
using a One-Way ANOVA (Dunnett’s post hoc test, for A see also Figure 18A, for B also Figure 22A). Values 
represent means  SD. 
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in the fractions 9 and 10 (9: 4.50 ± 0.35% vs. 1.79 ± 0.14% for neg. ctrl. siRNA cells; 
10: 3.00 ± 0.24% vs. 0.76 ± 0.03% in neg. ctrl. siRNA cells; Figure 23B).  
These results show an influence of IDE knockdown not only on the secretion but also on the 
subcellular distribution of Alix. They, moreover, indicate a role of IDE itself in the regulation of 
exosome formation (possibly the budding of ILVs) or sorting of exosomal cargo to MVBs. Thus, 
it can be suggested that knockdown of IDE leads to an enhanced transport or association of 
Alix to MVBs and exosomes. The data indicate that IDE could selectively inhibit the sorting to 
and secretion of Alix with exosomes. 
 
2.2.7 No influence on Alix release and distribution in BV-2 cells with shRNA-mediated 
stable knockdown of IDE 
In contrast to the effects of siRNA-mediated knockdown of IDE in BV-2 cells on Alix distribution 
and secretion, examinations of stable IDE knockdown in shRNA-expressing BV-2 cells (see 
2.2.3) show different observations. Stable knockdown of IDE in BV-2 cells (IDE: 16.3 ± 9.4% 
vs. neg. ctrl. shRNA cells) has no significant effect on Alix secretion in comparison to control 
cells (see Figure 24A). The IDE knockdown efficiency ranges between 70 and 94% in the 
individual experiments. In addition, stable IDE knockdown does not change the subcellular 
distribution of Alix especially concerning its localisation to MVBs showing comparable levels 
as in control cells (fraction 10-12, see Figure 24B).  
Stable knockdown of IDE, however, enhances the release of Flotillin-1 (182.9 ± 144.9% vs. 
neg. ctrl. shRNA cells, Figure 24A). It is significantly increased in 2 out of 4 experiments 
whereas the other two show no effect, leading to the high standard deviation. Furthermore, a 
significant but moderate increase in cellular Flotillin-1 levels is detected (129.9 ± 26.2% vs. 
neg. ctrl. shRNA cells, Figure 24A). However, the cellular accumulation of Flotillin-1 is only 
observed in the two experiments that do not show enhanced Flotillin-1 release. Subcellular 
fractionation does not reveal altered distribution of Flotillin-1 upon knockdown of IDE (see 
Figure 24B). Flotillin-1 is known as a marker for lipid rafts and is localised at the plasma 
membrane, late endosomes or lysosomes, and to a lesser extent in early endosomes and 
exosomes (Kim, et al., 2006; Bickel, et al., 1997; Otto & Nichols, 2011). Therefore this 
technique most likely reaches its limits in assessing shifts in Flotillin-1 distribution due to a very 
probable overlapping of its localisation in raft domains of plasma membrane, lysosomes and 
MVBs. Therefore a potential influence of decreased IDE presence on the intracellular 
distribution of Flotillin-1 cannot be excluded, but would not be detectable here. 
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Figure 24. Stable knockdown of IDE in BV-2 cells increases Flotillin-1 but not Alix secretion from BV-2 cells. 
Western blot analysis of IDE, Alix and Flotillin-1 protein levels in conditioned media and lysates of BV-2 cells after 
shRNA-mediated stable knockdown of IDE (A, n=4 in triplicates). Nor Alix neither Flotillin-1 distribution is 
significantly changed upon knockdown of IDE illustrated by fractionation of intracellular vesicles and organelles by 
density gradient centrifugation of PNS (B, n=3). Relative secretion is expressed as ratio of secreted to intracellular 
protein levels, relative expression as normalization of intracellular IDE/Flotillin-1 to Actin levels. Statistical analysis 
was done using a One-Way ANOVA (Dunnett’s post hoc test; for A see also Figure 20A) or unpaired two-sided 
t-test (B). Values represent means, partly  SD. 
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In conclusion it can be stated that seemingly the observed effect on Alix distribution and 
secretion upon transient knockdown of IDE in BV-2 cells (see 2.2.6) is attributed to an ad hoc 
reaction on the changed IDE levels. This effect would then not be detectable during stable 
knockdown of IDE. Additional mechanisms might compensate the deficits in the sorting and 
secretion of Alix upon stable knockdown of IDE. In contrast to the release of Alix, the release 
of Flotillin-1 is only significantly affected upon constant knockdown of IDE and not during 
transient fluctuations in IDE levels. 
 
2.2.8 Differences in the knockdown efficiency of Alix, IDE and Vps4B after longer-
lasting siRNA transfection 
Differential effects of transient and stable knockdown in BV-2 cells on the secretion and 
subcellular distribution of different exosomal cargo proteins (see 2.2.2 - 2.2.7) lead to the 
assumption that there are processes concerning exosome formation and sorting that are 
influenced differently by “short-term” and “long-term” changes in IDE and Vps4B intracellular 
levels. Furthermore, secretion assays carried out 72 instead of 48 hours after siRNA 
transfection show obvious differences in the knockdown efficiency of IDE and Vps4B but not 
of Alix. 
72 hours after siRNA transfection of BV-2 cells levels of Vps4B are almost similar in control 
and in Vps4B-specific siRNA-treated cells (86.0 ± 8.3% vs. neg. ctrl. siRNA cells). In cells 
transfected with IDE-specific siRNA levels of cellular IDE are even slightly increased 
(137.2 ± 7.6% vs. neg. ctrl. siRNA cells). In contrast, cellular levels of Alix are strongly 
decreased 72 hours after transfection with Alix-specific siRNA (see Figure 25). 
Notably, despite the slightly elevated levels of IDE in cell lysates of cells treated with IDE-
specific siRNA after 72 hours of RNAi, IDE secretion is significantly decreased (37.4 ± 4.3% 
vs. neg. ctrl. siRNA cells, Figure 25). This suggests an efficient IDE knockdown earlier. 
Furthermore, an enhanced secretion of Alix from these cells, also observable after 48 hours 
(see 2.2.6), can be detected (263.8 ± 93.6% vs. neg. ctrl. siRNA cells, Figure 25). In Vps4B-
siRNA cells, however, no increase in IDE release, that was observed after 48 hours (2.2.2), is 
found. IDE secretion is even slightly but not significantly decreased (70.9 ± 13.1% vs. neg. ctrl. 
siRNA cells, Figure 25). The complete knockdown of Alix does not result in any significant 
effect on IDE (79.7 ± 15.8% vs. neg. ctrl. siRNA cells) and Flotillin-1 secretion (83.6 ± 6.8% vs. 
net. ctrl. siRNA, Figure 25). 
These observations, first, suggest different regulatory mechanisms for Alix and for IDE and 
Vps4B in case of potential expression changes. Obviously, processes to compensate or 
reactivate expression are activated after siRNA-mediated downregulation especially for IDE 
but also Vps4B. For Alix, however, these mechanisms are, possibly still, not in place after 
72 hours. Furthermore, the observable stimulated Alix release in IDE siRNA-transfected cells 
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despite missing IDE knockdown let assume that possible effects of IDE expression changes 
still have an influence, even though IDE levels turned back to normal again. This possibly also 
suggests that formation of exosomes is a longer-lasting process. In comparison to that, 
secretion of IDE is, probably no more, affected in cells transfected with Vps4B siRNA.  
 
 
Figure 25. Knockdown efficiencies of Alix, IDE and Vps4B and their effects on exosome secretion 72 hours 
after siRNA transfection. Western blot analysis of IDE, Alix, Flotillin-1 and Vps4B protein levels in conditioned 
media and/or lysates of BV-2 cells 72 hours after siRNA transfection (n=1 in triplicates). Relative secretion is 
expressed as ratio of secreted to intracellular protein levels, relative expression as normalization of intracellular 
Alix/IDE/Vps4B to Actin levels. Statistical analysis was done using a One-Way ANOVA (Dunnett’s post hoc test). 
Values represent means  SD. 
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2.2.9 Cell type-dependent differences of Vps4B-mediated regulation of IDE secretion 
Several studies already addressed the involvement of ESCRT-dependent and -independent 
mechanisms in exosome release and also showed differences not only between different 
exosome cargo proteins but also between different cell types (van Niel, et al., 2011; Phuyal, et 
al., 2014; Trajkovic, et al., 2008). Similar observations have also been made for the 
involvement of Vps4B (Kunadt, et al., 2015; Baietti, et al., 2012; Trajkovic, et al., 2008; 
Colombo, et al., 2013). To assess the role of Vps4B and IDE on the secretion of exosomal 
proteins in distinct cell lines, primary rat astrocytes and cos-7 fibroblasts were transfected with 
mouse or human Vps4B- and IDE-specific siRNAs, respectively, for a transient knockdown of 
both proteins. The results indeed show apparent variations between BV-2 microglial cells (see 
2.2.2 and 2.2.6), primary rat astrocytes and cos-7 fibroblast cells.  
In primary rat astrocytes a knockdown of Vps4B of approximately 70% on average (Vps4B: 
32.2 ± 4.1% vs. neg. ctrl. siRNA cells, Figure 26) does not significantly influence IDE secretion 
but significantly decreases intracellular IDE levels (64.4 ± 5.9% vs. neg. ctrl. siRNA cells). On 
contrary to BV-2 cells, Vps4B knockdown significantly reduces Alix secretion (58.6 ± 22.2% 
vs. neg. ctrl. siRNA cells, Figure 26). Also Flotillin-1 secretion might be affected by Vps4B 
knockdown, but shows high variation in the effect size between the individual experiments.  
 
Figure 26. Decreased release of Alix upon knockdown of Vps4B and IDE in primary rat astrocytes. Western 
blot analysis of IDE, Alix, Flotillin-1 and Vps4B protein levels in conditioned media and/or lysates of primary rat 
astrocytes after siRNA-mediated knockdown of Vps4B and IDE 48 hours after transfection (n=2 in triplicates). 
Relative secretion is expressed as ratio of secreted to intracellular protein levels, relative expression as 
normalization of cellular IDE/Vps4B to Actin levels. Statistical analysis was done using a One-Way ANOVA 
(Dunnett’s post hoc test). Values represent means  SD. 
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Surprisingly, the knockdown of IDE by 80% on average (IDE: 19.5 ± 1.4% vs. neg. ctrl. siRNA, 
Figure 26) significantly decreases the release of Alix (34.2 ± 6.5% vs. neg. ctrl. siRNA cells, 
Figure 26). Levels of Flotillin-1 in the supernatant are slightly but not significantly decreased 
upon knockdown of IDE. 
In cos-7 cells, a fibroblast cell line (Gluzman, 1981), the knockdown of Vps4B (Vps4B: 
21.7 ± 2.5% vs. neg. ctrl. siRNA cells, Figure 27A) reveals a significant increase of all 
 
Figure 27. Vps4B knockdown in cos-7 cells causes an increased release of all examined exosome marker 
proteins, knockdown of IDE influences only Flotillin-1 secretion. Western blot analysis of IDE, Alix, Flotillin-1 
and Vps4B protein levels in conditioned media and/or lysates of cos-7 cells after siRNA-mediated knockdown of 
Vps4B (A+C, n=1 in triplicates) and IDE (B+D, n=1 in triplicates) 48 hours after transfection. Relative secretion is 
expressed as ratio of secreted to intracellular protein levels, relative expression as normalization of intracellular 
IDE/Vps4B to Actin levels. Statistical analysis was done using a One-Way ANOVA (Dunnett’s post hoc test). Values 
represent means  SD. 
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examined exosome markers in the supernatant (IDE: 189.0 ± 29.6%; Alix: 308.7 ± 46.3%; 
Flotillin-1: 261.9 ± 15.1%; all vs. neg. ctrl. siRNA cells; Figure 27A+C). Knockdown of IDE 
(IDE: 25.1 ± 5.0% vs. neg. ctrl siRNA cells, Figure 27B) has no effect on Alix, but slightly and 
significantly reduces the release of Flotillin-1 (75.8 ± 3.0% vs. neg. ctrl. siRNA, Figure 27B+D). 
In conclusion it can be stated that the secretion of IDE and the other exosomal cargo proteins 
Alix and Flotillin-1 is differently influenced by knockdown of IDE and Vps4B in the different cell 
lines analysed in this work. This indicates that the release of IDE, Alix and Flotillin-1 is 
differently regulated in distinct cell types. Interestingly, both Vps4B and IDE seem to play a 
functional role in the secretion of exosome-associated proteins in all examined cell types, 
although exerting differential effects on individual exosomal proteins. 
 
2.2.10 Modulation of Amyloid-β and insulin degradation in BV-2 microglial cells 
Several studies already showed the involvement of secreted IDE in degradation of extracellular 
Aȕ in BV-2 microglial cells (Tamboli, et al., 2010; Farris, et al., 2003). Therefore the 
involvement of Vps4B in the IDE-dependent degradation of Aȕ and insulin was examined with 
BV-2 cells. BV-2 cells stably expressing Vps4B-specific shRNA were subjected to a 
degradation assay for Aȕ and insulin adding 1 M Aȕ or insulin, respectively, to the medium. 
IDE knockdown cells served as control. 
Extracellular Aȕ and insulin are efficiently degraded in the conditioned media of neg. ctrl. 
shRNA cells (Aȕ: 46.9 ± 7.3%; insulin: 63.5 ± 3.3%; both vs. time point 0 set to 100%; Figure 
28A+B). The knockdown of IDE completely inhibits the degradation of both peptides, indicating 
that IDE is the major protease involved in the degradation of Aȕ and insulin in this cell model 
(Aȕ: 103.2 ± 9.0%; insulin: 102.2 ± 5.1%; both vs. time point 0; Figure 28A+B). Interestingly, 
knockdown of Vps4B leads to even more decreased levels of extracellular Aȕ and insulin in 
comparison to control cells (Aȕ: γβ.6 ± 4.0%; insulin: 43.5 ± 2.4%; both vs. time point 0; Figure 
28A+B). In line with an increased degradation the levels of secreted IDE in the conditioned 
media are significantly increased upon Vps4B knockdown in the presence of insulin 
(155.5 ± 9.5% vs. neg. ctrl. shRNA cells, Figure 28B), however, only slightly enhanced in the 
presence of Aȕ (11β.5 ± 10.9% vs. neg. ctrl. shRNA cells, Figure 28A).  
Levels of cell-associated Aȕ (cell-associated insulin was not detectable) are strongly increased 
in IDE knockdown cells (263.4 ± 134.0% vs. neg. ctrl. shRNA set to 100%, Figure 28A), also 
indicating decreased degradation. Furthermore, levels of cell-associated Aȕ levels are 
decreased in Vps4B knockdown cells in comparison to control cells (51.6 ± 22.1% vs. neg. ctrl. 
shRNA cells, Figure 28A), as it is also found for extracellular Aȕ levels. The ratio of both 
extracellular and cell-associated Aȕ between Vps4B knockdown and control cells is similar. 
Therefore it can be assumed, that the observed decrease in extracellular Aȕ is not caused by 
increased uptake and intracellular degradation upon knockdown of Vps4B. 
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Figure 28. Involvement of Vps4B in the degradation of Aβ and insulin by IDE. Western blot analysis of IDE, 
Aȕ and Vps4B protein levels in conditioned media and/or lysates of BV-2 cells upon stable knockdown of Vps4B 
and IDE in the presence of Aȕ (A, n=β in triplicates) and insulin (B, n=1 in triplicates) for 7 hours. Insulin was 
detected by Coomassie blue staining after SDS-PAGE. Time point 0 sample was taken immediately after the start 
of the assay from neg. ctrl. shRNA cells. Relative protein levels of extracellular Aȕ and insulin were normalized on 
time point 0 protein levels, set to 100%. Relative protein levels of secreted IDE or cell-associated Aȕ were 
normalized on neg. ctrl. shRNA cells. Statistical analysis was done using a One-Way ANOVA (Dunnett’s post hoc 
test). Values represent means  SD. Aȕ – monomeric Aȕ. 
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These results demonstrate a major involvement of IDE in the degradation of both Aȕ and 
insulin by BV-2 microglial cells. Furthermore, the data also indicate a role of Vps4B in the IDE-
mediated degradation of both peptides. In the presence of insulin an increased IDE secretion 
upon knockdown of Vps4B is detectable. Thus, the stimulated degradation of insulin by Vps4B 
knockdown cells might be attributed to an increase in secreted IDE. Interestingly, this effect 
seems to be weakened in the presence of Aȕ. Hence the enhanced Aȕ degradation upon 
Vps4B knockdown is rather related to other effects that were not examined. 
 
2.3 Pharmacological inhibition of conventional secretion leads to an increased 
release of exosomal marker proteins. 
IDE is released in association with exosomes and its secretion is not blocked by inhibition of 
the conventional secretory pathway (Bulloj, et al., 2010; Zhao, et al., 2009). To test this with 
BV-2 cells, Brefeldin A and Monensin, two known inhibitors of conventional secretion that block 
the transport of secretory vesicles from ER to Golgi or in the Golgi system, respectively, were 
used (Donaldson, et al., 1992; Griffiths, et al., 1983). 
 
Figure 29. Inhibition of conventional secretion leads to an increase in the release of exosome marker 
proteins in BV-2 cells. Western blot analysis of IDE and Alix protein levels in conditioned media and/or lysates of 
BV-2 cells upon treatment with 5 µg/ml Brefeldin A (A, n=2 in triplicates) or 10 µM Monensin (B, n=2 in triplicates) 
for 5 hours. Relative secretion is expressed as ratio of secreted to intracellular protein levels. Statistical analysis 
was done using an unpaired, two-sided student’s t-test. Values represent means  SD. 
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Both inhibitors strongly stimulate the secretion of IDE from BV-2 cells (Brefeldin A: 
218.2 ± 37.3% vs. NTC; Monensin: 446.2 ± 81.8% vs. NTC; Figure 29). Also the release of 
Alix is significantly increased by both compounds (Brefeldin A: 180.4 ± 37.3% vs. NTC; 
Monensin: 440.5 ± 267.5% vs. NTC; Figure 29). 
These data suggest that inhibition of the conventional secretory pathway in BV-2 cells leads 
to stimulation of the unconventional protein secretion via exosomes. The comparable effect on 
the two different exosome-associated proteins IDE and Alix further suggests that Brefeldin A 
and Monensin directly affect the release process of exosomes rather than their intracellular 
formation or sorting of protein cargo to exosomes. 
 
2.4 Y2H screen to find interaction partners of IDE potentially involved in IDE 
secretion regulation 
Only a few proteins like ubiquitin, the androgen and glucocorticoid receptors (AR and GR) as 
well as the intermediate filament proteins vimentin and nestin are known to interact with IDE. 
Some of them were demonstrated to modulate the catalytic activity of the enzyme in the 
degradation of insulin and other substrates (Chou, et al., 2009; Kupfer, et al., 1994; Saric, et 
al., 2003). The interaction with IDE enhances the DNA binding of AR and GR (Kupfer, et al., 
1994). However, little is known about interaction partners of IDE that might regulate its 
trafficking and secretion. To further understand the mechanism of unconventional IDE release, 
the yeast two-hybrid (Y2H) system was used to identify new interaction partners of IDE that 
might play a role in the intracellular transport of IDE and its release via exosomes. 
 
2.4.1 Y2H screen for IDE 
Truncation of the IDE C-terminus significantly decreased the release of the enzyme. A 
so-called SlyX domain in the C-terminal region of IDE was found to modulate the 
unconventional secretion of IDE (Glebov, et al., 2011) suggesting a functional role of this 
domain in the intracellular trafficking and exosome-associated secretion of this protein. 
Furthermore, in-silico analysis, using The Eukaryotic Linear Motif Resource (EML) (Dinkel, et 
al., 2014), predicted several protein interaction or modification domains additional to the SlyX 
domain in the C-terminal sequence of IDE. For example, SH2 and SH3 domain binding motifs, 
a MAPK docking domain and a SUMO interaction site. Therefore a C-terminal sequence 
(aa 848 - 1019) was used as bait protein to identify IDE interacting proteins with the Y2H 
system (see Figure 30). To confine the screen to interaction partners that might be important 
for brain-specific functions of IDE a mouse brain cDNA library was utilized. 
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Figure 30. Generation of IDE Bait based on the C-terminal sequence of mouse IDE. Domain map and amino 
acid (aa) numbering scheme for mouse IDE, based on (Glebov, et al., 2011). Sequence homology of IDE Bait with 
the C-terminal part of IDE (aa 848-1019) is indicated by grey pattern. EML analysis of this sequence predicted 
several protein interaction and modification sites. NLS – nuclear localisation sequence, PTS – peroxisome targeting 
signal.  
A first screen has resulted in 7 putative IDE interacting proteins. In a second screen 19 new 
potential interacting proteins have been identified (see Table 16). However, only three proteins 
have been detected in both screens, i.e. malate dehydrogenase 1, the electron transferring 
flavoprotein α polypeptide and the prolin-rich coiled-coil protein 2b. In the second screen the 
proteins lactate dehydrogenase A and the Zn2+ finger protein 365 are found in two and four 
replications, respectively. 
 
Potential IDE interaction 
partner Cellular compartment Characteristics 
Vacuolar protein sorting-
associated protein 4B 
(Vps4B) 
cytosol, endosome 
membrane 
involved in the late steps of the 
endosomal MVB pathway 
Rab GTPase activating 
protein 1-like (RabGAP1l) 
Golgi, endosomes, 
nucleus 
regulation of protein localisation, 
activation of Rab GTPases 
Carboxypeptidase E (CPE) cytoplasmic vesicles, 
secretory vesicle 
membrane, secreted 
binding and processing of 
regulated secretory pathway 
proteins 
Secretory carrier membrane 
protein 5 (SCAMP5) 
cell membrane, Golgi, 
endosomes, secretory 
and synaptic vesicles 
required for Ca2+-triggered 
exocytosis of signal sequence-
containing cytokines 
Tripeptidyl peptidase 2 
(TPP2) 
cytoplasm acting downstream of 26S 
proteasome in ubiquitin-
proteasome pathway 
87  Results 
Ubiquitin-like containing PHD 
and RING finger domains 
(Uhrf2) 
nucleus E3 ubiquitin ligase, important for 
G1/S transition 
Kelch-like 13 (Klhl13) cytoplasm, nucleus? adaptor of Cullin 3-based E3 
ubiquitin ligase complex, 
important for chromosome 
segregation  
E1A binding protein p400 
(EP400) 
nucleus belongs to the chromatin 
remodelling complex, cell cycle 
control, apoptosis 
COMM domain containing 
protein 8 (COMMd8) 
cytoplasm mediates degradation of IκBα 
and increases NFκB activity by 
binding Cullin 1-based E3 
ubiquitin ligase complex 
F-Box protein 38 (Fbxo38) cytoplasm, nucleus probably ubiquitination and 
degradation of phosphorylated 
proteins, transcriptional co-
activator of Krueppel-like factor 7 
Neuroblastoma apoptosis-
related RNA binding protein 
(NAPOR) 
nucleus, cytoplasm region-specific alternative 
splicing in the nervous system 
  
 
Zn2+ finger RAN binding 
domain containing protein 2 
(ZranB2) 
nucleus alternative splicing, suppression 
of BMP-signalling via Smad-
binding 
  
 
Zn2+ finger protein 365 
(ZFP365) 
cytoplasm centrosome-associated, 
essential for cell division, high 
expression levels in brain 
Heat shock protein 90 beta 
member 1 (Hsp90b1)/ Grp94 
ER molecular chaperone, paralogue 
of Hsp90, processing and 
transport of secreted proteins, 
involved in ER stress signalling 
Aminoadipate-semialdehyd 
dehydrogenase-phospho-
panthetheinyl transferase 
(Aasdhppt) 
cytoplasm catalyses the post-translational 
modification of target proteins by 
phosphopantetheine 
Sirtuin 3 (SIRT3) mitochondrion matrix, 
nucleus? 
role in dietary restriction, 
controlling metabolism at 
transcriptional level 
Electron transferring 
flavoprotein α polypeptide 
(ETFA) 
mitochondrion 
membrane 
part of the respiratory chain 
(complex II) 
Aldo-keto reductase 1 
(Akr1a1) 
cytosol, apical plasma 
membrane 
NADPH-dependent reduction of a 
variety of aromatic and aliphatic 
aldehydes 
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Tissue specific transplanta-
tion antigen P35B (Tsta3) 
cytoplasm NADPH-binding protein, role in 
GDP-D-mannose metabolism 
GABAA receptor subunit ȕβ 
(Gabrb2) 
cell membrane activation of GABAA receptors 
provides an inhibitory effect on 
neurotransmission  
Lactate dehydrogenase A 
(LDH A) 
cytosol, mitochondrion pyruvate fermentation to lactate 
Enolase 1 cytoplasm, cell 
membrane 
role in glycolysis 
Malate dehydrogenase 1 
(Mdh1) 
cytoplasm, 
mitochondrion 
role in gluconeogenesis and 
other processes like malate and 
oxalacetate metabolism 
Asparaginase like 1 (Asrgl 1) cytoplasm role in asparagine catabolism 
Prolin-rich coiled-coil protein 
2b (prrcb2) 
cytoplasm unknown function 
RIKEN cDNA D030056L22 unknown unknown function 
  
 
Table 16. Potential interaction partners of IDE identified by Y2H cDNA library screen. Two Y2H cDNA library 
screens with IDE Bait utilizing a mouse brain cDNA library reveal 26 putative IDE-interacting proteins. Eight have 
to be excluded (highlighted in grey). Their protein sequence interacting with IDE Bait is coded by a part of their 
mRNA sequence that is located in the γ’ untranslated region outside their coding sequence (CDS). This generates 
protein sequences which are normally not expressed. 
Eight IDE putative interaction partners are considered false positive, because their protein 
sequence interacting with IDE Bait is coded by a part of their γ’ untranslated mRNA region. 
The other 18 putative interaction partners can be related to energy metabolism, cell cycle 
regulation, ubiquitination and the proteasomal protein degradation pathway. The majority 
(83%) of these proteins are associated to energy and protein metabolism (see Figure 31A). 
Most interestingly, Vps4B being examined in parallel for its regulatory role in the exosome-
associated release of IDE, is identified as potential interaction partner of IDE as well. The 
fragment of Vps4B that is able to interact with IDE Bait corresponds to a protein sequence of 
Vps4B of 237 aa including almost the whole AAA ATPase domain as well as a small part of 
the MIT domain (microtubule interacting and trafficking domain), that is responsible for binding 
the ESCRT III complex (Scott, et al., 2005), (see Figure 31B). Furthermore, another interesting 
protein, Carboxypeptidase E (CPE), involved in sorting of conventionally secreted proteins in 
the brain and rather part of the conventional secretory pathway (Cawley, et al., 2012) is found. 
Interaction of Vps4B and IDE Bait could be confirmed by an additional Y2H candidate co-
transformation assay, while CPE has to be excluded due to autoactivation in this system. 
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Figure 31. Analysis of the potential interaction partners of IDE. (A) Pie chart of biological functions of putative 
interaction partners of IDE, see Table 16 above. (B) Domain map and amino acid (aa) numbering scheme for mouse 
Vps4B, based on (Scott, et al., 2005), indicated: interaction site of the Vps4B fragment (62-298 aa) interacting with 
IDE Bait. MIT – microtubule interacting and trafficking. 
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2.4.2 Interaction of IDE and Vps4B 
IDE and Vps4B are mainly localised to the cytosol (Duckworth, et al., 1998; Bishop & 
Woodman, 2000). The results presented in 2.2.5 (see Figure 21) also demonstrate 
predominant localisation of both proteins in the cytosol in BV-2 cells. Hence, the main 
proportion of IDE and Vps4B are present in the same compartment, which topologically could 
allow an interaction. Additionally, IDE as cargo of exosomes (Bulloj, et al., 2010; Tamboli, et 
al., 2010) and Vps4B as regulatory protein for the MVB pathway (Hanson & Cashikar, 2012; 
Babst, et al., 1998), can both be associated with intracellular vesicles like endosomes or MVBs.  
 
Figure 32. Detection of IDE and Vps4B in similar subcellular fractions and in exosomes. Western blot analysis 
of IDE, Vps4B and other proteins after fractionation of intracellular vesicles and organelles or exosomes, 
respectively, by density gradient centrifugation of PNS (A) or the exosome fraction P100 from conditioned medium 
(B) of BV-2 cells. A partial overlap of IDE and Vps4B in subcellular vesicle fractions and a strong co-migration with 
other exosomal markers in exosome vesicles of the same density is detectable. 
Density gradient centrifugation reveals an overlap of both proteins, predominantly in fractions 
2-4 (see Figure 32A). Interestingly, IDE is not detected in fraction one, representing most likely 
the main cytosolic fraction, and peaks in fraction three. Vps4B, however, shows an almost 
complete overlap with Alix in fractions 1-4 that also contain LC3-I. IDE and Vps4B also show 
co-fractionation with the endosomal marker EEA1. Only about 11-13% of both proteins are 
detected in fractions of higher density that contain larger compartments surrounded by 
membranes (fraction 6-12), where markers as Lamp2, LC3-II and Calnexin are found. Thus, 
smaller proportions of IDE and Vps4B can be detected in fractions potentially containing MVBs 
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 Figure 33. Immunocytochemical staining of IDE and Vps4B in cos-7 cells. Immunofluorescence staining of 
IDE, Vps4B and Actin in cos-7 cells. IDE was detected using a monoclonal mouse antibody (MAB2496) and an 
Alexa Fluor® 488-coupled anti-mouse antibody and Vps4B was stained by a polyclonal rabbit antibody (NBP1-
19119) and an Alexa Fluor® 546-coupled anti-rabbit antibody. Phalloidin coupled to Alexa Fluor® 647 served to 
detect F-Actin. Nuclei were visualized by DAPI staining. 
IDE Vps4B 
Actin DAPI 
IDE 
Vps4B 
Actin 
DAPI 
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(fraction 7-10, Figure 32A). A strong overlap of IDE and Vps4B is also observed upon isolation 
and fractionation of exosomes by density gradient centrifugation, together with the other 
exosomal marker proteins Alix and Flotillin-1 (fraction 4 and 5; Figure 32B). 
Immunocytochemical staining of endogenous IDE and Vps4B in cos-7 cells shows a similar, 
mainly cytosolic distribution of both proteins. In addition, both proteins show punctate pattern 
in the cytoplasm slightly concentrated around the nuclear region. Vps4B also displays a partial 
co-localisation with the Actin cytoskeleton (see Figure 33). 
To further examine the interaction of IDE and Vps4B a co-immunoprecipitation (Co-IP) 
approach was carried out. However, little if any specific co-IP with the endogenous proteins is 
detected. In contrast, overexpression of both proteins reveals co-immunoprecipitation of myc-
tagged IDE and Vps4B (lane 2, Figure 34A and B). 
Since the high size similarity of Vps4B (49.4 kDa) and the heavy chain of the IP antibody 
(~50 kDa) prevented an adequate Vps4B detection and IP-suitable IDE and Vps4B antibodies 
had the same host organism, an alternative approach was carried out using the fusion protein 
Vps4B-MBP with the size of approximately 100 kDa. Here, IDE-myc co-immunoprecipitates 
Vps4B-MBP (lane 2, Figure 34C) and vice versa (lane 3, Figure 34C). 
 
Figure 34. Co-immunoprecipitation of IDE and Vps4B. (A+B) Western blot analysis of IDE-myc and Vps4B after 
immunoprecipitation (IP) of IDE-myc or Vps4B/Vps4B-Flag, respectively, from lysates of Vps4B/IDE-myc-
overexpressing HEK293. A control IP using lysates of only Vps4B-overexpressing cells + the myc antibody for IP 
(lane 4+5, respectively) and a bead control without addition of IP antibody (lane 6, respectively) were carried out. 
Co-IP of Vps4B with IDE-myc (lane 3, A+B) is not possible to distinguish significantly from the control IP without 
IDE-myc overexpression showing a weak signal at the size of Vps4B as well (lane 5, A+B). (C) Modified Co-IP 
approach: Detection of Vps4B-MBP after IP of IDE-myc from lysates of IDE-myc-overexpressing HEK293 cells 
complemented with the fusion protein Vps4B-MBP. OE – overexpression, Ab – antibody 
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The combined results indicate an interaction of IDE and Vps4B. However, this interaction might 
be weak or transient. 
 
2.4.3 Interaction of IDE and Vps4B does not affect the usual complex formation of 
both proteins. 
Vps4B exists in monomeric and dimeric states. In addition, higher order dodecameric 
assemblies have been described in the presence of ATP (Scott, et al., 2005; Babst, et al., 
1998). IDE was shown to exist primarily as a dimer (Safavi, et al., 1996; Shen, et al., 2006; 
Song, et al., 2003). Native gel electrophoresis should provide an insight into the complex 
formation of IDE and Vps4B. Blue Native PAGE (BN-PAGE) (Wittig, et al., 2006) enables the 
electrophoretic separation of protein complexes. A subsequent SDS/Urea PAGE results in 
dissociation and separation of these protein complexes. 
BV-2 cells were lysed without detergent or with different concentrations of the mild nonionic 
detergent Digitonin and resultant lysates subjected to BN-PAGE. IDE is prominently detected 
at approximately 242 kDa (see Figure 35A) consistent with the expected size of a dimer. In 
contrast, Vps4B is predominantly detected at around 1.2 MDa and a smear of lower size than 
242 kDa (see Figure 35A). The high molecular weight form (1.2 MDa) could represent the 
ATPase complex formed by Vps4A and Vps4B, and probably additional proteins (Scott, et al., 
2005). The smear at lower molecular mass (below 242 kDa) likely represents monomeric and 
dimeric forms of Vps4B. Cell lysis with Digitonin decreases the detection of the high molecular 
weight form (1.2 MDa), suggesting the Vps4B ATPase complex is sensitive and partly or 
almost completely dissociates with 0.5% or 1% Digitonin, respectively. 
Complexes reactive for both IDE and Vps4B are not detectable. Nevertheless, an interaction 
of IDE and Vps4B is not excluded since lower amounts of such a complex might not be 
detectable with this method. Furthermore, epitopes of the respective antibodies used for 
detection might be masked in potential complexes. Subsequent separation by SDS/Urea 
PAGE reveals two strong signals for IDE in the 2nd dimension (see Figure 35B) which most 
likely represent the dimer (left) and monomer (right) forms. The two signals partly overlap, a 
characteristic observation for 2D-separations. Detection of Vps4B demonstrates a weak signal 
(left) that can be attributed to the 1.2 MDa ATPase complex and an intense smear (right) most 
likely representing the monomer and/or dimeric assemblies. 
 
Results  94 
 
Figure 35. Native protein complexes of IDE and Vps4B. (A) Western blot analysis of Vps4B and IDE upon BN-
PAGE of BV-2 cell lysates in the presence/absence of Digitonin. (B) Subsequent SDS/Urea PAGE in the 2nd 
dimension and detection of IDE and Vps4B by Western immunoblotting. 
 
To further examine a potential role of IDE or Vps4B in the complex formation of both proteins 
BV-2 cells stably expressing IDE- or Vps4B-shRNAs (see 2.2.3) were also analysed. Neither 
knockdown of Vps4B nor of IDE does cause overt changes in the migration of the individual 
complexes (see Figure 36A and B). Notably, knockdown of one of the two proteins increased 
the signal of the other protein (see Figure 36A). Separation in the 2nd dimension by SDS/Urea 
PAGE reveals a similar pattern for IDE and Vps4B under both, knockdown and control 
conditions. As expected the signal intensity for the downregulated protein is decreased. 
In conclusion, complex formation of IDE with Vps4B could not be detected unambiguously 
using native gel electrophoresis and subsequent SDS/Urea PAGE. However, the observed 
changes in the amounts of higher molecular weight complexes containing IDE and Vps4B upon 
the knockdown of the other, respectively, could hind to a potential functional interaction of both 
proteins. 
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Figure 36. Complex formation of neither Vps4B nor IDE is affected by downregulation of both proteins. 
BN-PAGE (A) and subsequent SDS/Urea PAGE in the 2nd dimension (B) of BV-2 cell lysates upon stable 
knockdown of IDE and Vps4B and detection of IDE and Vps4B by Western immunoblotting. 
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D Discussion 
1. Stimulation of IDE secretion by serotonin in microglia 
Since the discovery that IDE can degrade Aȕ and thereby could contribute to Aȕ clearance in 
the brain, it became an interesting enzyme to be investigated in Alzheimer’s research. It was 
shown that the expression of IDE is significantly decreased in familial and late-onset AD (Cook, 
et al., 2003; Pérez, et al., 2000; Zhao, et al., 2004; Miners, et al., 2009). The IDE-mediated 
clearance of Aȕ occurs mainly extracellularly, but the exact mechanisms and possible stimuli 
that promote the release of IDE are not fully understood. In this study, it could be demonstrated 
that 5-HT stimulates the release of IDE from microglia cells via activation of several 5-HTRs 
(see Figure 7 and Figure 9). As shown recently by Tamboli and colleagues an increased 
release of IDE results in decreased extracellular levels of Aȕ (Tamboli, et al., 2010).  
The serotonergic system in the brain is affected already in the early stages of AD pathogenesis 
(Benton, et al., 1982; Reynolds, et al., 1995; Cross, 1990; Geldenhuys & Schyf, 2011). The 
functional relationship between the serotonergic system and AD aetiology, however, is not fully 
understood. It has also been shown that antidepressants based on 5-HT or inducing an 
increased serotonergic neurotransmission via inhibition of 5-HT reuptake can shift APP 
processing towards increased non-amyloidogenic cleavage by the α-secretase, which 
increases the secretion of the neuroprotective sAPPα and leads to decreased levels of Aȕ 
(Lezoualc'h & Robert, 2003; Cirrito, et al., 2011; Hashimoto, et al., 2012; Nitsch, et al., 1996; 
Robert, et al., 2005; Cochet, et al., 2013; Tesseur, et al., 2013). In this context, Nitsch et al. 
showed an involvement of the 5-HT2aR and 5-HT2bR-mediated signalling, independent on 
PKC activation (Nitsch, et al., 1996). Furthermore, the activation of ERK signalling upon 
inhibition of 5-HT reuptake has been demonstrated to increase the α-secretase activity, likely 
by post-translational modification (Cirrito, et al., 2011). 5-HT4R-mediated signalling may 
promote the α-cleavage of APP also via activation of AC and increased levels of cAMP but 
appears to be independent of PKA activation (Lezoualc'h & Robert, 2003; Maillet, et al., 2003; 
Robert, et al., 2005; Cochet, et al., 2013; Tesseur, et al., 2013). Cochet and colleagues further 
suggest an additional effect of 5-HT4R by constitutively inducing α-cleavage of APP through a 
physical interaction with the α-secretase ADAM10 (Cochet, et al., 2013). The present study 
revealed that 5-HT, in addition to its effect on the proteolytic generation, can also promote the 
degradation of extracellular Aȕ.  
The results obtained in this study indicate that the activation of the 5-HTRs 2a, 2b and 4 
stimulates IDE release via a PLC-dependent elevation of [Ca2+]i (see Figure 37). The Gαq-
dependent activation of PLC is the classical and exclusive signalling pathway mediated by 
5-HT2Rs that increases [Ca2+]i by IP3 formation and IP3-mediated Ca2+ release from the ER 
(Raymond, et al., 2001; Bockaert, et al., 2006; Peroutka, 1995). 5-HT4R is known to induce 
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an AC-dependent increase of cAMP levels via Gαs (Fagni, et al., 1992). Recently it was shown 
that increased cAMP levels can switch on the Epac-Rap1/βB pathway that can activate PLCε 
(de Rooij, et al., 1998; Schmidt, et al., 2001; Oestreich, et al., 2007; Maillet, et al., 2003; Robert, 
et al., 2005). In this context, Maillet and Robert et al. also found that 5-HT4R-induced signal 
transduction increases sAPPα secretion attributed to a modulation of α-secretase activity. 
They show that cAMP activates the Epac-Rap1 signalling pathway that results in the activation 
of the small GTPase Rac that may increase α-secretase activity, possibly by its 
phosphorylation (Maillet, et al., 2003; Robert, et al., 2005). In the present study, by using 
specific activators of 5-HT4R (ML10302), Epac (8-CPT) and PLC (3m3FBS) and the 
 
 
Figure 37. Proposed signalling pathways regulating 5-HT-stimulated IDE release from microglia cells. 
Adapted from (Glebov, et al., 2015). Serotonin/5-HT activates 5-HT2a, 2b and 4 receptors in microglia/BV-2 cells. 
The selective 5-HTR antagonists RS127445, Altanserine and GR113808 block the receptor activation. 5-HT2a and 
βb receptor activation leads to activation of Gαq mediating an increase of [Ca2+]i upon PLC-dependent formation of 
IP3. Activation of 5-HT4R stimulates an elevation of [cAMP]i dependent on AC activation by Gαs, which can be also 
obtained by treatment with PTX that blocks Gαi-mediated AC inhibition. cAMP activates the GEF Epac leading to a 
Rap1/2B-dependent activation of PLCε and a subsequent [Ca2+]i increase. Elevated [Ca2+]i promotes the secretion 
of IDE. 
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PLC inhibitor U73122, it could be shown that, at least in part, 5-HT-dependent stimulation of 
IDE secretion involves 5-HT4R and Epac-Rap1/2B-dependent activation of PLCε (see Figure 
10 and Figure 11). The findings presented here therefore indicate that 5-HT4R-mediated 
signalling could contribute to the degradation of extracellular Aȕ and thereby exert beneficial 
effects of 5-HT in the protection against AD. 
Additionally, this work demonstrated that 5-HT elevates [Ca2+]i in BV-2 cells and that a rise of 
[Ca2+]i is associated with the stimulated release of IDE (see Figure 12). Earlier studies already 
demonstrated that increased [Ca2+]i stimulates the secretion of exosomes by promoting the 
fusion of MVBs with the plasma membrane (Savina, et al., 2003; Savina, et al., 2005; 
Emmanouilidou, et al., 2010). In line with this, very recent investigations of Vingtdeux and 
colleagues showed a CALHM1-mediated increase in IDE secretion in N2A cells (Vingtdeux, et 
al., 2015). CALHM1 (calcium homeostasis modulator 1) is a plasma membrane ion channel 
permeable for Ca2+ and has been found to be a genetic risk factor for AD (Ma, et al., 2012; 
Dreses-Werringloer, et al., 2008). The expression and activation of the CALHM1 ion channel 
in N2A cells induces an influx of extracellular Ca2+ and elevates the [Ca2+]i which most 
probably, although the authors do not directly refer to it, triggers the elevated release of IDE 
through fusion of MVBs with the plasma membrane (Vingtdeux, et al., 2015). 
It could be furthermore shown, that the increased release of IDE is linked to an increased 
release of other exosomal markers like Alix, Flotillin-1 and Actin (see Figure 13), indicating that 
this stimulation is not selective for IDE but rather leads to a general increase of exosome 
release. However, the extent of secretion of the individual exosome-associated proteins 
differed. For example the release of IDE and Flotillin-1 is significantly increased by more than 
40 and even 100%, respectively, whereas release of Alix and Actin shows only a weaker rise 
of 20% upon treatment with 5-HT in the exosome fraction (see Figure 13A). Here the question 
arises whether this might indicate the presence of distinct exosome pools, possibly whole 
MVBs, that exhibit a distinct composition of proteins. This is also discussed in literature. First, 
previous data suggested specific populations of MVBs that could either fuse with lysosomes 
or with the plasma membrane (Colombo, et al., 2013; Raposo & Stoorvogel, 2013). It could be 
established that MVBs destined for lysosomal degradation in contrast to secretory MVBs 
contain the MVB marker LBPA, but much less cholesterol (Möbius, et al., 2002; Wubbolts, et 
al., 2003; White, et al., 2006). Colombo and colleagues found by using a capture-based assay 
specific for particular exosome marker proteins to prepare exosomes, that cells secrete a 
heterogeneous population of exosomes not only differing in size, but also in the protein 
composition. Thereby they also support the concept that cells could contain different 
subpopulations of MVBs (Colombo, et al., 2013). 
Co-culture experiments of BV-2 microglial cells with primary hippocampal or ES-derived 
serotonergic neurons (ESN), respectively, showed that neurons can stimulate the release of 
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IDE in microglial cells (see Figure 14). Pretreatment and simultaneous administration of 
selective antagonists for the 5-HTRs 2a, 2b and 4 during co-culture attenuated IDE release. 
These data further support that the neuronal release of 5-HT might promote the secretion of 
IDE from microglial cells. On the other hand, it was observed that antagonist treatment of BV-2 
cells in the absence of ESN as well causes a decrease in IDE secretion. This rather suggests 
a 5-HT-independent effect. Further investigations could address whether the three 5-HTRs 
probably exhibit a constitutive activity in microglial cells, what has not been described so far. 
The constitutive activity of the 5-HTRs 1A, 1B, 1D, 2A, 2C, 3, 4 and 6 was already found in 
other cell types (Seifert, et al., 2005; Spencer, 2015; Claeysen, et al., 2000; Berg, et al., 2008). 
It is observed under specific conditions, e.g. low receptor density, or in certain tissues. 
Selective antagonists may exert distinct effects on constitutively active receptors in comparison 
to non-activated receptors and may act for example as inverse agonists. If considered 
antagonists behave as inverse agonists they not only block the effects of binding agonists but 
also inhibit the basal activity of constitutive active receptors (Chidiac, et al., 1994; Greasley & 
Clapham, 2006). That was observed already for 5-HT4R antagonists in 5-HT4R-transfected 
cells (Claeysen, et al., 2000) and for 5-HT3- and -4R antagonists in investigations of gut motility 
in vivo (Spencer, 2015). GR113808, however, could be proven as neutral antagonist that has 
no activity in the absence of an agonist in case of a constitutive active 5-HT4R (Claeysen, et 
al., 2000). Possibly Altanserin acts as an inverse agonist, in case the 5-HT2aR would exhibit 
a constitutive activity. The same might be suggested for the 5-HT2bR and its selective 
antagonist RS127445. However, this needs to be investigated. 
Additionally to the increased IDE release also a more than 1.5-fold elevated IDE protein level 
can be detected in BV-2 cells upon co-culture with ESN (see Figure 14F). This increased 
expression is only slightly reduced upon simultaneous antagonist treatment suggesting a minor 
importance of 5-HT-mediated signalling in that effect. This is supported by the fact that 5-HT 
treatment of BV-2 cells does not cause an increase in IDE expression. The absolute amount 
of secreted IDE from BV-2 cells shows, as expected, an increase upon co-culture with ESN 
(see Figure 14E). It needs to be determined whether the increased cellular levels of IDE upon 
co-culture with neurons contributes to the increased IDE secretion. However, what catches the 
eye is the fact that in BV-2 cells co-cultured with ESN the amount of secreted IDE rises of 
larger magnitude than the expression of IDE (2.3-fold in comparison to 1.7-fold). Interestingly 
this effect can be observed in the same extent in BV-2 cells that were treated with 5-HTR 
antagonists (2.4-fold in comparison to 1.6-fold). These observations could, first, indicate that 
the secretion of IDE is influenced by other mechanisms than the increased expression in BV-2 
cells upon co-culture with ESN. On the other hand, this could also point to differences in the 
intra- and extracellular metabolism of IDE. However, the fact that the amount of secreted IDE 
is increased to the same extent also in BV-2 cells under the influence of 5-HTR antagonists 
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rather suggests no effect of neuronal 5-HT in the stimulation of IDE release from BV-2 cells. 
Other mechanisms of neuron-glia interaction, as for example direct physical interaction or 
probably the release of other signalling molecules, seem to play a role and a more detailed 
investigation of these communication pathways is required. 
Together, the present results indicate that 5-HTR-mediated signalling in microglia, either by 
constitutive active or stimulated receptors, plays an important role in the secretion of IDE via 
exosomes. This suggests an important and beneficial function of the communication between 
neurons and microglia also for the extracellular degradation of Aȕ. A probable disturbance of 
these communication pathways might contribute to the pathogenesis and progression of 
Alzheimer’s disease. 
 
2. Molecular mechanisms in IDE secretion 
2.1 Inhibition of conventional secretion increases the release of exosomal proteins 
in BV-2 microglial cells. 
Several years ago it was proven that IDE secretion occurs independent of the conventional 
secretory pathway (Zhao, et al., 2009; Bulloj, et al., 2010). In hepatocytes, HeLa cells and the 
neuroblastoma cell line N2A known inhibitors of the conventional protein secretion revealed 
no or even an increasing effect on IDE release. In the present study, an increasing effect could 
be observed in microglial BV2 cells. Two inhibitors of the conventional secretory pathway, 
Brefeldin A and Monensin, do not block, but significantly elevate the release of IDE, 
accompanied by a simultaneous increase in the secretion of the exosome marker Alix (see 
Figure 29). Due to the comparable effect on two distinct exosome-associated proteins it can 
be assumed that the inhibition of the conventional secretory pathway promotes the secretion 
of exosomes in general, especially as the sorting of both proteins to MVBs seems to be 
regulated differently (discussed below). Therefore it might be suggested that Brefeldin A- and 
Monensin-mediated inhibition stimulates the fusion of MVBs with the plasma membrane rather 
than exosome biogenesis.  
It has already been shown that Monensin increases the [Ca2+]i by inducing a reversed activity 
of the Na+/Ca2+ exchanger, which leads to a Ca2+ entry into the cell, and this way also 
stimulates the secretion of exosomes (Savina, et al., 2003). Interestingly Savina and 
colleagues found that Monensin treatment leads to formation of enlarged MVBs in K562 cells, 
a human myelogenous leukemia cell line. Most probable this is induced by its function as 
Na+/H+ antiporter that promotes swelling of acidic compartments, including endosomes and 
lysosomes. MVBs also accumulate Ca2+ intraluminally which is indicated to play a role for the 
secretory process as well. Savina et al discuss the requirement of released luminal Ca2+ to 
induce the docking and fusion process of MVBs with the plasma membrane (Savina, et al., 
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2003). Bulloj and colleagues observed an almost 3-fold enhanced release of IDE and its 
localisation in the enlarged MVBs upon Monensin treatment also in N2A cells (Bulloj, et al., 
2010). They also found enlarged MVBs upon administration of the calcium ionophor A23187, 
supporting an involvement of intracellular Ca2+. Thus, a similar effect of Monensin on the 
secretion of IDE can be suggested for BV-2 cells as well. It can be further assumed that the 
Monensin-induced increase in IDE secretion is not mediated by blocking the ER-Golgi 
transport, although it cannot be completely excluded. In addition, this supports the conclusion 
that 5-HT-stimulated IDE secretion is triggered by an 5-HTR-induced increase in [Ca2+]i. 
Additional experiments, i.e. immunocytochemistry or subcellular fractionation, with BV-2 cells 
should provide further insight in the localisation of IDE and formation of enlarged MVBs upon 
Monensin treatment. However, a specific MVB marker still remains to be identified, because 
LBPA staining, used for example by Bulloj et al., was not possible in BV-2 cells (data not 
shown). 
For Brefeldin A, distinct observations in affecting secretion of exosome-associated proteins 
are found in literature. McCready and colleagues observed that inhibition of the conventional 
secretory pathway through Brefeldin A leads to an increased release of Hsp90α that is 
secreted via exosomes in the breast cancer cell line MDA-MB231 (McCready, et al., 2010). 
On the contrary, two groups, examining exosome release in J77 T cells and the lung cancer 
cell line A549, respectively, observed a strong decrease in the release of the exosome-
associated proteins CD81 and CD63 (Mittelbrunn, et al., 2011; Wilson, et al., 2014). The 
release of the exosomal Hsp70, in contrast, was not influenced by inhibition of Brefeldin A in 
the monocytic cell line THP1, and in peripheral blood mononuclear cells (Lancaster & 
Febbraio, 2005; Tulapurkar, et al., 2015). Notably, the release of IDE was not affected by BFA 
in hepatocytes and HeLa cells (Zhao, et al., 2009). Brefeldin A blocks the transport of secretory 
vesicles from ER to Golgi by inhibiting ARFs - GTP-binding protein ADP-ribosylation factors - 
leading to the disassembly of the Golgi apparatus (Donaldson, et al., 1992; Sciaky, et al., 1997; 
Schekman & Orci, 1996). Thus, Brefeldin A seems to influence the release of exosomes by a 
distinct mechanism than described above for Monensin. Possibly, Brefeldin A rather affects 
the sorting of cargo into exosomes or the budding of ILVs into MVBs. So far, MVBs are 
described as a part of the endosomal compartment and the endocytic pathway and thus, are 
not directly connected to vesicular transport to and from the trans-Golgi. However, it is 
imaginable that MVBs also originate from the trans-Golgi, at least indirectly. So, for example a 
sorting of proteins from the trans-Golgi to the endosomal/lysosomal system via vesicular 
transport is not unlikely. First, typical exosomal marker as the tetraspanins CD63 and CD81 
are found in the Golgi network (Laulagniera, et al., 2005; Mori, et al., 2008; Shoham, et al., 
2006). Furthermore, a maturation of MVBs from the trans-Golgi network was proven already 
in plants. In plants, however, the trans-Golgi network and the early endosome compartments 
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are not comparably separated as in mammalian cells (Scheuring, et al., 2011). Thus, at least 
some exosomal cargo might originate from Golgi compartments. Due to the assumed distinct 
subpopulations of exosomes (discussed above) the effect of Brefeldin A might vary for different 
exosomal proteins and also between different cell types.  
Findings by Lippincott-Schwartz et al. revealed moreover that upon Brefeldin A treatment the 
trans-Golgi network, which is separated from the rest of the Golgi system that is redistributed 
into the ER, may fuse with the endosomal recycling system, whereas the transport between 
endosomes and lysosomes is impaired (Lippincott-Schwartz, et al., 1991). They could show 
that the typical trans-Golgi network marker TGN38 mixes with the endosomal recycling system 
upon treatment with Brefeldin A and could cycle to and from the cell surface. Probably this 
could give another explanation how under the influence of Brefeldin A also exosomal proteins, 
that might originate from the trans-Golgi network, could reach the plasma membrane and could 
be secreted. 
In conclusion the observed increase in IDE and general exosome release from BV-2 cells upon 
inhibition of conventional secretion shows a rather unexpected effect, in particular for 
Brefeldin A because it was shown not to alter IDE secretion in other cell types (Bulloj, et al., 
2010; Zhao, et al., 2009). It needs further investigation especially concerning its influence on 
the formation of MVBs, e.g. by immunofluorescence staining and subcellular fractionation of 
intracellular vesicles. This could help to elucidate, if the increase in IDE release might be 
caused by a disassembly of the Golgi system by partial redistribution of the Golgi into the ER. 
Possibly also preparation of microvesicles and exosomes from Monensin- and Brefeldin A-
treated cells could provide more detailed insight into their effect on IDE secretion. The findings, 
either way, indicate a closer relation between conventional and the unconventional exosome-
mediated secretory pathway than previously assumed. 
 
2.2 Differential influence of nSMase2 and ceramide levels on the release of IDE in 
distinct cell types 
Exosomes originate from intraluminal vesicles that are generated by inward budding of the 
endosomal membrane. However, the regulation of their biogenesis is controversial until now. 
The ESCRT machinery was soon presumed to play an important role in this budding process 
and there are several studies that could confirm its involvement in exosome formation and 
release (Babst, et al., 1998; Tamai, et al., 2010; Gan & Gould, 2011; Baietti, et al., 2012; 
Colombo, et al., 2013). However, the release of certain exosome-associated proteins can 
occur independently from ESCRT function. One striking example was the discovery that 
exosome formation is triggered by raft-based microdomains enriched in ceramides (Trajkovic, 
et al., 2008). Trajkovic et al. proposed that due to its cone-shaped structure, ceramide 
promotes the inward budding of unilamellar vesicles. To decrease ceramide levels they treated 
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cells with GW4869, an inhibitor for the neutral sphingomyelinase 2 (nSMase2) that catalyses 
the conversion of sphingomyelin to ceramide, or downregulated nSmase2 by RNAi. Thereupon 
they observed a significant decrease in exosome secretion, indicated by the release of the 
proteolipid protein (PLP) that is secreted via exosomes from the oligodendrocyte cell line 
Oli-neu and partly also by the release of CD63 in Oli-neu and PC-3 cells, a prostate cancer 
cell line. By additionally investigating EGFR degradation, a characteristic example of lysosomal 
degradation mediated by transport via the MVB pathway, they propose that the ESCRT 
machinery is only needed for ILV formation for the lysosomal degradation pathway whereas 
ILV formation of later exosomes requires ceramide (Trajkovic, et al., 2008; Heinrichs, 2008). 
Examining the effect of nSMase2 inhibition on exosome secretion in microglial cell lines and 
primary rat astrocytes the present study revealed differences not only between different cell 
types, but also between different exosome-associated proteins (see Figure 15 and Figure 16). 
In the microglial BV-2 and N9 cells, the release of IDE is significantly increased upon inhibition 
of nSMase2 by GW4869 whereas the secretion of the exosomal proteins Alix and Flotillin-1 is 
significantly decreased in N9 cells by approximately 50% and tendencially rather decreased 
also in BV-2 cells. In primary rat astrocytes, however, nSMase2 inhibition displays an entirely 
different effect especially on the secretion of IDE. Here, the release of all three examined 
exosomal marker proteins - IDE, Alix and Flotillin-1 - was almost completely blocked upon 
treatment with GW4869. This indicates that exosome secretion seems to be differentially 
regulated in microglial cells and astrocytes. While formation and the subsequent release of 
exosomes in astrocytes seems to be strongly dependent on ceramide levels, they appear to 
be rather independent on nSMase2 function in microglial cells, as indicated by the differential 
susceptibility of both cell types to inhibition of nSMase2. Not only IDE showed opposite effects 
upon nSMase2 inhibition in the two cell types. Also the secretion of Alix and Flotillin-1 is much 
stronger affected by nSMase2 inhibition in primary rat astrocytes than in N9 and especially in 
BV-2 cells. It needs to be tested, however, whether this might also be attributed to a distinct 
sensitivity to GW4869 in the two different cell types. 
These findings reflect the varying observations of several studies on the regulation of exosome 
release and protein sorting into MVBs by nSMase2 (Phuyal, et al., 2014; van Niel, et al., 2011; 
Yuyama, et al., 2012), and underline existing differences between different exosome-
associated proteins and between different cell types. So, for example van Niel and colleagues 
found no influence of GW4869-mediated inhibition of nSMase2 on the sorting of PMEL 
(premelanosome protein) into ILVs of MVBs for melanosome generation. Instead, CD63, a 
common exosomal marker protein was discovered to play a role in ILV biogenesis (van Niel, 
et al., 2011). Yuyama and colleagues demonstrated a significant decrease of exosome release 
upon treatment with GW4869 or downregulation of nSMase2 in N2A neuroblastoma cells and 
primary neurons, indicated by the exosomal proteins Alix, Tsg101 and GM1 (Yuyama, et al., 
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2012). On the other hand, in the cell line PC-3 inhibition of nSmase2 or its RNAi-mediated 
downregulation did not affect the release of the exosomal proteins Caveolin-1 and Annexin A2 
(Phuyal, et al., 2014). In the study by Trajkovic, however, GW4869 treatment decreased the 
release of the exosome marker protein CD63 in PC-3 cells (Trajkovic, et al., 2008), also 
suggesting differently regulated secretion or MVB sorting for distinct exosomal proteins in the 
same cell line. 
Nevertheless, no study has described an increased release of an exosome-associated protein 
upon inhibition of nSMase2 leading to decreased ceramide levels as it was observed for IDE 
in BV-2 and N9 cells. The fact that secretion of other exosomal proteins is rather unaffected or 
even decreased raises the question, if the inhibition of the nSMase2 indeed affects the release 
of IDE via exosomes. Bulloj and colleagues suggested that only about 50-60% of secreted IDE 
is released via exosomes in N2A cells (Bulloj, et al., 2010). Possibly the decreased ceramide 
levels rather influence another pathway that is involved in the secretion of IDE. Several studies 
already described a localisation of IDE at the cell surface in various cell types (Vekrellis, et al., 
2000; Seta & Roth, 1997; Lynch, et al., 2006; Yaso, et al., 1987), but until now the exact 
mechanism of membrane attachment and translocation is unknown. Furthermore, the amino 
acid sequence of IDE has no canonical motif for secretion or association with the cellular 
membrane. The present study revealed by using cell fractionation that only a small proportion 
of IDE is associated with intracellular membrane systems as well as the plasma membrane of 
BV-2 cells (see Figure 21). Also immunocytochemical staining of endogenous IDE in BV-2 
cells (data not shown) did not show a prominent localisation of IDE at the plasma membrane. 
This might be further examined using for example cell surface biotinylation. Nevertheless also 
in BV-2 cells, a fraction of IDE might be exposed at the cell surface, which would require an 
uncharacterised non-vesicular export mechanism for IDE. This potential mechanism might be 
affected by ceramide.  
As an example, a secretory process which could be influenced by ceramide is membrane 
translocation via ABC transporters. ABC transporters have been implicated in the 
unconventional secretion of proteins (compare introduction 2.3) and might represent a further 
possibility of IDE membrane translocation. The functionality of ABC transporters depends also 
on the surrounding lipid composition (Aye, et al., 2009). For instance, the ABCA1-mediated 
cholesterol efflux is affected by the ceramide content in the plasma membrane (Ghering & 
Davidson, 2006). Furthermore, accumulation of cell surface ceramide during keratinocyte 
differentiation appears to increase ABCA7 expression (Kielar, et al., 2003; Aye, et al., 2009). 
Accordingly, an elevated expression of the respective ABC transporter through increased 
ceramide levels might then also enhance the protein transport via the membrane. Thus, in 
case IDE might additionally be secreted by an ABC transporter this could be influenced by 
ceramide levels in the plasma membrane. However, the observation by Zhao and colleagues 
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that the broad-spectrum ABC transporter inhibitor glyburide did not affect IDE secretion in 
HeLa cells (Zhao, et al., 2009) would speak against an IDE export by ABC transporters. On 
the other hand, Brefeldin A and Monensin displayed distinct effects on IDE secretion in HeLa 
cells (Zhao, et al., 2009) and BV-2 cells (see Figure 29) as well. Thus, it would be important to 
test an influence of ABC transporter inhibitors on the release of IDE also in BV-2 and other cell 
types.  
Another example is the influence of ceramide on the release of hyaluronan, a part of the 
extracellular matrix. A recent study described that decreased levels of ceramide in the plasma 
membrane increase the secretion of hyaluronan. Decreased ceramide in the plasma 
membrane activates the Akt pathway that in turn stimulates transcription of certain genes. 
Thereby the secretion of hyaluronan is increased due to an upregulation of hyaluronan 
synthase leading to an enhanced hyaluronan production at lipid rafts in the plasma membrane 
(Qin, et al., 2012). Another study dealing with hyaluronan synthesis and microvesicle release 
observed an increased release of microvesicles in hyaluronan synthase-overexpressing cells 
(Rilla, et al., 2013). Rilla et al. found that the increased release of microvesicles in these cells 
was associated with the hyaluronan synthesis rate and that the released microvesicles were 
coated with hyaluronan. Therefore, another mode of unconventional secretion for IDE, which 
might be affected by ceramide levels in the plasma membrane, is the release via microvesicles. 
Microvesicles bud from the plasma membrane and are directly pinched off to the extracellular 
space. They display an expected size of 100-500 nm whereas they most probably can be 
separated from exosomes by differential centrifugation (compare Material and Methods 2.2.9) 
(Cocucci & Meldolesi, 2015). As also found in this work, IDE is, additionally to the exosome 
fraction, as well found in the microvesicle fraction from BV-2 cells (see Figure 13A). As 
described above, decreased ceramide levels in the plasma membrane may activate the Akt 
pathway which activates hyaluronan synthase expression leading to an increased hyaluronan 
synthesis at the plasma membrane (Qin, et al., 2012). Thus, it could be speculated, if 
decreased ceramide levels in the plasma membrane through nSMase2 inhibition might 
increase hyaluronan synthesis at the plasma membrane and thereby also enhance 
microvesicle release. Therefore it would be interesting to assess, if GW4869 is able to affect 
the Akt pathway, the hyaluronan synthase expression and hyaluronan synthesis in microglial 
cells. In addition, it should be tested first if hyaluronan synthase isoforms are expressed in 
microglia. So far only the expression and activation of hyaluronan receptors in microglia is 
described (Wang, et al., 2006; Austin, et al., 2012). In particular the influence of GW4869 
treatment on microvesicle-associated IDE should be examined in BV-2 cells. 
The present results, firstly, show that the secretion and the sorting of distinct exosomal proteins 
into MVBs may be regulated differently in the same cell type. In addition, the release/sorting 
of the same protein may be regulated differently in distinct cell types, as shown here for IDE. 
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This could also indicate that IDE is secreted by different secretory mechanisms in these cells. 
To conclude, this study shows that nSMase2 inhibition and therewith probably associated 
lower ceramide levels stimulate IDE release in microglial cells. It furthermore might indicate a 
potentially higher importance of the microvesicle-associated or the existence of another new 
IDE secretory mechanism distinct from exosome release in particular in microglial cells. 
 
2.3 ESCRT-dependent effects in IDE secretion and the role of the interaction of IDE 
and Vps4B 
As described earlier, the ESCRT machinery has been suspected to be involved in the 
biogenesis of exosomes due to its function in MVB generation, and a functional role for several 
proteins of the individual ESCRT complexes in the release of exosome-associated proteins 
could already be proven. For example, RNAi-mediated downregulation and knockout of Hrs, a 
member of ESCRT-0, in dendritic cells led to a significant decrease of typical exosome marker 
proteins as Tsg101 and Hsp70 in isolated exosomes, and also decreased the amount of 
ubiquitinated and total protein in the exosome fraction (Tamai, et al., 2010). Furthermore, 
RNAi-mediated knockdown of Tsg101 and CHMP4A/B/C, members of ESCRT-I and -III, 
respectively, caused strongly decreased levels of exosomal proteins like CD63 and syntenin 
in isolated exosomes of MCF-7 cells, a breast cancer cell line, shown recently by a detailed 
study on ESCRT function in exosome release of Baietti et al. (Baietti, et al., 2012). 
Downregulation of Hrs, Tsg101 and the further ESCRT-I member Stam1 by stable shRNA-
expression in HeLa cells also led to a decreased release of exosomes positive for CD63 and 
CD81 in another large-scale study on ESCRT function (Colombo, et al., 2013). In addition to 
the ESCRT proteins, the ESCRT accessory proteins Alix and the ATPase Vps4B, that mediate 
ESCRT-III recruitment or the final step of membrane abscission by disassembly of the 
ESCRT-III members, respectively, are interesting proteins to investigate the involvement of the 
ESCRT machinery in exosome biogenesis. Baietti and colleagues could furthermore prove a 
function of Alix in sorting and release of exosomal cargo, including syntenin, syndecan, CD63, 
Tsg101 and Hsp70 in MCF-7 cells (Baietti, et al., 2012). Combined RNAi-mediated knockdown 
of Vps4A and B inhibited the secretion of the exosomal marker CD63, syntenin and syndecan 
(Baietti, et al., 2012; Hurley & Odorizzi, 2012). An influence of both ESCRT accessory proteins 
on the secretion of exosomes could be verified also by previous and following studies (Gan & 
Gould, 2011; Colombo, et al., 2013; Kunadt, et al., 2015). Therefore it was important to 
examine the ESCRT function in the secretion of IDE from BV-2 cells. 
 
2.3.1 Minor effects of Alix in the release of IDE from BV-2 cells 
RNAi-mediated knockdown of Alix in MCF-7 cells strongly decreased the secretion of several 
exosomal marker proteins and the sorting of syntenin and syndecan into exosomes (Baietti, et 
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al., 2012). In contrast, the siRNA-mediated downregulation of Alix showed only minor effects 
on the release of IDE in BV-2 cells (see Figure 17). IDE secretion slightly and not significantly 
increased upon knockdown of Alix which indicates a minor role for Alix in the sorting or release 
of IDE in BV-2 cells. Knockdown of Alix resulted in a slight but significant increase also in 
cellular IDE levels, probably causing the elevated amount of secreted IDE. However, this effect 
was detected only for one of the used siRNAs, which indicates potential off-target effects. 
Colombo and colleagues discovered increased expression levels of MHC II in MHC II-
overexpressing HeLa cells upon RNAi-mediated downregulation of Alix (Colombo, et al., 
2013). They also found an increased number in released CD63-positive exosomes and an 
increased exosomal secretion of MHC II upon downregulation of Alix, in contrast to the results 
of Baietti mentioned above (Baietti, et al., 2012). The accumulation of MHC II could be 
attributed to an increase in the HLA-DRB1 and HLA-DRA mRNAs, encoding MHC II, revealing 
an unexpected effect of Alix on mRNA expression or stability (Colombo, et al., 2013). Thus, it 
would be interesting to further analyse whether IDE expression is affected by Alix knockdown 
in a similar manner, for example by analysing IDE mRNA level. Nevertheless, the effects 
observed after downregulation of Alix are rather small considering the knockdown efficiency of 
90-95% at the protein level. Thus, the functional relevance of Alix for IDE secretion or 
potentially compensatory mechanisms remains unclear. That the effect of downregulation of 
Alix might be compensated is indicated by an experiment analysing secretion and expression 
of exosomal proteins upon siRNA-mediated knockdown of Alix, IDE and Vps4B for longer time 
periods (72 hours) (see Figure 25). In cells treated with Alix-specific siRNA a very efficient and 
prolonged knockdown was detectable. In IDE- and Vps4B-knockdown cells, however, protein 
expression of IDE or Vps4B, respectively, turned back to control levels or even higher after 
72 hours. This suggests the existence of rather rapid mechanisms to reestablish the protein 
levels of IDE and Vps4B in comparison to Alix protein levels. Possibly there are compensatory 
mechanisms for the loss of Alix function or Alix has only little contribution to the regulation of 
exosome secretion in BV-2 cells. In its capacity as ESCRT accessory protein, the function of 
Alix could possibly be taken over by ESCRT-II, as it was suggested that both exert a similar 
function in the recruitment of ESCRT-III (compare introduction 2.2). It is proposed that Alix 
potentially replaces the ESCRT-II function in cytokinesis and virus budding, where the ESCRT 
machinery is involved as well (Raiborg & Stenmark, 2009; Christ, et al., 2016). Downregulation 
of Alix for 72 hours in BV-2 cells, moreover, did not affect IDE secretion or expression anymore. 
This together with the observed slightly increased IDE expression in IDE-siRNA cells after 
72 hours (see Figure 25) suggests that the maintenance of a certain IDE protein level seems 
to be important. 
Thus, Alix appears of limited importance in the regulation of IDE secretion, but might be 
involved in control of IDE expression. 
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2.3.2 Vps4B exerts an inhibitory function in regulation of IDE secretion in BV-2 cells. 
The role of the ATPase Vps4B was examined in detail in this study. A siRNA-mediated 
downregulation of Vps4B protein by more than 50% in BV-2 cells induced a significant 2-fold 
increase in secretion of IDE, whereas the release of Alix and Flotillin-1, other exosomal 
proteins, is unaffected (see Figure 18). It should be noted here that the effect size for the 
increased IDE release highly varied between the individual experiments. High variation of the 
effect size between different experiments was also observed upon stable expression of Vps4B-
specific shRNA in BV-2 cells yielding a stronger and stable Vps4B knockdown of 70-80% (see 
Figure 20). Also here a significantly enhanced IDE release is detectable upon depletion of 
Vps4B. As in siRNA-treated cells Alix secretion remains unaffected, but a trend to an increased 
release of Flotillin-1 is observed. The high interexperimental variations appear to be 
characteristic for secretion and exosome analyses upon knockdown of Vps4B. Higher 
interexperimental fluctuations were also observed in other studies on exosome secretion. High 
standard deviations of up to 100-150% (n=3-5) (Baietti, et al., 2012) and sometimes even 
opposite effects in different experiments are also described previously (Colombo, et al., 2013). 
Colombo et al. showed for shRNA-mediated knockdown of Vps4B interexperimental variations 
in the effect size on exosome secretion of about 100-200% for CD63, 100-400% for MHC II 
and even 6000% for Hsc70, which are comparable and partly even higher values as observed 
in the present study on IDE secretion. As all experiments were carried out under apparently 
similar technical conditions, using also a similar passage number of the cells, the higher 
variations might indicate a dependency on the state of the cell, as for example metabolic state 
or the stage of the cell cycle. It is discussed and also proposed for multicellular organisms that 
a population of actually identical cells still maintains a diversity of cell phenotypes to be able 
to respond to novel environments (Dueck, et al., 2016). It is further argued that the rapid 
response of small subsets of cells on perturbations and emitted signals may coordinate the 
whole population behaviour. That was already observed for example for inflammatory 
responses (Dueck, et al., 2016). Possibly, mechanisms that compensate functional 
consequences of the Vps4B downregulation are activated only in a subset of the cells and 
depending on their presence or strength this affects the behaviour of the whole cell population 
more or less leading to variations in the observed effect strength. 
In the context of the known function of Vps4B in the formation of ILVs and potentially exosomes 
in the MVB pathway, the increased release of IDE upon Vps4B downregulation is a rather 
unexpected finding. Considering that depletion of Vps4B might result in disruption of the final 
step in ILV formation, a reverse effect would be expected, provided that IDE release depends 
on ESCRT-mediated exosome biogenesis. The findings eventually indicate that Vps4B rather 
suppresses the secretion of IDE. On the other hand, also Colombo and colleagues found an 
increased release for all examined exosomal marker proteins as MHC II, CD63 and Hsc70 
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upon RNAi-mediated downregulation of Vps4B (Colombo, et al., 2013). However, potential 
mechanisms underlying these observed results were not discussed. Another study on an 
ESCRT-independent pathway of exosome secretion shows in the supplementary data a 
statistically non-significant increased release (~1.5-fold) of CD63-positive exosomes upon 
overexpression of a Vps4 variant that is deficient in ATP-binding. Also here a high standard 
deviation indicates high interexperimental variations (Trajkovic, et al., 2008). However, Baietti, 
as described earlier, observed a decrease in the release of exosomal proteins upon RNAi-
mediated downregulation of Vps4B (Baietti, et al., 2012) which contradicts the observations of 
Colombo and in this work. Besides the studies by Baietti and Colombo all other studies 
addressing the function of ESCRT in exosome biogenesis and release used only 
overexpression of ATPase-deficient variants for analysing Vps4B function, but used RNAi 
approaches for all other ESCRT members. Possibly overexpression of an ATP-binding- or 
ATPase-deficient Vps4B variant exhibits a different effect on exosome secretion as its RNAi-
mediated protein downregulation. For IDE secretion in N2A cells, Bulloj and colleagues 
observed a slight decrease upon overexpression of the ATPase-deficient variant of Vps4B in 
comparison to empty vector-transfected cells indicating a minor role of Vps4B and its ATPase 
function (Bulloj, et al., 2010). In this work, stable expression of the wild type Vps4B and the 
ATPase-deficient variant Vps4B-E235Q in BV-2 cells using a lentiviral transduction system 
was tried (compare Material and Methods 2.1.9). However, stable expression of these variants 
could not be achieved, likely by downregulation or silencing of the transgene after transduction 
(data not shown). Also the attempt to transiently overexpress Vps4B and its ATPase-deficient 
variant in cos-7 cells was not successful due to toxic effects and induced cell death. An 
explanation for distinct effects of the Vps4B ATPase-deficient variant and a depletion of the 
whole protein might be, as proposed recently already from Hurley and Odorizzi (Hurley & 
Odorizzi, 2012), an additional non-catalytic function of Vps4B in the exosome formation or 
release pathway which, however, is not examined until now.  
Interestingly, analysis of separated exosome and microvesicle fractions from the media of 
stable Vps4B-depleted cells revealed that Vps4B knockdown might rather affect the secretion 
of IDE, as well as Flotillin-1 and Alix, via microvesicles, whereas their release via exosomes is 
only slightly or not influenced (see Figure 20B). This is consistent with the observation that Alix 
levels in the supernatant of the cells are rather unaffected upon downregulation of Vps4B, 
because Alix is predominantly present in the exosome fraction and to a much lesser extent in 
the microvesicle fraction. Flotillin-1 showing as IDE similar proportions in the exosome and 
microvesicle fraction, however, was influenced by Vps4B-depletion in 50% of the experiments. 
This finding supports the idea, as discussed earlier, that microvesicles might contribute 
stronger to the release of IDE than exosomes in microglial cells (compare 2.2). A function of 
Vps4B and also other ESCRT members in the formation of microvesicles, that bud from the 
Discussion  110 
plasma membrane and are directly pinched off to the extracellular space, was recently proven 
(Nabhan, et al., 2012; Cocucci & Meldolesi, 2015). A role of the ESCRT machinery in shedding 
of microvesicles is further supported by its involvement in other processes at the plasma 
membrane as virus budding and membrane abscission during cytokinesis (Raposo & 
Stoorvogel, 2013; Cocucci & Meldolesi, 2015). However, involvement of the ESCRT machinery 
in the release of microvesicles is much less investigated as it is for exosomes. The protein 
composition of microvesicles appears to be even more heterogeneous than that of exosomes, 
and no representative marker proteins exclusively found in microvesicles have been identified 
(Turola, et al., 2012). However, also characteristic exosomal marker proteins are detected in 
microvesicles, as for example Alix and Hsp70 (Bernimoulin, et al., 2009). Possibly, Vps4B 
affects additionally to its ATPase-dependent function in vesicle abscission also the sorting of 
proteins into microvesicles. Such a function for Vps4B was already described in sorting of the 
viral protein Gag during virus budding at the plasma membrane and sorting of CD63 and CD81 
into extracellular vesicles (Gan & Gould, 2011). The procedure by Gan and Gould to isolate 
extracellular vesicles slightly differed to the common protocol for exosome isolation also used 
in this work (compare Material and Methods 2.2.9), and therefore could rather result in a 
fraction containing both microvesicles and exosomes. Nevertheless, the study of Gan and 
Gould suggests a sorting function of Vps4B by direct interaction with cargo proteins of 
microvesicles, and probably also exosomes. As mentioned above, in case Vps4B might be 
implicated in the sorting of IDE, Alix and Flotillin-1 into microvesicles in BV-2 cells, the present 
results would suggest an inhibitory function of Vps4B. This would contrast with the findings of 
Gan and Gould, that indicate a promoting effect of Vps4B in sorting of CD63 and CD81 (Gan 
& Gould, 2011). 
Interestingly, Vps4B was identified in the Y2H screen performed during this project to identify 
interaction partners of IDE (see Table 16). This interaction could be confirmed by co-
immunoprecipitation approaches in extracts of IDE- and Vps4B-overexpressing cells (see 
Figure 34). However, co-immunoprecipitation of these proteins was of low efficiency, probably 
indicating weak or transient interactions. In extracts with endogenous levels of IDE and Vps4B 
an interaction was not detectable. Nevertheless, both proteins show a very similar subcellular 
localisation that is predominantly cytosolic as indicated by density gradient fractionation of 
subcellular compartments and by immunocytochemical stainings of the endogenous proteins 
(see Figure 32A and Figure 33). Moreover, Vps4B and IDE are both found in exosomes of the 
same density indicating their presence in the same exosome pool (see Figure 32B). Thus, the 
topological conditions in the cells would allow an interaction of both proteins. However, using 
native gel electrophoresis and subsequent denaturing gel electrophoresis in the second 
dimension a protein complex which contains both proteins IDE and Vps4B could not be 
detected (see Figure 35). This again indicates a rather weak interaction or a low prevalence of 
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this complex below the detection limit of the used method. It is also conceivable, that method-
dependent limitations as for example epitope masking in the complex prevent the efficient 
precipitation or detection of the complex by the used antibodies. 
The question that now arises is whether the interaction with Vps4B is functionally involved in 
IDE sorting into exosomes or microvesicles and if, which mechanisms might contribute. A 
potential influence on the complex formation of Vps4B and IDE, respectively, appears rather 
unlikely. Neither IDE depletion affected the formation of the Vps4B ATPase complex in BV-2 
cells, nor Vps4B downregulation disturbed dimerization of IDE (see Figure 36). The Vps4B 
ATPase complex consists of two hexameric rings of Vps4A and B subunits, that assemble in 
the presence of ATP by interactions between their C-terminal oligomerisation domains and 
additionally bind LIP5 proteins (Scott, et al., 2005). IDE predominantly exists as a dimer and 
the C-terminal part (IDE-C, compare Figure 1) is responsible for IDE oligomerisation (Li, et al., 
2006). The Y2H screen was carried out using a C-terminal sequence of IDE (IDE Bait, compare 
Figure 30). The respective encoded amino acid sequence of Vps4B found to interact with IDE 
Bait in the Y2H screen encloses a small part of the N-terminal MIT domain (microtubule 
interacting and trafficking domain) and almost the whole AAA ATPase domain (compare Figure 
31B). Therefore an interruption of IDE dimerization or ATPase function of Vps4B by the 
interaction of both proteins might be possible. Further characterization of the exact interaction 
domains of IDE and Vps4B would enable functional analyses using interaction mutants. The 
current results of this study do not allow a definite statement on the function of the interaction. 
Therefore, a potential effect of the IDE-Vps4B interaction on IDE release needs further 
examination.  
Moreover, it should be assessed how known stimuli of microvesicle release affect IDE release, 
as for example the impact of PKC-activating phorbol esters that stimulate microvesicle release 
or ATP treatment triggering microvesicle release by activating P2X7 receptors also in microglia 
(Cocucci, et al., 2009; Cocucci & Meldolesi, 2015). In addition, the obtained results showing 
increased (but not statistical significant) protein levels in the microvesicle fraction upon Vps4B 
knockdown need further verification to consolidate the made conclusions that Vps4B rather 
influences microvesicle than exosome release.  
Furthermore, it should be examined, as mentioned earlier (see 2.2) if hyaluronan synthesis 
and activation of the Akt pathway may influence IDE release via microvesicles. Fractionation 
of microvesicle and exosome fraction by gradient centrifugation (compare Material and 
Methods 2.2.9) could then give an insight into the distribution of IDE to microvesicles and 
exosomes, possibly even to their subpopulations. Bobrie and other scientists, who have 
investigated exosomes and their secretion for years, published a joint study on subpopulations 
of secreted vesicles. They discuss that the exosome preparations obtained by the common 
differential ultracentrifugation also used in this work might contain subpopulations of vesicles 
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secreted by different intracellular mechanisms and not only exosomes originating from 
endosomes/MVBs. This way they contain also microvesicles that budded from the plasma 
membrane (Bobrie, et al., 2012). Therefore, density gradient fractionation of prepared 
extracellular vesicles might provide more precise information on the distribution of IDE to 
exosomes and microvesicles. 
Due to the known function of Vps4B in intracellular trafficking (Scheuring, et al., 2001; 
Yoshimori, et al., 2000; Fujita, et al., 2003), the influence of Vps4B depletion on the subcellular 
distribution of IDE was analysed. A well-studied example of Vps4B-dependent intracellular 
trafficking is the EGFR. Upon binding of EGF, the EGFR undergoes endocytosis and is 
targeted for lysosomal degradation via the ESCRT-mediated MVB pathway (Fader & Colombo, 
2009; Katzmann, et al., 2002; Saksena, et al., 2009). Recent studies indicate that loss of 
Vps4B or inhibition of its enzymatic activity disturbs EGFR degradation and thereby prolongs 
EGF-induced signalling (Yoshimori, et al., 2000; Lin, et al., 2012; Fujita, et al., 2003). Yoshimori 
and colleagues additionally found that the structure of endosomal compartments and 
endosomal trafficking from and to the plasma membrane as well as to the lysosome depend 
on the ATPase function of Vps4B (Yoshimori, et al., 2000). Also the retrograde transport of 
endosomes from the plasma membrane to the trans-Golgi network is abrogated through a 
deficient ATPase function of Vps4B as shown by Fujita and colleagues (Fujita, et al., 2003). 
However, neither transient nor stable knockdown of Vps4B significantly affected the subcellular 
distribution of IDE in BV-2 cells as demonstrated in the present study (see Figure 21 and Figure 
22): 95% of IDE is found in the cytosolic fraction of the Vps4B knockdown cells, as it is 
observed in control cells. Only a small fraction of IDE is associated with cellular membranes. 
Downregulation of Vps4B did not significantly affect the distribution of IDE between individual 
subcellular compartments as cytosol, the endosomal and the lysosomal compartment. In 
addition, the amount of IDE as well as the exosomal marker Alix in the MVB fractions is not 
changed (see Figure 22) indicating no effect of Vps4B depletion on the sorting of exosomal 
proteins to MVBs. This might also explain the observation that Alix secretion is unaffected by 
knockdown of Vps4B (see Figure 18 and Figure 20). In addition, this again supports the notion 
that the increase in IDE in conditioned media upon knockdown of Vps4B is rather caused by 
stimulated shedding of microvesicles, than secretion of exosomes. 
The effect of Vps4B depletion on IDE secretion could also be independent from alterations in 
sorting of IDE to microvesicles or another mechanism of regulated membrane translocation. 
Several studies showed the formation of aberrant endosomes upon overexpression of the 
ATPase-deficient variant Vps4B-E235Q, also sometimes called E235Q compartments, in 
which several proteins, that are transported in the endosomal system, accumulate. Examples 
are the EGFR destined for lysosomal degradation, the protein TGN38 destined for recycling to 
the trans-Golgi network from the plasma membrane, and the transferrin receptor destined for 
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recycling or distribution to the plasma membrane after synthesis (Scheuring, et al., 2001; 
Yoshimori, et al., 2000; Fujita, et al., 2003). Fujita and colleagues furthermore found 
accumulation of immature forms of lysosomal hydrolases as Cathepsin D in these aberrant 
endosomes. Moreover, these immature forms of Cathepsin D are secreted to a much higher 
extent than in control cells indicating a fusion of these aberrant endosomes with the plasma 
membrane (Fujita, et al., 2003). This process is called hyper-secretion and was described 
already earlier by Babst et al. upon overexpression of a Tsg101 mutant and in class E vps 
mutants in yeast (Babst, et al., 2000; Babst, et al., 1997). Class E vps proteins are yeast 
homologues of the mammalian ESCRT proteins. Hyper-secretion might serve to remove 
proteins that accumulated in these aberrant endosomes. It would be interesting to analyse 
whether also downregulation of Vps4B could result in the formation of aberrant endosomal 
compartments and thereby increase the secretion of certain proteins, including IDE. This might 
represent a mechanism which is influenced by the downregulation of Vps4B, but independently 
of the release via exosomes or microvesicles. IDE could reach these compartments by the 
endocytosis of cell surface IDE which is also discussed by Bulloj and colleagues as a possible 
mechanism of IDE localisation to MVBs (Bulloj, et al., 2010). A luminal endosomal localisation 
and activity of IDE was already shown (Hamel, et al., 1988; Hamel, et al., 1991; Duckworth, et 
al., 1998). 
Endosomal hyper-secretion could also contribute to increased release of Flotillin-1, which was 
observed in some of the experiments upon stable knockdown of Vps4B. Flotillins also play a 
role in endocytic processes and are suggested to recruit transmembrane cargo proteins as for 
example the EGFR into Flotillin microdomains in the plasma membrane for pre-endocytic 
cluster formation. Flotillins do not seem to be directly involved in the endocytic process, but 
function in sorting of cargo to endosomes for recycling to the plasma membrane or retrograde 
transport to the Golgi and ER (Meister & Tikkanen, 2014). Of course, these assumptions would 
urgently need further examinations. Aberrant endosomes in BV-2 cells upon RNAi-mediated 
downregulation of Vps4B might be characterised by detecting EGFR, TGN38 and transferrin 
receptor by immunocytochemical staining or biochemical subcellular fractionation (compare 
Material and Methods 2.1.10 and 2.2.11 and Results 2.2.5 and 2.4.2). Furthermore, the 
potential hyper-secretion of immature Cathepsin D could be investigated. An initial analysis of 
EGFR degradation in cells with a transient Vps4B knockdown gave a first hint to an increased 
stability of the receptor (data not shown), but would need further verification. 
In conclusion, the present results of this work indicate complex functional implications of Vps4B 
in different secretory pathways in BV-2 cells and suggest that depletion of Vps4B might cause 
an imbalance of these pathways and additional compensating mechanisms. Vps4B seems to 
be of limited relevance for the secretion of IDE via exosomes, but might be rather important in 
the regulation of IDE release via microvesicles, possibly by affecting IDE sorting by direct 
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interaction. Furthermore, if it could be confirmed that Vps4B depletion also leads to the 
formation of aberrant endosomes causing hyper-secretion of their content into the extracellular 
space, a potential pool of IDE in these compartments could be hyper-secreted and thereby 
contribute to elevated levels of IDE in the conditioned media upon downregulation of Vps4B. 
The present results further support the presence of different subpopulations of exosomes and 
MVBs, and that IDE, Flotillin-1 and Alix might be sorted into distinct subsets of extracellular 
vesicles which might contribute to the differential release of these proteins. 
 
2.3.3 Cell type-dependent differences in Vps4B-mediated regulation of IDE release 
The influence of Vps4B depletion on the secretion of IDE and other exosomal proteins was 
also studied using primary rat astrocytes and cos-7 cells (see Figure 26 and Figure 27). The 
results indicated not only cell type-, but also cargo-dependent differences in the Vps4B-
mediated regulation of exosome, possibly microvesicle, release which was discovered and 
discussed in several other studies (Baietti, et al., 2012; Colombo, et al., 2013; Trajkovic, et al., 
2008).  
Knockdown of Vps4B in primary rat astrocytes did not change IDE relative secretion, but 
significantly decreased its cellular level, indicating a potential new function of Vps4B in IDE 
metabolism or transcription regulation. Thus, it would be interesting to assess IDE mRNA 
expression or IDE protein turnover including, for example, analysis of lysosomal and 
proteasomal degradation pathways upon knockdown of Vps4B. Vps4B depletion in primary rat 
astrocytes, moreover, significantly decreased the secretion of Alix to almost 50% indicating a 
functional involvement of Vps4B in the release and possibly sorting of Alix into exosomes or 
other extracellular vesicles. Earlier discussed results concerning the strong influence of 
ceramide levels in Alix and in general exosome release in astrocytes (see 2.2) could also 
indicate that both, ESCRT-dependent and ceramide-driven mechanisms contribute to the 
secretion of Alix. For Flotillin-1 release, no clear statement on Vps4B-mediated influence can 
be made due to varying effects observed in independent experiments. In conclusion this 
indicates, first, that in astrocytes IDE and Alix might occur in distinct subpopulations of 
exosomes or other extracellular vesicles, which are generated independently of the ESCRT 
machinery or at least independent of Vps4B. Second, the observed effect of nSMase2 
inhibition causing an almost completely blocked IDE, Alix and Flotillin-1 secretion (see Figure 
16) rather indicates a downstream of Vps4B function located effect of ceramide levels on the 
release of exosomes or other extracellular vesicles. In any case these results suggest that IDE 
secretion might involve distinct secretory pathways or at least that it is differently regulated in 
microglia and astrocytes. 
In cos-7 cells, depletion of Vps4B affects the release of all three examined exosomal proteins 
similarly. The secretion of IDE, Alix and Flotillin-1 is increased indicating a general inhibitory 
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function of Vps4B in exosome formation and release as in BV-2 cells. However, the secretion 
of all three proteins is affected in the same tendency, suggesting that all three proteins might 
be located in the same subpopulation of exosomes or other extracellular vesicles, and that 
their biogenesis might be regulated the same way. An initial experiment examining the 
influence of ceramide on the secretion of the three proteins in cos-7 cells displayed no effect 
of nSMase2 inhibition (data not shown) which would support the latter assumption.  
Although the present results need further validation for verification and also further 
investigations (as undertaken in BV-2 cells), they underline that the mechanism, that is 
involved in the regulation of cargo sorting and secretion of exosomes, may change depending 
on cell types as well as the cargos associated with different exosome subpopulations 
(Colombo, et al., 2013).  
 
2.4 Modulation of IDE-mediated Aβ- and insulin degradation by Vps4B in BV-2 
microglial cells 
The importance of extracellular IDE for the degradation of Aȕ in the brain was demonstrated 
already by several studies, and referred to both secreted and cell surface-associated pools of 
the enzyme (Qiu, et al., 1998; Vekrellis, et al., 2000; Lynch, et al., 2006; Zhao, et al., 2009; 
Bulloj, et al., 2010; Tamboli, et al., 2010). Especially microglial cells were in the focus in 
degradation of extracellular Aȕ, because they not only internalize Aȕ for lysosome-mediated 
removal of the peptide, but also degrade extracellular Aȕ by secreted IDE (Qiu, et al., 1997; 
Qiu, et al., 1998; Mandrekar, et al., 2009). So for example, Tamboli and colleagues could prove 
that stimulation of IDE release from BV-β cells promotes the degradation of extracellular Aȕ 
(Tamboli, et al., 2010). Thus, it was interesting to study the influence of Vps4B in IDE-mediated 
degradation of extracellular Aȕ and insulin. 
The stable knockdown of IDE strongly inhibited degradation of extracellular Aȕ (see Figure 
28A). This finding is consistent with previous studies, showing that IDE is a major protease in 
the degradation of extracellular Aȕ by microglia (Qiu, et al., 1998; Tamboli, et al., 2010). 
Depletion of IDE decreased not only removal of extracellular Aȕ (and insulin) but also the 
degradation of cell-associated and potentially internalized Aȕ indicating also an important role 
for the IDE-mediated intracellular and potentially cell-surface Aȕ degradation. Interestingly, 
depletion of Vps4B increased the degradation of extracellular Aȕ (and insulin) as well as cell-
associated Aȕ in comparison to control conditions by additional γ0% (see Figure 28). The 
same magnitude of enhancement in Aȕ and insulin degradation suggests the same 
mechanism mediated by the depletion of Vps4B. First, it could be assumed that an increased 
secretion of IDE caused by the knockdown of Vps4B might be responsible for the enhanced 
removal of Aȕ and insulin. Whereas in insulin-administered cells the amount of secreted IDE 
is increased, Aȕ-treated cells only show a slightly enhanced release of IDE (see Figure 28). 
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This might be attributed to a particular effect of Aȕ preventing an increase in IDE release. An 
effect of insulin or Aȕ exposure on the secretion of IDE has not been described yet, but both 
peptides were shown to enhance IDE expression (Zhao, et al., 2004; Leal, et al., 2006). The 
increased degradation of insulin might be attributed to the increased release of IDE upon 
knockdown of Vps4B, whereas then the enhanced removal of extracellular Aȕ would involve 
another mechanism which is not known and rather unlikely. However, in both cases the equally 
decreased levels of Aȕ and insulin, respectively, could also indicate an effect of Vps4B 
downregulation on the enzymatic activity of IDE, for example by direct interaction. As 
determined in earlier studies several interaction partners of IDE were already found to 
modulate the degradation of its substrates. Chou and colleagues found that interaction with 
the intermediate filament proteins nestin and especially phosphorylated vimentin decreased 
the insulin-degrading activity of IDE, but increased its ability to degrade a bradykinin-mimetic 
(Chou, et al., 2009). Furthermore, ubiquitin was found to interact in a non-covalent manner 
with IDE and inhibit its insulin-degrading activity by preventing insulin-binding to the enzyme 
(Saric, et al., 2003). Also somatostatin, a substrate of IDE itself, enhanced IDE degrading 
activity for synthetic Aȕ10-25 by an allosteric mechanism (Ciaccio, et al., 2009). Thus, possibly 
the interaction with Vps4B (see Table 16 and Figure 34) might inhibit IDE enzymatic activity 
and the degradation for Aȕ and insulin, but further investigations would be necessary to clarify 
this. A possible approach would be to test the ability of IDE to degrade insulin and Aȕ upon 
addition of Vps4B in vitro (e.g. the Vps4B-MBP fusion protein used in the interaction study, 
compare Material and Methods 2.2.7 and Figure 34C). 
Another point that should be considered is, if depletion of Vps4B might influence the 
internalization and subsequent lysosomal degradation of Aȕ, which could also affect the 
amount of extracellular Aȕ. The internalization of soluble monomeric Aȕ via macropinocytosis 
by BV-2 cells and an immediate further transport to the lysosome could already be proven 
(Mandrekar, et al., 2009). However, dysfunction of Vps4B leads to a disturbance of endosomal 
transport, especially the transport of proteins destined for lysosomal degradation (Scheuring, 
et al., 2001; Yoshimori, et al., 2000; Fujita, et al., 2003; Lin, et al., 2012) (also mentioned 
above). Therefore, an increased lysosomal degradation of Aȕ upon knockdown of Vps4B is 
very unlikely. Nevertheless, additional experiments would be important that specifically 
address potential effects of Vps4B depletion on Aȕ uptake and intracellular degradation. In this 
context also the actual role of IDE in intracellular degradation of Aȕ would need further 
investigation. If Vps4B indeed could modulate the enzymatic activity of IDE, this might also 
influence the IDE-mediated intracellular Aȕ degradation. 
Another possibility would include the earlier discussed presumption (see 2.3.2) that Vps4B 
depletion might cause the formation of aberrant endosomes that harbour also IDE. 
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Macropinocytosed Aȕ could be transported to these compartments and meet IDE or potentially 
also other Aȕ-degrading enzymes.  
In conclusion the work further demonstrates the importance of IDE for Aȕ degradation in BV-2 
cells. Moreover, Vps4B influences Aȕ and insulin degradation potentially through a modulation 
of the catalytic activity of IDE which might be mediated by the direct interaction of both proteins. 
To get a better understanding of this, further investigations are necessary as activity assays to 
test e.g. the insulin-degrading activity of IDE upon knockdown of Vps4B and cell-free 
experiments on the degradation of Aȕ in conditioned media of control and Vps4B-depleted 
cells. 
 
2.5 Potential role of IDE in the release and intracellular trafficking of exosomal 
proteins in BV-2 microglial cells 
Due to its function in insulin and Aȕ degradation, IDE is considered to play a role in the 
pathogenesis of DM2 and AD. In addition, IDE is involved in several cellular processes by 
cleaving various other substrates as TGF α, ȕ-endorphin, glucagon and other bioactive 
peptides (Wang, et al., 2006; Ciaccio, et al., 2009; Qiu & Folstein, 2006; Bennett, et al., 2000). 
Moreover, IDE has been shown to interact with non-substrate proteins, for example the steroid 
receptors GR and AR (glucocorticoid and androgen receptor), the 26S proteasome, ubiquitin 
and the intermediate filaments nestin and vimentin (Authier, et al., 1996; Kupfer, et al., 1994; 
Bennett, et al., 2000; Fawcett, et al., 2007; Chou, et al., 2009; Udrisar, et al., 2005; Saric, et 
al., 2003; Leissring, et al., 2004; Vieira, et al., 2011). This suggests that IDE is a multifunctional 
protein that could not only regulate biological processes by its enzymatic function, but might 
also affect the biological activity of other proteins independently. In line with multiple functions, 
IDE is found in different subcellular localisations. It was detected in the cytosol and in 
association with mitochondria, peroxisomes, ER, nucleus and endosomes, and also at the cell 
surface and in extracellular fluids (compare also introduction 1.). In this study, a Y2H screen 
revealed novel potential interaction partners of IDE which could indicate additional functions 
of this protein (see Table 16 and Figure 31A). The interaction with Uhrf2, Klhl13 and EP400 
could indicate a function of IDE in the regulation of cell cycle, with Fbxo38 in transcriptional 
regulation, suggesting a role of IDE in the nucleus. Little is known about the nuclear functions 
of IDE. Only Kupfer and colleagues showed about 20 years ago that IDE may modulate the 
DNA-binding of the steroid receptors GR and AR (Kupfer, et al., 1994), probably independent 
from its catalytic activity. Interestingly, additional data indicate that IDE might not possess 
insulin-degrading activity in the nucleus (Kupfer, et al., 1994; Udrisar, et al., 2005), further 
supporting a protease-independent function.  
Another interesting observation from the Y2H screen is that most of the potential interaction 
partners (44%) are related to the cellular energy metabolism. Due to its role in the degradation 
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of insulin and glucagon, IDE is considered to regulate energy metabolism mainly through its 
protease function. However, the present results suggest that IDE might also participate in 
cellular energy metabolism by direct interaction with enzymes like enolase 1 or lactate 
dehydrogenase A. Thus, it would be interesting to investigate the physiological relevance of 
the identified interaction of IDE with other metabolic proteins. 
Proteins as Fbxo38, the E3 ubiquitin ligase Uhrf2, Klhl13 and COMMd8, adaptor proteins of 
E3 ubiquitin ligase complexes, and TPP2 acting downstream of the 26S proteasome further 
support a role for IDE in ubiquitination and proteasomal protein degradation. It was shown 
previously, that IDE directly interacts with the 20S and 26S proteasome and inhibits 
proteasomal degradation (Bennett, et al., 2000; Tundo, et al., 2013; Fawcett, et al., 2007; 
Sbardella, et al., 2015). IDE also binds to ubiquitin and might regulate poly-ubiquitination of 
proteins (Saric, et al., 2003; Ralat, et al., 2011; Tundo, et al., 2013). 
Other identified potential interaction partners of IDE show an involvement in protein folding 
and posttranslational modification in ER and cytoplasm (Hsp90b1/Grp94, Aasdhppt). An 
interesting connection opens up by the finding of Tundo and colleagues that IDE seems to 
represent a heat shock-like protein being upregulated in a Hsp-like fashion upon cell stress as 
heat and exposure to H2O2 (Tundo, et al., 2013). In the present work, Grp94 was identified as 
a potential binding partner for IDE. Grp94 is a paralogue of Hsp90ȕ, localised in the ER, and 
involved in processing and transport of proteins destined for secretion (Marzec, et al., 2012). 
This might indicate a role for IDE in protein folding under both physiological conditions and 
cellular stress and suggests a specialized function for IDE in the ER. 
Functional studies on the role of IDE in the release of exosomes and sorting of exosomal 
cargos performed during this project showed that transient knockdown of IDE in BV-2 cells 
resulted in a significant increase in the release of Alix (see Figure 23A). This same effect was 
still detectable after IDE expression turned back to even increased levels (see Figure 25). 
Furthermore, IDE depletion resulted in an increased localisation of Alix in MVB fractions 
suggesting a regulatory function of IDE in the sorting of Alix into ILVs of MVBs (see Figure 
23B). This might indicate a longer-lasting process that influences sorting of Alix into MVBs and 
exosomes. Nevertheless, this would need further investigation. Shorter time periods in the 
experimental set-up should be examined to be able to analyse Alix secretion levels in direct 
comparison to the normalising IDE cellular levels. Possibly Alix secretion turns back to normal 
after the gradual increase in IDE expression. A surprising finding was that stable 
downregulation of IDE by shRNA expression in BV-2 cells did not affect Alix secretion and 
sorting into exosomes, which contrasts to the results obtained upon transient knockdown of 
IDE. This suggests that it might be an ad-hoc reaction of the cells on sudden fluctuations in 
IDE expression, which seems to be balanced upon constantly low IDE levels. In stable IDE-
depleted cells, furthermore, the release of Flotillin-1 was found to be increased, as well in 
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contrast to cells with transient IDE knockdown (see Figure 24). Downregulation of IDE did not 
influence Flotillin-1 subcellular distribution. However, minor differences in the distribution of 
Flotillin-1 might not be detected by the used method, as mentioned before (compare Results 
2.2.7). Thus, the molecular mechanisms underlying these complex effects remain to be 
identified in more detail.  
How might IDE exert a function in exosome biogenesis and secretion? Based on the identified 
interaction with Vps4B, a potential influence of IDE on the ATPase activity and function of 
Vps4B in exosome release was tested. As mentioned above, the Vps4 ATPase complex is 
described as a dodecamer formed by two hexameric rings formed of Vps4A and B subunits 
that additionally bind ATP and LIP5 proteins (Scott, et al., 2005). The rationale was, first, that 
IDE might affect the formation of this ATPase complex. However, native gel electrophoresis 
did not reveal an effect of IDE-depletion on Vps4B complexes (see Figure 36). IDE might also 
inhibit Vps4B ATPase activity by direct interaction. In the Y2H screen the Vps4B fragment 
interacting with IDE Bait indeed contained parts of its ATPase domain. Furthermore, as 
mentioned above, there are preliminary results that Vps4B depletion stabilized EGFR (data 
not shown). The downregulation of IDE, however, here induced a slight decrease in EGFR 
levels (data not shown), probably indicating a rather increased EGFR degradation, which in 
turn might suggest a decrease in the ATPase activity of Vps4B by IDE indeed. An alternative 
approach to investigate potential effects of IDE on the ATPase activity of Vps4B would be to 
analyse the release of HIV-1 and its infectivity which requires ATP binding and hydrolysis of 
Vps4B (Scott, et al., 2005; Garrus, et al., 2001; von Schwedler, et al., 2003). On the other 
hand, the finding that Vps4B depletion, which would also result in decreased Vps4B ATPase 
activity, does neither affect Alix subcellular distribution and localisation to MVB fractions (see 
Figure 22) nor its secretion (see Figure 18 and Figure 20) rather speaks against the hypothesis 
that the decreased secretion of Alix upon IDE knockdown involves the inhibition of Vps4B 
activity. 
Nevertheless, other functions already examined for the “multifunctional” protein IDE (Vieira, et 
al., 2011) could give a hint on its potential role in the regulation of exosome biogenesis. First, 
it should be mentioned that Axl1p, a yeast orthologue of IDE, was found to be involved in 
vesicular budding as a key determinant for the bud site selection in haploid cells during mitosis. 
Its expression leads to the axial budding usually observed for haploid cells instead of the 
bipolar budding that is typical for diploid cells in yeast (Fujita, et al., 1994). Axl1p assembles 
with other proteins to form a “landmark” complex. This complex is recognized by GTPases that 
in turn influence the polarization of the actin cytoskeleton, which then is involved in endocytic 
or exocytic processes (Gao, et al., 2007). Spiliotis compared these by the “landmark” 
determined areas for axial budding in the yeast membrane with distinct regions for exocytosis 
in the plasma membrane of other eukaryotic cells that are restricted by certain cytoskeleton-
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membrane domains (Spiliotis & Nelson, 2003). Distinct membrane microdomains in 
membranes of endosomes might also modulate formation of ILVs, indicated by results of 
Trajkovic et al. on the effect of ceramide on inward budding (Trajkovic, et al., 2008). It is 
intriguing to speculate that IDE might play a role in such a “landmark”-like protein complex in 
mammalian cells determining particular regions for ILV budding in MVBs. 
Interestingly, Axl1p is also involved in the maturation of the yeast mating pheromone a-factor 
that is secreted via an unconventional pathway through the ABC transporter Ste6p. The Axl1p-
mediated processing of the a-factor is the last step before secretion and most probably 
performed at the membrane due to the fact that the last precursors of the a-factor are 
prenylated and membrane-bound (Michaelis, 1993; Chen, et al., 1997). Mutants of Axl1p block 
the secretion of the a-factor (Adames, et al., 1995) indicating a role of Axl1p also in regulation 
of an unconventional secretory pathway. If this could be transferred to the mammalian 
orthologue IDE, this might, first, indicate a functional association of the protein to the 
membrane, which secondly, might be expanded to a potential influence of IDE on the 
unconventional protein secretion. Either way, this would indicate a possibility of IDE membrane 
association. 
A further mechanism in IDE-dependent exosome biogenesis, potentially connected to the 
former, would be the modulation of protein ubiquitination that might also regulate exosome 
sorting and biogenesis. Polyubiquitination or multiple monoubiquitination of cargo proteins 
regulates their sorting into invaginations at the endosomal membrane which precedes ILV 
formation into MVBs. As mentioned above, IDE not only shows a non-covalent interaction with 
ubiquitin, which leads to an inhibition of its insulin-degrading activity (Saric, et al., 2003), it is 
also able to proteolytically cleave ubiquitin itself (Ralat, et al., 2011), although Ralat and 
colleagues did not describe if IDE might also degrade ubiquitin in poly-ubiquitin protein tags. 
Furthermore, the findings of the present study indicate an interaction of IDE with E3 ubiquitin 
ligases or adaptor proteins which might additionally hint to a potential role of IDE in regulating 
ubiquitination of proteins. Interestingly, Tundo and colleagues detected a decrease in the total 
amount of poly-ubiquitinated proteins upon siRNA-mediated knockdown of IDE 48-36 hours 
after transfection (Tundo, et al., 2013; Sbardella, et al., 2015). They rather attributed this effect 
to an increased proteasomal activity upon knockdown of IDE leading to an enhanced turnover 
of poly-ubiquitinated proteins. However, ubiquitination of proteins as a posttranslational 
modification not only regulates their degradation, but also the subcellular targeting and their 
function (Moreno-Gonzalo, et al., 2014; d'Azzo, et al., 2005). Polyubiquitination or multiple 
monoubiquitination, as described above, regulates protein sorting into MVBs, and is 
recognized by the ESCRT machinery, specifically ESCRT-0 and -I (compare also Introduction 
2.2). Although some cargo for ILVs is deubiquitylated before vesicle abscission also 
ubiquitinated proteins were detected in isolated exosomes (Moreno-Gonzalo, et al., 2014), 
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indicating a role of ubiquitination in cargo sorting into exosomes as well. However, exosomal 
protein sorting can occur also independent on ubiquitination (Buschow, et al., 2009; Villarroya-
Beltri, et al., 2014), further demonstrating the complexity in the molecular mechanisms that 
regulate exosomal protein targeting, and also defining distinct subpopulations of exosomes 
(Colombo, et al., 2013).  
Monoubiquitination can also regulate protein activity. Monoubiquitination was found for 
ESCRT-0 subunits and might regulate the directional flow of cargo to additional complexes 
(Moreno-Gonzalo, et al., 2014; d'Azzo, et al., 2005). Also Alix was described to be 
monoubiquitinated regulating its activity (Sette, et al., 2010; Dores, et al., 2015). Furthermore, 
Sette and colleagues by analysing the release of HIV, revealed that Alix is able to recruit an 
E3 ubiquitin ligase (Nedd4-1) which facilitates virus budding from the plasma membrane 
(Sette, et al., 2010). In general, E3 ubiquitin ligases, in particular members of the Nedd4 family 
or their adaptors, are involved in several vesicle budding processes, including virus budding, 
endocytosis, microvesicle shedding from the plasma membrane and also exosome biogenesis 
in MVBs (d'Azzo, et al., 2005; Sette, et al., 2010; Chung, et al., 2008; Moreno-Gonzalo, et al., 
2014; Putz, et al., 2008; Nabhan, et al., 2012).  
It could now be speculated that IDE might influence protein ubiquitination through ubiquitin 
degradation and thereby modulate either the polyubiquitination of exosome cargo or the 
monoubiquitination of proteins that are involved in exosome biogenesis. Moreover, IDE might 
recruit an E3 ubiquitin ligase and thereby drive vesicle budding or prevent it by an inhibitory 
ubiquitination of certain target proteins. Concerning the secretion of Alix, IDE might rather exert 
an inhibitory effect. A possible connection might be that IDE influences the monoubiquitination 
of Alix thereby negatively regulating its activity. This would interfere with its function in exosome 
release and also inhibit its own sorting into exosomes, which involves syndecans and syntenin 
(Baietti, et al., 2012). The mechanisms underlying the effect of IDE on protein ubiquitination 
possibly affecting the sorting of Alix and other proteins as Flotillin-1 would require further 
investigation. In this regard, an inducible shRNA-based RNAi system would be more 
appropriate than the used stably shRNA-expressing cells. 
The examination of IDE depletion in other cell types, namely primary rat astrocytes and cos-7 
cells, revealed, as observed already for the downregulation of Vps4B (discussed above in 
2.3.3), different and partly opposite effects than detected in BV-2 microglial cells (see Figure 
26 and Figure 27). In rat astrocytes, in contrast to BV-2 cells, IDE transient depletion caused 
a decrease in the release of Alix by more than 65% whereas Flotillin-1 secretion is not 
significantly affected. In cos-7 cells, however, IDE knockdown did not influence Alix secretion, 
but slightly and significantly decreased the release of Flotillin-1 by approximately 25%. This 
once again supports that exosome biogenesis might be regulated differently in distinct cell 
types. On the other hand it underlines again that Alix and Flotillin-1, most probably, are located 
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in different exosome subpopulations in astrocytes as well as in cos-7 and BV-2 cells. Together, 
these combined observations also indicate a regulatory function of IDE in the biogenesis of 
exosomes or sorting of exosomal cargo proteins not only in BV-2 cells. 
 
3. Conclusions 
The present investigations on molecular mechanisms of IDE secretion, predominantly in BV-2 
cells, showed that not only the release of distinct exosomal marker proteins is regulated 
differently, but also the exosome secretion in distinct cell types. 
First, this study revealed that IDE secretion in microglial cells is stimulated by 5-HT and 
indicates an important function of 5-HTR-mediated signalling in the release of IDE. Moreover, 
the present results suggest that communication between neurons and microglia might play a 
beneficial role for the microglia-mediated degradation of extracellular monomeric Aȕ in the 
brain. 
The findings of the study further suggest that the regulation of IDE release from microglial cells 
seems to be multi-facetted due to the possible involvement of several distinct secretory 
pathways. The modulation of ceramide metabolism indicated that this lipid plays a minor role 
in exosome biogenesis in BV-2 cells, but promotes this process in primary rat astrocytes. 
Interestingly, ceramide appears to even inhibit the secretion of IDE in microglial cells, leading 
to the assumption that in microglial cells a pool of IDE is possibly released by an additional 
secretory pathway distinct from exosome-mediated export. The study also showed an 
interaction of IDE with the ESCRT accessory ATPase Vps4B. Even though the functional 
implication remains to be determined in much more detail, Vps4B unexpectedly exerts an 
inhibitory effect on IDE release in BV-2 cells. Although Vps4B is known for an influence on 
exosome biogenesis and endosomal transport of proteins mediated by its ATPase function in 
the MVB pathway, its contribution to the sorting and intracellular trafficking of IDE appears to 
be limited. The present findings indicate that Vps4B rather affects the release of IDE via 
microvesicles than via exosomes, which might be attributed to an ATPase-independent 
function. On the other hand, the loss of Vps4B might also cause a hyper-secretion of several 
proteins accumulated in aberrant endosomes involving also IDE. Furthermore, depletion of 
Vps4B stimulated the IDE-mediated degradation of insulin and Aȕ in BV-2 cells.  
The most surprising finding of this study is probably that IDE itself plays a functional role in 
unconventional release of certain exosome cargo proteins and possibly selected exosome 
pools, potentially mediated by a modulated exosome biogenesis or modulated sorting of 
exosomal cargo. 
All in all, the combined results of this work reflect the controversial and sometimes opposing 
results on the regulation of exosome biogenesis and release described in the literature. The 
present data support the existence of several distinct subpopulations of exosomes varying not 
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only in their protein composition, but also in their existence in distinct cell types. Moreover, 
also regulatory mechanisms for exosome (and probably microvesicle) biogenesis and the 
presence or absence of these same mechanisms are varying between the cell types. 
Furthermore, most exosomal proteins are not exclusively found in exosomes, but as well in 
microvesicles. Also other unconventional pathways as export via ABC transporter are 
conceivable. But even inhibition of the conventional secretory pathway, especially by 
interrupting the vesicular transport inside the Golgi network, seems to stimulate the exosomal 
release in general, indicating a closer but also very complex relation and conjunction of the 
distinct secretory pathways in the cell than possibly expected at the moment. 
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E Outlook 
The regulation of exosome biogenesis and release in mammalian cells is not fully understood 
and an involvement of the ESCRT machinery in this process is controversial. The underlying 
regulatory mechanisms could differ between individual cargo proteins and cell types. The 
present work on molecular mechanisms of IDE secretion supports the existence of different 
subpopulations of exosomes. Until now it is difficult to determine these subpopulations. In 
addition, there are mainly no uniform methods for the isolation of exosomes. For example, a 
common procedure of exosome preparation by differential centrifugation (Théry, et al., 2006), 
which is utilized also in this study, seems to be susceptible to variation especially concerning 
the separation of microvesicles and exosomes (Bobrie, et al., 2012). Therefore, an important 
focus should be placed on the development of improved isolation procedures to separate 
microvesicles and exosomes and, furthermore, a standardisation of these used methods 
should happen to enable more comparability between distinct studies on exosome regulation. 
Then, it would be important to further characterise the molecular details of unconventional 
secretion of IDE. In particular, given that the present study indicates additional secretory 
mechanisms to the known exosome-associated pathway. An involvement of the ESCRT-
accessory Vps4B in IDE secretion could be determined in this study, thereby supporting 
previous studies on a role of Vps4B in the release of exosome-associated proteins (Baietti, et 
al., 2012; Colombo, et al., 2013; Kunadt, et al., 2015; Gan & Gould, 2011). Further analyses 
of Vps4B function in the exosome and microvesicle but also other unconventional secretory 
pathways could elucidate the partly contradictory effects obtained by the different studies. It 
would be also interesting to further characterise the interaction of IDE and Vps4B by 
determining the precise sequences of the interaction domain in both proteins and subsequent 
mutation analyses. 
Interestingly, ESCRT dysfunction is associated to AD (Lee & Gao, 2012). Already in early 
stages of the disease a disturbed endosomal-lysosomal system leads to an impaired 
maturation of autophagic vacuoles (AVs) to lysosomes and thereby the accumulation of such 
AVs in dystrophic neurites, most likely promoting neuronal cell death and contributing to 
disease progression (Funk, et al., 2011; Lee, et al., 2011; Nixon & Yang, 2012). Therefore, 
altered Vps4B function and thereby induced aberrant endosomes and hyper-secretion 
(Scheuring, et al., 2001; Yoshimori, et al., 2000; Fujita, et al., 2003) might contribute to the 
pathogenesis of AD. It would be crucial to investigate the formation of aberrant endosomes 
that are observed during Vps4B ATPase-deficiency mainly in its potential consequences for 
protein secretion, which might affect not only IDE release, but also other unconventionally 
secreted proteins. Moreover, an effect of Vps4B deficiency on Aȕ clearance would represent 
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an important point to be analysed in more detail, especially after the unexpected finding of this 
work that Vps4B depletion causes an γ0% increased degradation of Aȕ in microglial cells. 
Finally, this study strongly suggests a regulatory function of IDE in the exosome biogenesis 
and release. It would be interesting to assess if this potential new role of IDE might be 
associated with its assumed function in protein ubiquitination and the possible recruitment of 
E3 ubiquitin ligases that might influence membrane budding, as it is described for example for 
Alix (Sette, et al., 2010) or whether IDE might be part of a membrane “landmark” complex, 
marking particular membrane domains for vesicle budding. In this context, it might be 
furthermore interesting to examine the consequences of IDE deficiency in AD given the fact 
that increased exosome secretion was shown to have both beneficial and detrimental effects 
on the progression of the disease affecting mainly Aȕ clearance and its aggregation (Dinkins, 
et al., 2014; Rajendran, et al., 2006; Perez-Gonzalez, et al., 2012; Yuyama, et al., 2014). 
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F Abstract 
Extracellular deposition of amyloid- (A) plaques in the brain, a hallmark of Alzheimer’s 
disease (AD), results from an imbalance between production and clearance of the peptide. 
Insulin-degrading enzyme (IDE) is one of the major proteases that degrade monomeric Aȕ in 
the brain and is suggested to be mainly involved in the removal of extracellular Aȕ. Recent 
studies demonstrated that the enzyme is released by microglial cells via the unconventional 
exosome secretory pathway, but little is known about the regulation of IDE secretion and 
sorting into extracellular vesicles. 
This work revealed that serotonin (5-HT) stimulates the secretion of exosome associated IDE 
from microglial cells. Activation of the 5-HT receptors 2a, 2b and 4 induces an elevation of 
intracellular Ca2+ which is likely to promote the release of IDE. Co-culture experiments showed 
that the presence of neurons stimulates secretion from and expression of IDE in microglial 
cells. 
Further experiments revealed that inhibition of nSMase2 that decreases ceramide production 
unexpectedly increased IDE release from microglial cells, whereas the secretion of other 
exosomal proteins rather decreased or remained unaffected. RNAi-mediated knockdown of 
the ESCRT-associated ATPase Vps4B elevated secretion of IDE without affecting the 
trafficking of IDE to MVBs or its secretion via exosomes. Vps4B depletion promoted IDE 
release by increasing microvesicle shedding. Interestingly, Vps4B was identified as potential 
interaction partner of IDE in a yeast two-hybrid screen and confirmed by 
co-immunoprecipitation. Depletion of IDE or Vps4B, respectively, did not influence the usual 
complex formation of both proteins. But because knockdown of Vps4B in BV-2 microglial cells 
also increased IDE-mediated degradation of extracellular Aȕ and insulin, it could be assumed 
that the interaction of IDE and Vps4B might modulate IDE protease activity. 
Moreover, transient knockdown of IDE increased the release of Alix from microglial cells by 
enhancing its subcellular transport to MVBs suggesting a role for IDE itself in the regulation of 
exosome secretion. Secretion analyses in primary rat astrocytes and fibroblast cos-7 cells 
revealed cell type- and cargo-dependent differences in the ceramide-, Vps4B- and IDE-
mediated regulation of exosome release. This suggests not only the existence of distinct 
exosome subpopulations but also distinct mechanisms of exosome biogenesis dependent on 
cell type and the particular cargo protein. 
Together these results indicate a complex interaction of several regulatory mechanisms for 
IDE secretion in microglial cells and suggest the potential involvement of further pathways for 
IDE export regulated by Vps4B and nSMase2. 
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